JP2014518220A - Metalloenzyme inhibitor compounds - Google Patents

Abstract

The present invention describes compounds having metalloenzyme modulating activity and methods for treating such diseases, disorders or conditions mediated by such metalloenzymes.

Description

  Living organisms have developed tightly controlled processes that specifically take up metals, transport them to intracellular storage sites, and ultimately transport them to the site of use. One of the most important functions of metals such as zinc and iron in biological systems is to enable the activation of metalloenzymes. A metalloenzyme is an enzyme that incorporates a metal ion into the enzyme active site and uses metal as part of the catalytic process. More than one-third of all enzymes with known characteristics are metalloenzymes.

  The function of metalloenzymes depends largely on the presence of metal ions in the active site of the enzyme. It is well recognized that substances that bind to and inactivate active site metal ions dramatically reduce the activity of the enzyme. Nature uses this same strategy to reduce the activity of certain metalloenzymes while enzyme activity is unnecessary. For example, the protein TIMP (a tissue inhibitor of metalloproteases) binds to zinc ions at the active site of various matrix metalloprotease enzymes, thereby stopping the enzyme activity. The pharmaceutical industry has used the same strategy in the design of therapeutic agents. For example, the azole antifungals, fluconazole and voriconazole contain a 1- (1,2,4-triazole) group that binds to heme iron present in the active site of the target enzyme lanosterol demethylase, thereby inactivating the enzyme Turn into. Another example includes zinc-linked hydroxamic acid groups incorporated into the most published inhibitors of matrix metalloproteinases and histone deacetylases. Another example is a zinc-linked carboxylic acid group that is incorporated into the most published angiotensin converting enzyme inhibitors.

  In designing clinically safe and effective metalloenzyme inhibitors, the use of metal binding groups that are most suitable for specific targets and clinical indications is very important. If weakly binding metal binding groups are used, efficacy may be insufficient. On the other hand, if a metal binding group that binds very strongly is used, the selectivity to the target enzyme may be insufficient compared to the related metalloenzyme. The lack of optimal selectivity can cause clinical toxicity due to unintentional inhibition of these off-target metalloenzymes. An example of such clinical toxicity is the unintentional inhibition of human drug-metabolizing enzymes such as cytochrome P450 2C9 (CYP2C9), CYP2C19 and CYP3A4 by currently available azole antifungal agents such as fluconazole and voriconazole. This off-target inhibition is thought to be mainly caused by the indiscriminate binding of currently utilized 1- (1,2,4-triazole) to the active site iron of CYP2C9, CYP2C19 and CYP3A4. Another example of this is arthralgia that has been observed in many clinical trials of matrix metalloproteinase inhibitors. This toxicity appears to be related to the inhibition of off-target metalloenzymes due to the indiscriminate binding of hydroxamic acid groups to off-site active site zinc.

  Therefore, research on metal binding groups that can achieve a balance between better efficacy and selectivity is still an important goal and is currently being met in treating and preventing diseases, disorders and their symptoms. There is significant significance in the realization of therapeutic agents and methods to address the unmet need.

  Fungicides are compounds of natural or synthetic origin and act to protect and restore plants from damage caused by agricultural-related fungi. In general, there are no fungicides useful alone in all situations. As a result, research is ongoing to produce fungicides that have better performance, are easier to use, and can be less expensive.

  The present disclosure relates to the compounds of formula I shown below and their derivatives and their use as fungicides. The compounds of the present disclosure may provide a protective effect against ascomycetes, basidiomycetes, imperfect fungi and oomycete.

  The present invention relates to compounds (eg, any of those described herein), methods for modulating the activity of metalloenzymes, and methods for treating diseases, disorders or symptoms thereof. The method can include a compound herein.

ＭＢＧは、場合によっては置換されているテトラゾリル、場合によっては置換されているトリアゾリル、場合によっては置換されているオキサゾリル、場合によっては置換されているピリミジニル、場合によっては置換されているチアゾリルまたは場合によっては置換されているピラゾリルであり；
Ｒ_１は、Ｈ、ハロ、アルキルまたはハロアルキルであり；
Ｒ_２は、Ｈ、ハロ、アルキルまたはハロアルキルであり；
Ｒ_３は、独立に、Ｈ、アルキル、ニトロ、シアノ、ハロアルキル、アルコキシ、ハロ、ハロアルコキシ、アルケニル、ハロアルケニル、シクロアルキル、ハロシクロアルキル、アルキニル、ハロアルキニル、チオアルキル、ＳＦ_３、ＳＦ_６、ＳＣＮ、ＳＯ_２Ｒ_６、−Ｃ（Ｏ）−アルキル、−Ｃ（Ｏ）ＯＨ、−Ｃ（Ｏ）Ｏ−アルキル、Ｃ（Ｏ）Ｈ、ＣＨ＝Ｎ−Ｏ−アルキル、−ＣＨ＝Ｎ−Ｏ−アリールアルキルであり；
Ｒ_４は、０、１、２または３個の独立したＲ_３で場合によっては置換されている、アリール、ヘテロアリールまたはシクロアルキルであり；
Ｒ_５は、アルキル、ハロアルキル、シクロアルキル、Ｃ_２−Ｃ_８アルケニル、Ｃ_２−Ｃ_８アルキニル、アリール、ヘテロアリール、アリールアルキルまたはヘテロアリールアルキルであり、それぞれ、０、１、２または３個の独立したＲ_３で場合によっては置換され；
Ｒ_６は、アルキル、アリール、置換されているアリール、ヘテロアリールまたは置換されているヘテロアリールであり；
Ｒ_７は、Ｈ、アルキル、−Ｓｉ（Ｒ_８）_３、−Ｐ（Ｏ）（ＯＨ）_２、−ＣＨ_２−Ｏ−Ｐ（Ｏ）（ＯＨ）_２または、場合によってはアミノで置換されている−Ｃ（Ｏ）−アルキルであり；
Ｒ_８は、独立にアルキルまたはアリールであり；
Ｒ_９は、独立にＨ、アルキル、ハロまたはハロアルキルであり；
ＸはＯまたはＳである。 An embodiment is a compound of formula I or a salt, solvate, hydrate or prodrug thereof, wherein

MBG is optionally substituted tetrazolyl, optionally substituted triazolyl, optionally substituted oxazolyl, optionally substituted pyrimidinyl, optionally substituted thiazolyl or optionally Is substituted pyrazolyl;
R ₁ is H, halo, alkyl or haloalkyl;
R ₂ is H, halo, alkyl or haloalkyl;
R ₃ is independently H, alkyl, nitro, cyano, haloalkyl, alkoxy, halo, haloalkoxy, alkenyl, haloalkenyl, cycloalkyl, halocycloalkyl, alkynyl, haloalkynyl, thioalkyl, SF ₃ , SF ₆ , SCN , SO ₂ R ₆ , —C (O) -alkyl, —C (O) OH, —C (O) O-alkyl, C (O) H, CH═N—O-alkyl, —CH═N—O. -Arylalkyl;
R ₄ is aryl, heteroaryl or cycloalkyl, optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
R ₅ is alkyl, haloalkyl, cycloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, each of 0, 1, 2 or 3 Optionally substituted with independent R ₃ ;
R ₆ is alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R ₇ is H, alkyl, —Si (R ₈ ) ₃ , —P (O) (OH) ₂ , —CH ₂ —O—P (O) (OH) _2, or optionally substituted with amino. -C (O) -alkyl;
R ₈ is independently alkyl or aryl;
R ₉ is independently H, alkyl, halo or haloalkyl;
X is O or S.

式中、
ＭＢＧは、場合によっては置換されているテトラゾリル、場合によっては置換されているトリアゾリル、場合によっては置換されているオキサゾリル、場合によっては置換されているピリミジニル、場合によっては置換されているチアゾリルまたは場合によっては置換されているピラゾリルであり；
Ｒ_１は、Ｈ、ハロ、アルキルまたはハロアルキルであり；
Ｒ_２は、Ｈ、ハロ、アルキルまたはハロアルキルであり；
Ｒ_３は、独立に、Ｈ、アルキル、ニトロ、シアノ、ハロアルキル、アルコキシ、ハロ、ハロアルコキシ、アルケニル、ハロアルケニル、シクロアルキル、ハロシクロアルキル、アルキニル、ハロアルキニル、チオアルキル、ＳＦ_３、ＳＦ_６、ＳＣＮ、ＳＯ_２Ｒ_６、−Ｃ（Ｏ）−アルキル、−Ｃ（Ｏ）ＯＨ、−Ｃ（Ｏ）Ｏ−アルキル、Ｃ（Ｏ）Ｈ、ＣＨ＝Ｎ−Ｏ−アルキル、−ＣＨ＝Ｎ−Ｏ−アリールアルキルであり；
Ｒ_４は、０、１、２または３個の独立したＲ_３で場合によっては置換されている、アリール、ヘテロアリール、アルキルまたはシクロアルキルであり；
Ｒ_５は、アルキル、ハロアルキル、シクロアルキル、Ｃ_２−Ｃ_８アルケニル、Ｃ_２−Ｃ_８アルキニル、アリール、ヘテロアリール、アリールアルキルまたはヘテロアリールアルキルであり、それぞれ、０、１、２または３個の独立したＲ_３で場合によっては置換されており；
Ｒ_６は、アルキル、アリール、置換されているアリール、ヘテロアリールまたは置換されているヘテロアリールであり；
Ｒ_７は、Ｈ、アルキル、−Ｓｉ（Ｒ_８）_３、−Ｐ（Ｏ）（ＯＨ）_２、−ＣＨ_２−Ｏ−Ｐ（Ｏ）（ＯＨ）_２または、場合によってはアミノで置換されている−Ｃ（Ｏ）−アルキルであり；
Ｒ_８は、独立にアルキルまたはアリールであり；
Ｒ_９は、独立にＨ、アルキル、ハロまたはハロアルキルであり；
ＸはＯまたはＳである。 Another aspect is the risk of developing a disease from a pathogen comprising contacting a composition of formula I or a salt, solvate, hydrate or prodrug thereof with a plant and one of the areas adjacent to the plant. A method of regulating pathogen-induced disease in a plant,

Where
MBG is optionally substituted tetrazolyl, optionally substituted triazolyl, optionally substituted oxazolyl, optionally substituted pyrimidinyl, optionally substituted thiazolyl or optionally Is substituted pyrazolyl;
R ₁ is H, halo, alkyl or haloalkyl;
R ₂ is H, halo, alkyl or haloalkyl;
R ₃ is independently H, alkyl, nitro, cyano, haloalkyl, alkoxy, halo, haloalkoxy, alkenyl, haloalkenyl, cycloalkyl, halocycloalkyl, alkynyl, haloalkynyl, thioalkyl, SF ₃ , SF ₆ , SCN , SO ₂ R ₆ , —C (O) -alkyl, —C (O) OH, —C (O) O-alkyl, C (O) H, CH═N—O-alkyl, —CH═N—O. -Arylalkyl;
R ₄ is aryl, heteroaryl, alkyl or cycloalkyl, optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
R ₅ is alkyl, haloalkyl, cycloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, each of 0, 1, 2 or 3 Optionally substituted with independent R ₃ ;
R ₆ is alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R ₇ is H, alkyl, —Si (R ₈ ) ₃ , —P (O) (OH) ₂ , —CH ₂ —O—P (O) (OH) _2, or optionally substituted with amino. -C (O) -alkyl;
R ₈ is independently alkyl or aryl;
R ₉ is independently H, alkyl, halo or haloalkyl;
X is O or S.

Another aspect is a compound of any of the formulas herein, wherein
MBG is optionally substituted tetrazolyl or optionally substituted triazolyl;
R ₁ is fluoro;
R ₂ is fluoro;
R ₁ and R ₂ are fluoro;
R ₄ is phenyl optionally substituted with 0, 1, 2, or 3 independent R ₃ ;
R ₄ is phenyl optionally substituted with 0, 1, 2 or 3 independent halo;
R ₄ is phenyl optionally substituted with 0, 1, 2 or 3 independent fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is aryl optionally substituted with 0, 1, 2, or 3 independent R ₃ ;
R ₅ is arylalkyl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
R ₅ is heteroarylalkyl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
R ₅ is heteroaryl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
R ₅ is pyridyl, pyridazinyl, pyrimidinyl, triazinyl, imidazolyl, triazolyl, tetrazolyl or pyrazolyl, each optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
R ₉ is H;
R ₉ is halo;
MBG is 1H-tetrazol-1-yl, 2H-tetrazol-2-yl, 4H-1,2,4-triazol-4-yl or 1H-1,2,4-triazol-1-yl;
MBG is 1H-tetrazol-1-yl or 2H-tetrazol-2-yl;
MBG is 4H-1,2,4-triazol-4-yl or 1H-1,2,4-triazol-1-yl;
Where
R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is aryl optionally substituted with 0, 1, 2, or 3 independent R ₃ ;
Where
R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is heteroaryl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
Where
R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is arylalkyl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
In the formula:
R ₅ is benzyl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
In the formula:
R ₅ is —CH ₂ -heteroaryl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
In the formula:
R ₅ is —CH ₂ CF ₂ -aryl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
In the formula:
X is O and R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
In the formula:
X is O and R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is heteroaryl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
In the formula:
X is O and R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is pyridyl, pyridazinyl, pyrimidinyl, triazinyl, imidazolyl, triazolyl, tetrazolyl or pyrazolyl, each optionally substituted with 0, 1, 2 or 3 independent R ₃ ;

  The compounds herein have one of the following types of chemical interactions or bonds to metals: sigma bond, covalent bond, coordination-covalent bond, ionic bond, pi bond, delta bond or reverse bond interaction. By the above formation, the compounds are identified at least in part as those that achieve affinity for metalloenzymes. The compound also gains affinity through weaker interactions with metals such as van der Waals forces, pi-cation interactions, pi-anion interactions, dipole interactions, and ion-dipole interactions. obtain. In some embodiments, the compound is identified as having a binding interaction with the metal via the 1-tetrazolyl moiety; in another embodiment, the compound is attached to the metal via the N2 of the 1-tetrazolyl moiety. Identified as having an interaction; in another embodiment, the compound is identified as having a binding interaction with the metal through the N3 of the 1-tetrazolyl moiety; in another embodiment, the compound is defined as 1 -Identified as having a binding interaction with the metal via N4 of the tetrazolyl moiety. In some embodiments, the compound is identified as having a binding interaction with the metal via the 4-triazolyl moiety; in another embodiment, the compound is attached to the metal via N1 of the 4-triazolyl moiety. Identified as having an interaction; in another embodiment, the compound is identified as having a binding interaction with the metal via N2 of the 4-triazolyl moiety.

  For example, "Principles of Bioinorganic Chemistry" by Lippard and Berg, University Science Books (1994); "Mechanisms of Inorganic Reactions" by Basolo and Pearson, John Wiley & Sons Inc; 2nd edition (September 1967); "Biological Inorganic Chemistry" by Ivano Bertini, Harry Gray, Ed Stiefel, Joan Valentine, University Science Books (2007); Xue et al. “Nature Chemical Biology”, vol. 4, no. Methods for assessing metal-ligand binding interactions as exemplified in the references, including 2,107-109 (2008) are known in the art.

In certain examples, the compounds of the present invention are selected from the following of formula I (and pharmaceutically and agriculturally acceptable salts, solvates or hydrates thereof):
1- (5- (4-Chloro-2-fluorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (1);
1- (5- (2,4-Difluorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane -2-ol (2);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (3-fluorobenzyloxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (3);
1- (5- (4-Chlorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane-2 -All (4);
4- (6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yloxy) benzonitrile (5 );
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (4-fluorophenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (6);
1- (5- (4-Chlorophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2- All (7);
2- (2,4-difluorophenyl) -1,1-difluoro-1- (5-methoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (8);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (9);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (10);
2- (2,4-difluorophenyl) -1,1-difluoro-1- (5-phenoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (11);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (2,2,2-trifluoroethoxy) pyridin-2-yl ) Propan-2-ol (12);
1- (4-((2,4-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (13);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (vinyloxy) pyridin-2-yl) propan-2-ol (14 );
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) thio) Methyl) -3-fluorobenzonitrile (15);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) thio) Methyl) -3-fluorobenzonitrile (16);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy)- 2-fluorobenzonitrile (17);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((2,2,2-trifluoroethyl) thio) pyridine- 2-yl) propan-2-ol (18);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((4-fluorobenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (19);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((4- (2,2,2-trifluoroethoxy) benzyl ) Oxy) pyridin-2-yl) propan-2-ol (20);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((4- (trifluoromethoxy) benzyl) oxy) pyridine-2 -Yl) propan-2-ol (21);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((4- (trifluoromethyl) benzyl) oxy) pyridine-2 -Yl) propan-2-ol (22);
1- (5-((2,3-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (23);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((2-fluoro-4- (trifluoromethyl) benzyl) oxy) pyridin-2-yl) -3- (1H -Tetrazol-1-yl) propan-2-ol (24);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((3- (2,2,2-trifluoroethoxy) benzyl ) Oxy) pyridin-2-yl) propan-2-ol (25);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((3- (trifluoromethyl) benzyl) oxy) pyridine-2 -Yl) propan-2-ol (26);
1- (5-((4-chloro-3-fluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (27);
1- (5-((3,4-Difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (28);
2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) acetonitrile (29);
1- (5- (benzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2-ol ( 30);
1- (5- (benzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) propan-2-ol ( 31);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) ) Propan-2-ol (32);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) ) Propan-2-ol (33);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((3-methoxybenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (34);
1- (5-((3,5-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (35);
1- (5-((3,5-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl ) Propan-2-ol (36);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyridin-2-ylmethoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (37);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyridin-2-ylmethoxy) pyridin-2-yl) -3- (2H-tetrazol-2-yl) propan-2 -All (38);
1- (5- (Cyclopropylmethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2-ol (39);
1- (5- (Cyclopropylmethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) propan-2-ol (40);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((4-methoxybenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (41);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-isopropoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (42) ;
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-isobutoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (43) ;
1- (5-((2,3-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,3 -Triazol-1-yl) propan-2-ol (44);
1- (5-((2,3-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4 -Triazol-1-yl) propan-2-ol (45);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((2-fluorobenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (46);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((1,1,1-trifluoropropan-2-yl) Oxy) pyridin-2-yl) propan-2-ol (47);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) -1- (5-((1,1,1-trifluoropropan-2-yl) Oxy) pyridin-2-yl) propan-2-ol (48);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (thiophen-2-ylmethoxy) pyridin-2-yl) propane-2 -All (49);
6-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) nicotinonitrile (50);
6-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) nicotinonitrile (51);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (52);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (53);
2- (4-Chloro-2-fluorophenyl) -1- (5- (cyclopropylmethoxy) pyridin-2-yl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane-2 -All (54);
4-(((6- (2- (4-chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) Oxy) methyl) benzonitrile (55);
4-(((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) Oxy) methyl) benzonitrile (56);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -3-fluorobenzonitrile (57);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) -3-fluorobenzonitrile (58);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -4-fluorobenzonitrile (59);
2- (2,4-Difluorophenyl) -1- (5-((3,5-difluoropyridin-2-yl) methoxy) pyridin-2-yl) -1,1-difluoro-3- (1H-tetrazole -1-yl) propan-2-ol (60);
6-(((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) Oxy) methyl) nicotinonitrile (61);
6-(((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) Oxy) methyl) nicotinonitrile (62);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (4-chloro-2-fluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (63);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (4-chloro-2-fluorophenyl) -1,1-difluoro-3- (2H-tetrazole-2) -Yl) propan-2-ol (64);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (65);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (66);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (67);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (68);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-1- (5-isobutoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol ( 69);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-1- (5-isobutoxypyridin-2-yl) -3- (2H-tetrazol-2-yl) propan-2-ol ( 70);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (2,2,2-trifluoroethoxy) pyridine-2 -Yl) propan-2-ol (71);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) -1- (5- (2,2,2-trifluoroethoxy) pyridine-2 -Yl) propan-2-ol (72);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) thiophene-2-carbonitrile (73);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) thiophene-2-carbonitrile (74);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (4- (trifluoromethyl) phenoxy) pyridin-2-yl) Propan-2-ol (75);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (4- (trifluoromethoxy) phenoxy) pyridin-2-yl) Propan-2-ol (76);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (3-fluorophenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (77);
3-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) benzo Nitrile (78);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy ) Benzonitrile (79);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy ) Benzonitrile (80);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy ) -2-fluorobenzonitrile (81);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy ) -2-Fluorobenzonitrile (82);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (83);
1- (5- (3-Chlorophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2- Oar (84);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (3-methoxyphenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (85);
1- (5- (3,4-Difluorophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane- 2-ol (86);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (4-methoxyphenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (87);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (2-fluorophenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (88);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy)- 3-fluorobenzonitrile (89);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy)- 3-fluorobenzonitrile (90);
Methyl 2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) thio) Acetate (91);
1- (5-((3-chloro-5- (trifluoromethyl) pyridin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro- 3- (1H-tetrazol-1-yl) propan-2-ol (92);
6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) nicochi Nononitrile (93);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((5- (trifluoromethyl) pyridin-2-yl) oxy ) Pyridin-2-yl) propan-2-ol (94);
1- (5-((5-chloropyridin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (95);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) picoli Nononitrile (96);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyrimidin-2-yloxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (97);
1- (5-((5-chloropyrimidin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (98);
1- (5-((5-Bromopyrimidin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (99);
5-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) pyrimidine -2-carbonitrile (100);
6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) nicotine An aldehyde (101);
(E) -6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl ) Oxy) nicotinaldehyde O-methyl oxime (102);
(E) -6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl ) Oxy) nicotinaldehyde O-benzyloxime (103);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((3-fluoro-5- (trifluoromethyl) pyridin-2-yl) oxy) pyridin-2-yl)- 3- (1H-tetrazol-1-yl) propan-2-ol (104);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((5- (trifluoromethyl) pyrimidin-2-yl) oxy ) Pyridin-2-yl) propan-2-ol (105);
1- (5-((5-Bromopyridin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (106);
2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) thiazole -5-carbonitrile (107);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (quinolin-2-yloxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (108);
1- (5-((5-chlorobenzo [d] thiazol-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H- Tetrazol-1-yl) propan-2-ol (109);
1- (5-((6-Chlorobenzo [d] thiazol-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H- Tetrazol-1-yl) propan-2-ol (110);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((6- (trifluoromethyl) pyridin-3-yl) oxy ) Pyridin-2-yl) propan-2-ol (111);
5-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) picoli Nononitrile (112);
1- (5-((5-chloropyridin-2-yl) methoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (113);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((5- (trifluoromethyl) pyridin-2-yl) methoxy ) Pyridin-2-yl) propan-2-ol (114);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((6- (trifluoromethyl) pyridin-3-yl) methoxy ) Pyridin-2-yl) propan-2-ol (115);
1- (5-((6-chloropyridin-3-yl) methoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (116);
1- (5-((2-chloropyridin-4-yl) methoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (117);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyridin-4-ylmethoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (118);
1- (5- (2,2-difluoro-2-phenylethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1- Yl) propan-2-ol (119);
1- (5- (2- (4- (difluoromethoxy) phenyl) -2,2-difluoroethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3 -(1H-tetrazol-1-yl) propan-2-ol (120);
1- (5- (2- (4-chlorophenyl) -2,2-difluoroethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H- Tetrazol-1-yl) propan-2-ol (121);
4- (2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) Oxy) -1,1-difluoroethyl) benzonitrile (122);
1- (5- (2- (4- (difluoromethoxy) phenyl) -2-fluoroethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- ( 1H-tetrazol-1-yl) propan-2-ol (123); or 2- (2,4-difluorophenyl) -1,1-difluoro-1- (5- (2-fluoro-2-phenylethoxy) Pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (124).

  In another aspect, the present invention provides an agricultural composition comprising a compound of formula I and an agriculturally acceptable carrier.

  In other embodiments, the invention provides a compound of any of the formulas herein that inhibits (or is identified as inhibiting) lanosterol demethylase (CYP51).

  In other embodiments, the present invention relates to target organisms (eg, C. albicans minimum inhibitory concentration (MIC) <0.25 microgram / milliliter (μg / mL)); S. tritici minimum inhibitory concentration (MIC) <0.5 microgram / milliliter (μg / mL); Provided are compounds of any of the formulas herein, identified as having a range of activity against triticina (P. trisitina) minimal inhibitory concentration (MIC) <0.5 μg / mL (μg / mL).

  In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier.

  In other embodiments, the invention includes contacting a subject with a compound of any of the formulas herein (eg, Formula I) under an amount and under conditions sufficient to modulate metalloenzyme activity. Provides a method for modulating metalloenzyme activity.

  In certain embodiments, the invention suffers from a metalloenzyme-related disease or disorder comprising administering to a subject an effective amount of any compound of the formulas herein (eg, Formula I) or a pharmaceutical composition thereof. A method of treating a subject who is or is susceptible to disease is provided.

  In another aspect, the invention provides a method of treating a subject suffering from or susceptible to a metalloenzyme related disorder or disease, wherein the subject is in need of treatment for a metalloenzyme related disorder or disease. A compound of any of the formulas herein (e.g., Formula I) or a pharmaceutical thereof, as identified and to a subject in need thereof so that the subject is treated for a metalloenzyme-related disorder or disease A method is provided comprising administering an effective amount of the composition.

  In another aspect, the invention provides a method of treating a subject suffering from or susceptible to a metalloenzyme mediated disorder or disease, wherein the subject is in need of treatment for a metalloenzyme mediated disorder or disease. In order to modulate the metalloenzyme activity in this subject (eg down-regulation, inhibition), the subject in need thereof has any compound of the formulas herein (eg Formula I) or There is provided a method comprising administering an effective amount of the pharmaceutical composition.

  The methods herein include 4-hydroxyphenylpyruvate dioxygenase, 5-lipoxygenase, adenosine deaminase, alcohol dehydrogenase, aminopeptidase N, angiotensin converting enzyme, aromatase (CYP19), calcineurin, carbamoyl phosphate. Synthetase, carbonic anhydrase family, catechol-O-methyltransferase, cyclooxygenase family, dihydropyrimidine dehydrogenase-1, DNA polymerase, farnesyl diphosphate synthase, farnesyl transferase, fumarate reductase, GABA aminotransferase, HIF-prolyl hydroxylase, histone Deacetylase family, HIV integrase, HI -1 reverse transcriptase, isoleucine tRNA ligase, lanosterol demethylase (CYP51), matrix metalloprotease family, methionine aminopeptidase, neutral endopeptidase, nitric oxide synthase family, phosphodiesterase III, phosphodiesterase IV, phosphodiesterase V, pyruvate ferredoxin oxide Including those mediated by reductase, kidney peptidase, ribonucleoside diphosphate reductase, thromboxane synthase (CYP5a), thyroid peroxidase, tyrosinase, urease or xanthine oxidase.

  The methods herein include 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), 17-α hydroxylase (CYP17), aldosterone synthase (CYP11B2), aminopeptidase P, Anthrax lethal factor, arginase, β-lactamase, cytochrome P450 2A6, D-Ala D-Ala ligase, dopamine β-hydroxylase, endothelin converting enzyme-1, glutamate carboxypeptidase II, glutaminyl cyclase, glyoxalase, heme oxygenase , HPV / HSV E1 helicase, indoleamine 2,3-dioxygenase, leukotriene A4 hydrolase, methionine aminopeptidase 2, peptide deformylase, phosphodiesterase VII, relaxase, retinoic acid hydroxylase (CYP26), TNF-α converting enzyme (TACE), UDP- (3-O- (R-3-hydroxymyristoyl))-N-acetylglucosamine deacetylase (LpxC), Including those mediated by either vascular adhesion protein-1 (VAP-1) or vitamin D hydroxylase (CYP24).

  The method herein is such that the disease or disorder is cancer, cardiovascular disease, inflammatory disease, infectious disease, metabolic disease, ophthalmic disease, central nervous system (CNS) disease, urological disease or gastrointestinal disease including.

  The methods herein include those in which the disease or disorder is prostate cancer, breast cancer, inflammatory bowel disease, psoriasis, systemic fungal infection, skin structure fungal infection, mucosal fungal infection or onychomycosis.

  The methods described herein include those in which a subject is identified as requiring a specific defined treatment. Identifying a subject in need of such treatment can be at the discretion of the subject or medical professional, and can be subjective (eg, opinion) or objective (eg, measurable by a test or diagnostic method).

  Another aspect of the present invention is a composition comprising a compound of the formula (eg, Formula I) herein and an agriculturally acceptable carrier.

  Another aspect of the invention is a method of treating or preventing a metalloenzyme mediated disease or disorder in or on a plant comprising contacting the plant with a compound herein.

  Another aspect of the invention is a method of inhibiting metalloenzyme activity in or on a plant comprising contacting a compound herein with the plant.

DETAILED DESCRIPTION Definitions In order that the present invention may be more readily understood, certain terms are first defined herein for convenience.

  As used herein, the term “treating” a disorder includes preventing, ameliorating, alleviating and / or managing the disorder and / or a condition that can cause the disorder. The terms “treat” and “treatment” refer to methods of alleviating or alleviating a disease and / or its attendant symptoms. According to the present invention, “treating” means, for example, preventing, blocking, inhibiting, attenuating, preventing, modulating, reversing effects and reducing the appearance of harmful effects of a disorder. Including.

  As used herein, “inhibit” includes preventing, reducing, and stopping progression. Note that “enzyme inhibition” (eg, metalloenzyme inhibition) is distinguished and described below.

  The term “modulate” refers to increasing or decreasing the activity of an enzyme in response to exposure to a compound of the invention.

  The terms “isolated”, “purified” or “biologically pure” substantially or essentially includes components that normally accompany a substance when found in the native state of the substance. Refers to no substance. Purity and homogeneity are usually determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. In particular, in embodiments, the compound is at least 85% pure, more preferably at least 90% pure, more preferably at least 95% pure, and most preferably at least 99% pure.

  The term “administration” or “administering” includes the route of introducing a compound into a subject in order to exert the intended function of the compound. Examples of routes of administration that can be used include injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal), topical, oral, inhalation, rectal and transdermal.

  The term “effective amount” includes an amount that is effective at the time of administration and over the time required to achieve the desired result. The effective amount of the compound can vary depending on factors such as the disease state, age and weight of the subject and the ability of the compound to elicit the desired response in the control. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount can also be a therapeutically beneficial effect that exceeds any toxic or harmful effects (eg, side effects) of the inhibitor compound.

  The phrases “systemic administration”, “systemic administration”, “peripheral administration” and “peripheral administration” as used herein refer to compounds, drugs or other substances that are Means administration of a compound, drug or other substance that enters and is thus subject to metabolism and other similar processes.

  The term “therapeutically” or “agriculturally effective amount” refers to an administered compound sufficient to prevent or alleviate to some extent one or more of the symptoms of the condition or disorder being treated. Refers to the quantity.

  The therapeutically effective amount (ie, effective dose) of the compound is in the range of about 0.005 micrograms / kilogram (μg / kg) to about 200 milligrams / kilogram (mg / kg), preferably about 0.01 mg / kg. To about 200 mg / kg, more preferably about 0.015 mg / kg to about 30 mg / kg body weight. In other embodiments, the therapeutically effective amount can range from about 1.0 picomolar (pM) to about 10 μM. The skilled person effectively controls the subject with certain factors, including but not limited to the severity of the disease or disorder, the treatment received previously, the overall health status and / or the age of the subject and other diseases present. It will be appreciated that the dosage required to treat can be affected. Moreover, treatment of a subject with a therapeutically effective amount of a compound can include a single treatment or, preferably, can include a series of treatments. In one example, the subject is about 0. 0 once a day for about 1 to 10 weeks, preferably about 2 to 8 weeks, more preferably about 3 to 7 weeks and also more preferably about 4, 5 or 6 weeks. Treated with compounds ranging between 005 μg / kg to about 200 mg / kg body weight. In another example, a subject can be treated daily for several years in the case of a chronic condition or disease. It will also be appreciated that the effective dosage of the compound used in the treatment may increase or decrease over the course of a particular treatment.

  The term “chiral” refers to molecules that have non-superimposable properties of their mirror image partners, while the term “achiral” refers to molecules that are superimposable to their mirror image partners.

  The term “diastereomers” refers to stereoisomers with two or more asymmetric centers and the molecules are not mirror images of one another.

  The term “enantiomer” refers to two stereoisomers of a compound whose mirror images are not superimposable. An equimolar mixture of two enantiomers is called a “racemic mixture” or “racemic compound”.

  The terms “isomer” or “stereoisomer” refer to compounds that have the same chemical configuration but differ with respect to the arrangement of their atoms or groups in space.

  The term “prodrug” includes compounds with moieties that can be metabolized in vivo. In general, prodrugs are metabolized in vivo by esterases or by other mechanisms for active drugs. Examples of prodrugs and their uses are well known in the art (see, eg, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66: 1-19). Prodrugs can be prepared in situ during the final isolation and purification of the compound or by reacting the purified compound individually with its free acid form or hydroxyl with an appropriate esterifying agent. Hydroxyl groups can be converted to esters via treatment with carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branched or unbranched lower alkyl ester moieties (eg, propionic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (eg, dimethylamino). Ethyl ester), acylamino lower alkyl ester (eg acetyloxymethyl ester), acyloxy lower alkyl ester (eg pivaloyloxymethyl ester), aryl ester (phenyl ester), aryl-lower alkyl ester (eg benzyl ester), substituted ( Aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides and hydroxy amides (for example with methyl, halo or methoxy substituents). Preferred prodrug moieties are propionic acid esters and acyl esters. Also included are prodrugs that are converted to active forms in vivo through other mechanisms. In an embodiment, the compounds of the invention are prodrugs of any of the formulas herein.

  The term “subject” refers to animals such as mammals including, but not limited to, primates (eg, humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, and the like. In certain embodiments, the subject is a human.

  The terms “a”, “an” and “the” as used herein, including the claims, refer to “one or more”. Thus, for example, reference to “a sample” includes a plurality of samples, unless the context clearly indicates otherwise (eg, multiple of samples), and so forth.

  Throughout this application and the claims, the terms “comprise”, “comprises”, and “comprising” are used in a comprehensive sense unless the context demands otherwise. The

  As used herein, the term “about” when referring to a value, from a specified amount, is ± 20% in some embodiments, ± 10% in some embodiments, some It is intended to encompass variations of ± 5% in embodiments, ± 1% in some embodiments, ± 0.5% in some embodiments, and ± 0.1% in some embodiments, and so on. Such variations are appropriate for performing the disclosed methods or using the disclosed compositions.

  The use of the term “inhibitor” herein is intended to mean a molecule that exhibits activity for inhibiting metalloenzymes. As used herein, “inhibit” shall reduce the activity of a metalloenzyme compared to the activity of the metalloenzyme in the absence of an inhibitor. In some embodiments, the term “inhibit” means at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 50%, at least about 60%, at least about 70%, By a reduction in metalloenzyme activity of at least about 80%, at least about 90% or at least about 95%. In other embodiments, inhibiting means a reduction in metalloenzyme activity of about 5% to about 25%, about 25% to about 50%, about 50% to about 75%, or about 75% to 100%. To do. In some embodiments, inhibiting means a reduction in metalloenzyme activity of about 95% to 100%, such as a reduction in activity of 95%, 96%, 97%, 98%, 99% or 100%. To do. Such reduction can be measured using various techniques that are recognizable by those skilled in the art. Specific assays for measuring individual activities are described below.

  Further, the compounds of the present invention include olefins having either configuration: “Z” refers to what is referred to as the “cis” (same side) configuration, while “E” refers to “trans” (reverse) Side) Refers to what is called a configuration. With respect to asymmetric center nomenclature, the terms “d” and “l” configuration are as defined by IUPAC Recommendations. With respect to the use of the terms diastereomers, racemates, epimers and enantiomers, these are used in their usual context to describe the stereochemistry of the preparation.

As used throughout this application, the term "R", unless otherwise specified, _{C 1} - refers to _{C8 alkyl,} the group consisting of _{C 2-8} alkenyl or _{C 2-8} alkynyl.

As used herein. The term “alkyl” refers to a straight or branched hydrocarbon group containing 1 to 12 carbon atoms. The term “lower alkyl” refers to a C ₁ -C ₆ alkyl chain. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, tert-butyl and n-pentyl. An alkyl group can be optionally substituted with one or more substituents.

  The term “haloalkyl” refers to an alkyl group that is substituted with one or more halo substituents. Examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, chloromethyl and 2,2,2-trifluoroethyl.

  The term “alkenyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing from 2 to 12 carbon atoms and at least one carbon-carbon double bond. An alkenyl group can be optionally substituted with one or more substituents.

  The term “alkynyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon triple bond. An alkynyl group can be optionally substituted with one or more substituents.

The sp ² or sp carbons of the alkenyl group and alkynyl group can each optionally be the point of attachment of the alkenyl or alkynyl group.

  The term “alkoxy” refers to an —OR substituent.

  As used herein, the term “halogen”, “hal” or “halo” means —F, —Cl, —Br or —I.

  The term “haloalkoxy” refers to an —OR substituent, wherein R is fully or partially substituted with Cl, F, I or Br or any combination thereof. Examples of haloalkoxy groups include trifluoromethoxy and 2,2,2-trifluoroethoxy.

  The term “cycloalkyl” is a hydrocarbon 3-8 membered monocyclic having at least one saturated ring or having at least one non-aromatic ring, which may have some degree of unsaturation. Or refers to a 7-14 membered bicyclic ring system. Cycloalkyl groups can be optionally substituted with one or more substituents. In certain embodiments, 0, 1, 2, 3 or 4 atoms of each ring of the cycloalkyl group can be substituted with a substituent. Representative examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.

  The term “aryl” refers to a hydrocarbon monocyclic, bicyclic or tricyclic aromatic ring system. Aryl groups can be optionally substituted with one or more substituents. In certain embodiments, 0, 1, 2, 3, 4, 5 or 6 atoms of each ring of the aryl group can be substituted with a substituent. Examples of the aryl group include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl and the like.

  The term “heteroaryl” refers to 1 to 4 ring heteroatoms if monocyclic, 1 to 6 heteroatoms if bicyclic, or 1 to 9 if tricyclic. An aromatic 5-8 membered single atom having a heteroatom, wherein the heteroatom is selected from O, N or S and the remaining ring atoms are carbon (unless otherwise noted). Refers to a cyclic, 8-12 membered bicyclic or 11-14 membered tricyclic ring system. A heteroaryl group can be optionally substituted with one or more substituents. In certain embodiments, 0, 1, 2, 3 or 4 atoms of each ring of the heteroaryl group can be substituted with a substituent. Examples of heteroaryl groups include pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl, indazolyl and the like.

  The term “nitrogen containing heteroaryl” refers to 1 to 4 ring nitrogen heteroatoms if monocyclic, 1 to 6 ring nitrogen heteroatoms if bicyclic or tricyclic Refers to a heteroaryl group having 1 to 9 ring nitrogen heteroatoms.

  The term “heterocycloalkyl” refers to 1 to 3 heteroatoms in the case of monocyclic, 1 to 6 heteroatoms in the case of bicyclic or 1 to 9 heteroatoms in the case of tricyclic. A non-aromatic 3-8 membered monocyclic, 7-12 membered bicyclic or 10-14 membered tricyclic ring system, wherein the heteroatom is selected from O, N, S, B, P or Si Where the non-aromatic ring system is fully saturated. A heterocycloalkyl group can be optionally substituted with one or more substituents. In certain embodiments, 0, 1, 2, 3 or 4 atoms of each ring of the heterocycloalkyl group can be substituted with a substituent. Representative heterocycloalkyl groups include piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,3-dioxolane, tetrahydrofuranyl, tetrahydrothienyl, thylenyl and the like.

  The term “alkylamino” refers to an amino substituent that is further substituted with one or two alkyl groups. The term “aminoalkyl” refers to an alkyl substituent that is further substituted with one or more amino groups. The term “hydroxyalkyl” or “hydroxylalkyl” refers to an alkyl substituent that is further substituted with one or more hydroxyl groups. The alkyl or aryl portion of alkylamino, aminoalkyl, mercaptoalkyl, hydroxyalkyl, mercaptoalkoxy, sulfonylalkyl, sulfonylaryl, alkylcarbonyl and alkylcarbonylalkyl can be optionally substituted with one or more substituents.

  Acids and bases useful in the methods herein are known in the art. An acid catalyst is any acidic chemical, in fact inorganic (eg hydrochloric acid, sulfuric acid, nitric acid, aluminum trichloride) or organic (eg camphorsulfonic acid, p-toluenesulfonic acid, acetic acid, ytterbium (III) triflate). obtain. The acid is useful in either catalytic or stoichiometric amounts to promote chemical reactions. The base is any basic chemical, and may actually be inorganic (eg sodium bicarbonate, potassium hydroxide) or organic (eg triethylamine, pyridine). The base is useful in either a catalytic amount or a stoichiometric amount to promote the chemical reaction.

An alkylating agent is any reagent that can achieve alkylation of the functional group in question (eg, oxygen atom of alcohol, nitrogen atom of amino group). Alkylating agents are known in the art, including those in the references cited herein, and are known in the art to alkyl halides such as methyl iodide, benzyl bromide or benzyl chloride. ), Alkyl sulfates (eg methyl sulfate) or other alkyl group-leaving group combinations. A leaving group is any stable species that can be removed from a molecule during a reaction (eg, elimination reaction, substitution reaction), and is known in the art, including those in the references cited herein. Halides (eg I-, Cl-, Br-, F-), hydroxy, alkoxy (eg -OMe, -Ot-Bu), acyloxy anions (eg -OAc, -OC (O) CF) ₃ ), sulfonates (eg mesyl, tosyl), acetamides (eg -NHC (O) Me), carbamates (eg N (Me) C (O) Ot-Bu), phosphonates (eg -OP (O) (OEt) ₂ ), Water or alcohol (protic conditions).

  In certain embodiments, substituents on any group (eg, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl, etc.) can be at any atom of the group. Any group that may be substituted (eg, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl, etc.) optionally with one or more (same or different) substituents Each may replace a hydrogen atom. Examples of suitable substituents include alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, Oxo (ie carbonyl), carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl, amino, amino Alkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkoxycarbonylamino, Aryl substituted with killiamino, arylamino, diarylamino, alkylcarbonyl or arylamino; arylalkylamino, aralkylaminocarbonyl, amide, alkylaminosulfonyl, arylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, Examples include, but are not limited to, imino, carbamide, carbamyl, thioureido, thiocyanate, sulfoamide, sulfonylalkyl, sulfonylaryl, mercaptoalkoxy, N-hydroxyamidinyl or N′-aryl, N ″ -hydroxyamidinyl. .

The compounds of the present invention can be made by means known in the art of organic synthesis. Methods for optimizing reaction conditions that minimize competing by-products as needed are known in the art. Reaction optimization and scale-up, advantageously, may utilize fast parallel synthesis apparatus and a computer control the microreactor ^{(e.g., Design And Optimization in Organic Synthesis,} 2 nd Edition, Carlson R, Ed, 2005; Elsevier Science Ltd .; Jahnisch, K et al., Angew. Chem. Int. Ed. Engl. 2004, 43, 406; Further reaction schemes and protocols can be found in commercially available structure searchable database software, such as SciFinder® (Chemical Abstracts Service (CAS®) division of the American Chemical Society) and CrossFilleB® trademark. MDL) or by a suitable keyword search using an internet search engine such as Google® or by a keyword database such as the US Patent and Trademark Office text database.

  The compounds herein may also contain linkages (eg carbon-carbon bonds) in which the bond rotation is restricted around a particular linkage, for example due to the presence of rings or double bonds. Thus, all cis / trans and E / Z isomers are expressly included in the present invention. The compounds herein may also be expressed in multiple tautomeric forms, and in such cases, the present invention clearly expresses the present specification even though only one tautomeric form may be shown. Includes all tautomeric forms of the compounds described therein. All such isomeric forms of such compounds herein are expressly included in the present invention. All crystal forms and polymorphs of the compounds described herein are expressly included in the present invention. Extracts and fractions containing the compounds of the invention are also encompassed. The term “isomer” is intended to include diastereoisomers, enantiomers, positional isomers, structural isomers, rotational isomers, tautomers and the like. In the case of compounds containing one or more stereocenters, for example chiral compounds, the process according to the invention can be carried out using enantiomerically enriched compounds, racemates or mixtures of diastereomers.

  Compounds enriched for preferred enantiomers are over 50% in enantiomeric excess, more preferably the compounds are enantiomerically over 60%, 70%, 80%, 90%, 95%, 98% or 99% over It is. In preferred embodiments, only one enantiomer or diastereomer of a chiral compound of the invention is administered to a cell or subject.

  In another aspect, the present invention provides a method of synthesizing a compound of formula I (or any of the formulas herein) as described herein. Another embodiment is a method of making a compound of any of the formulas herein using any one or combination of the reactions described herein. The method can include the use of one or more intermediates or chemical reagents described herein.

Methods of Treatment In certain embodiments, the present invention provides a compound as described herein (eg, of any formula herein) in an amount and under conditions sufficient to modulate metalloenzyme activity. A method of modulating cellular metalloenzyme activity in a subject comprising contacting the subject with the subject.

  In certain embodiments, the modulation is inhibition.

  In another embodiment, the invention administers to a subject an effective amount of a compound as described herein (eg, of any formula herein) or a pharmaceutical or agricultural composition thereof. A method of treating a subject suffering from or susceptible to a metalloenzyme mediated disorder or disease.

  In other embodiments, the invention identifies a method of treating a subject suffering from or susceptible to a metalloenzyme mediated disorder or disease, wherein the subject is in need of treatment for a metalloenzyme mediated disorder or disease. Effective amount of a compound as described herein (eg, of any formula herein) such that the subject is treated for the disorder Or a method comprising administering a pharmaceutical or agricultural composition thereof.

  In certain embodiments, the present invention provides a method of treating a disease, disorder or symptom thereof, wherein the disorder is cancer, cardiovascular disease, inflammatory disease or infectious disease. . In other embodiments, the disease, disorder, or symptom thereof is a metabolic disease, ophthalmic disease, central nervous system (CNS) disease, urinary disease, or gastrointestinal disease. In certain embodiments, the disease is prostate cancer, breast cancer, inflammatory bowel disease, psoriasis, systemic fungal infection, skin structure fungal infection, mucosal fungal infection and onychomycosis.

  In certain embodiments, the subject is a mammal, preferably a primate or a human.

  In another embodiment, the present invention provides a method as described above, wherein the effective amount of a compound as described herein (eg, of any formula herein) is as described above. provide.

  In another embodiment, the invention provides that a compound as described herein (eg, of any formula herein) is intravenous, intramuscular, subcutaneous, intraventricular, oral or topical. A method as described above is administered.

  In other embodiments, the invention provides administration of a compound as described herein (eg, of any formula herein) alone or in combination with one or more other therapeutic agents. A method as described above is provided. In a further embodiment, the additional therapeutic agent is an anticancer agent, antifungal agent, cardiovascular agent, anti-inflammatory agent, chemotherapeutic agent, antiangiogenic agent, cytotoxic agent, antiproliferative agent, metabolic disease agent, ophthalmic disease agent, It is a central nervous system (CNS) disease agent, urological disease agent or gastrointestinal disease agent.

  Another object of the present invention is to provide a compound as described herein (eg of any formula herein) in the manufacture of a medicament for use in the treatment of a metalloenzyme mediated disorder or disease. ). Another object of the present invention is the use of a compound as described herein (eg of any formula herein) for use in the treatment of a metalloenzyme mediated disorder or disease. is there. Another object of the invention is a compound as described herein in the manufacture of an agricultural composition for use in the treatment or prevention of a metalloenzyme mediated disorder or disease in an agricultural or agricultural setting. (Eg, of any formula in this specification).

Pharmaceutical Compositions In certain embodiments, the present invention includes a pharmaceutical composition comprising a compound as described herein (eg, of any formula herein) and a pharmaceutically acceptable carrier. I will provide a.

  In another embodiment, the present invention provides a pharmaceutical composition further comprising an additional therapeutic agent. In a further embodiment, the additional therapeutic agent is an anticancer agent, antifungal agent, cardiovascular agent, anti-inflammatory agent, chemotherapeutic agent, antiangiogenic agent, cytotoxic agent, antiproliferative agent, metabolic disease agent, ophthalmic disease agent, It is a central nervous system (CNS) disease agent, urological disease agent or gastrointestinal disease agent.

  In certain embodiments, the present invention administers the present compounds to a subject suffering from or susceptible to a metalloenzyme-mediated disease or disorder, including cancer, solid tumors, cardiovascular diseases, inflammatory diseases, infectious diseases A kit comprising an effective amount of a compound as described herein (eg, of any formula herein) in a unit dosage form is provided. In other embodiments, the disease, disorder, or symptom thereof is a metabolic disease, ophthalmic disease, central nervous system (CNS) disease, urinary disease, or gastrointestinal disease.

  The term “pharmaceutically acceptable salt” or “pharmaceutically acceptable carrier” refers to a relatively non-toxic acid or compound, depending on the particular substituents found on the compounds described herein. It is intended to include salts of the active compounds prepared with a base. Where a compound of the invention contains a relatively acidic functional group, the neutral form of such compound is contacted with a sufficient amount of the desired base, either in the stock solution or in a suitable inert solvent. Thus, a base addition salt can be obtained. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. If the compound of the present invention contains a relatively basic functional group, contact a sufficient amount of the desired acid with the neutral form of such compound, either in the stock solution or in a suitable inert solvent. Acid addition salts can be obtained. Examples of pharmaceutically acceptable acid addition salts include hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogen carbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, monohydrogen sulfate, hydroiodic acid Or those derived from inorganic acids such as phosphorous acid, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzene Examples include salts derived from relatively non-toxic organic acids such as sulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid and the like. Also included are salts of amino acids such as alginates and salts of organic acids such as glucuronic acid or galactonic acid (see, for example, Berge et al., J. Pharm. Sci. 1977, 66, 1-19). . Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those skilled in the art are suitable for the present invention.

  The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but this salt is different from the parent form of the compound for the purposes of the present invention. It is equivalent.

  In addition to salt forms, the present invention provides compounds that are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

  Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

  The present invention also provides a pharmaceutical composition comprising an effective amount of a compound described herein and a pharmaceutically acceptable carrier. In embodiments, at least 12 hours, 24 hours, 36 hours, 48 hours, 1 week, 2 weeks after a pharmaceutically acceptable formulation, eg, a pharmaceutically acceptable formulation, is administered to a subject, The compound is administered to the subject using a pharmaceutically acceptable formulation that provides for sustained delivery of the compound to the subject over 3 or 4 weeks.

  The actual dosage level and series of administrations of the active ingredients in the pharmaceutical composition of the present invention will result in the desired treatment for a particular patient, composition and mode of administration without becoming toxic (or unacceptable) to the patient. It can be varied to obtain an amount of active ingredient that is effective to achieve the reaction.

  When used, at least one compound according to the invention is administered in a pharmaceutically effective amount to a subject in need thereof in a pharmaceutical carrier by intravenous, intramuscular, subcutaneous or intracerebral injection, or by oral administration or topical application. Be administered. According to the present invention, the compounds of the present invention can be administered alone or in combination with a second different therapeutic agent. “In combination” shall be taken together, substantially simultaneously or sequentially. In certain embodiments, the compounds of the invention are administered urgently. Accordingly, the compounds of the invention can be administered for short courses of treatment, such as from about 1 day to about 1 week. In another embodiment, the compounds of the invention can be administered over a longer period of time to ameliorate a chronic disorder, eg, from about 1 week to several months depending on the condition to be treated.

  “Pharmaceutically effective amount” as used herein is sufficiently high to adjust the condition to be treated in a significantly better way within the scope of sound medical judgment, By an amount of a compound of the invention that is low enough (a reasonable benefit / risk ratio) to avoid serious side effects. A pharmaceutically effective amount of a compound of the invention seeks to achieve, such as the age and health of the patient being treated, the severity of the underlying disease, the length of the treatment period, the combination therapy and the nature of the particular compound used. Varies depending on the specific purpose to be. For example, a therapeutically effective amount of a compound of the invention administered to a child or neonate is proportionally reduced according to sound medical judgment. Thus, an effective amount of a compound of the invention is the minimum amount that provides the desired effect.

  A crucial advantage of the present invention is that the compound can be administered in a conventional manner, such as by intravenous, intramuscular, subcutaneous, oral or intracerebral injection route, or by topical application such as a cream or gel. Depending on the route of administration, the active ingredient comprising the compound of the invention must be coated with a material to protect the compound from the action of enzymes, acids and other natural conditions that can inactivate the compound. possible. To administer a compound of the present invention other than by parenteral administration, the compound can be coated with, or administered with, a material to prevent inactivation.

  The compound can be administered parenterally or intraperitoneally. Dispersions can also be prepared, for example, in glycerol, liquid polyethylene glycols and mixtures thereof, and in oils.

  Some examples of substances that can be pharmaceutical carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth Malt; gelatin; talc; stearic acid; magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and theobroma oil; polyols such as propylene glycol, glycerin, sorbitol, mannitol and polyethylene glycol Agar; alginic acid; pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; Other compatible materials nontoxic to be used in, is, for example vitamin C, such as estrogen and echinacea. Wetting agents and lubricants such as sodium lauryl sulfate and the like, as well as colorants, flavoring agents, lubricants, excipients, tableting agents, stabilizers, antioxidants and preservatives may also be present. . Solubilizing agents can also be used in the pharmaceutical compositions herein, including, for example, cremaphor and β-cyclodextrin.

  A pharmaceutical composition comprising the active compound (or prodrug thereof) of the presently disclosed subject matter is manufactured by a conventional mixing, solubilization, granulation, dragee preparation, emulsification, encapsulation, encapsulation or lyophilization process. obtain. The compositions are formulated in a conventional manner with one or more physiologically acceptable carriers, diluents, excipients or adjuvants that facilitate processing of the active compound into a pharmaceutically usable formulation. Can be prescribed in

  The pharmaceutical compositions of the presently disclosed subject matter are in a form or inhalation or insufflation suitable for virtually any mode of administration, including, for example, topical, ocular, oral, buccal, systemic, nasal, injection, transdermal, rectal, vaginal, etc. May take a form suitable for administration by

  For topical administration, the active compound or prodrug may be formulated as a solution, gel, ointment, cream, suspension, etc.

  Systemic formulations are designed for administration by injection, for example subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as for transdermal, transmucosal, oral or pulmonary administration. Including those designed.

  Useful injectable formulations include sterile suspensions, solutions or emulsions of the active compound in aqueous or oily vehicles. The composition may also contain formulating agents such as suspending, stabilizing and / or dispersing agents. Injectable formulations may exist in unit dosage form (eg, in ampoules or multiple dose containers) and contain added preservatives.

  Alternatively, injectable formulations may be provided in powder form for reconstitution with an appropriate vehicle, including but not limited to sterile pyrogen-free water, buffers, dextrose solutions, etc. prior to use. To accomplish this goal, the active compound can be dried and reconstituted prior to use by any technique known in the art, such as lyophilization.

  For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art.

  For oral administration, the pharmaceutical composition comprises, for example, a binder (eg pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose); a filler (eg lactose, microcrystalline cellulose or calcium hydrogen phosphate); a lubricant ( Prepared by conventional means together with pharmaceutically acceptable excipients such as disintegrants (eg potato starch or sodium starch glycolate); or wetting agents (eg sodium lauryl sulfate); Or in the form of medicinal candies, tablets or capsules. The tablets may be coated by methods well known in the art, for example with sugars or enteric coatings.

  Liquid formulations for oral administration may take the form of, for example, elixirs, solutions, syrups or suspensions, or these are dry products for constitution with water or other suitable vehicle prior to use. It can be given as a thing. Such liquid formulations include suspension agents (eg, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifiers (eg, lecithin or acacia); non-aqueous vehicles (eg, almond oil, oily esters, ethyl alcohol or Fractionated vegetable oils); and pharmaceutically acceptable additives such as preservatives (eg methyl or propyl p-hydroxybenzoate or sorbic acid) may be prepared by conventional means. The formulation may also contain buffer salts, preservatives, flavoring agents, coloring agents and sweetening agents as desired.

  Formulations for oral administration may be suitably formulated to give controlled release of the active compound or prodrug, as is well known.

  For buccal administration, the composition may take the form of tablets or medicated candy formulated in a conventional manner.

  For the rectal and vaginal routes of administration, the active compounds may be formulated as solutions (in the case of retention enemas), suppositories or ointments containing conventional suppository bases such as cocoa butter or other glycerides.

  For nasal administration or administration by inhalation or insufflation, the active compound or prodrug contains an appropriate propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, fluorocarbon, carbon dioxide or other suitable gas. In use, it can be conveniently delivered in the form of an aerosol spray from a pressurized pack or nebulizer. In the case of a pressurized aerosol, the dosage unit can be determined by providing a value to deliver a metered amount. Capsules and cartridges for use in inhalers or inhalers (eg, capsules and cartridges composed of gelatin) may be formulated containing a powder mixture of the compound and a suitable powder base such as lactose or starch. .

  Specific examples of aqueous suspension formulations suitable for nasal administration using commercially available nasal spray devices include the following ingredients: active compound or prodrug (0.5 to 20 mg / mL); benzalkonium chloride (0.1 To 0.2 mg / mL); polysorbate 80 (TWEEN® 80; 0.5 to 5 mg / mL); sodium carboxymethylcellulose or microcrystalline cellulose (1 to 15 mg / mL); phenylethanol (1 to 4 mg / mL) ); And dextrose (20 to 50 mg / mL). The pH of the final suspension can be adjusted in the range of about pH 5 to pH 7, with about pH 5.5 being typical.

  For ocular administration, the active compounds or prodrugs may be formulated as solutions, emulsions, suspensions, etc. suitable for ocular administration. A variety of vehicles suitable for ocular administration of compounds are known in the art. Specific non-limiting examples include US Pat. No. 6,261,547; US Pat. No. 6,197,934; US Pat. No. 6,056, each incorporated herein by reference in its entirety. U.S. Patent No. 5,800,807; U.S. Patent No. 5,776,445; U.S. Patent No. 5,698,219; U.S. Patent No. 5,521,222; 841; US Pat. No. 5,077,033; US Pat. No. 4,882,150; and US Pat. No. 4,738,851.

  For sustained delivery, the active compound or prodrug can be formulated as a depot for administration by implant or intramuscular injection. The active ingredient may be formulated with a suitable polymeric or hydrophobic material (eg, as an emulsion in an acceptable oil) or ion exchange resin, or as a poorly soluble derivative, eg, a poorly soluble salt. Alternatively, transdermal delivery systems manufactured as an adhesive disc or patch that slowly releases the active compound for transdermal absorption can be used. For this purpose, penetration enhancers can be used to facilitate transdermal penetration of the active compound. Suitable transdermal patches are, for example, US Pat. No. 5,407,713; US Pat. No. 5,352,456; US Pat. No. 5,332, each incorporated herein by reference in its entirety. U.S. Patent No. 5,336,168; U.S. Patent No. 5,290,561; U.S. Patent No. 5,254,346; U.S. Patent No. 5,164,189; U.S. Patent No. 5,163. U.S. Pat. No. 5,088,977; U.S. Pat. No. 5,087,240; U.S. Pat. No. 5,008,110; and U.S. Pat. No. 4,921,475.

  Alternatively, other pharmaceutical delivery systems can be used. Liposomes and emulsions are well known examples of delivery vehicles that can be used to deliver active compounds or prodrugs. Certain organic solvents such as dimethyl sulfoxide (DMSO) can also be used.

  The pharmaceutical compositions may be given in packs or dispenser devices that may contain one or more unit dosage forms containing the active compound, as appropriate. The pack may include, for example, metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration.

  The active compounds or prodrugs or compositions thereof of the presently disclosed subject matter are generally effective in treating or preventing the particular disease being treated, for example, in an amount effective to achieve the intended result. Used in large quantities. The compounds can be administered therapeutically to achieve therapeutic utility, or prophylactically to achieve prophylactic utility. Therapeutic utility is the eradication or amelioration of the underlying disorder being treated and / or symptoms associated with the underlying disorder, although the patient may still suffer from the underlying disorder, but the patient reports an improvement in mood or condition. Means one or more eradications or improvements. For example, administration of a compound to a patient suffering from an allergy reduces the severity or duration of allergic-related symptoms after exposure to allergens, as well as when the underlying allergic reaction is eradicated or ameliorated The patient also reports therapeutic benefit. As another example, therapeutic benefits associated with asthma include improved breathing after the onset of an asthma attack or reduced frequency or severity of asthma episodes. Therapeutic utility also includes halting or delaying disease progression, whether or not improvement is noticed.

  In the case of prophylactic administration, the compound may be administered to a patient at risk of developing one of the previously mentioned diseases. A patient at risk of developing a disease can be a patient having characteristics that distinguish the patient from a designated group of risk patients, as defined by an appropriate medical professional or group. A patient at risk can also be a patient in an environment where the development of an underlying disease that can be treated, generally or routinely, by administration of a metalloenzyme inhibitor according to the present invention. In other words, at-risk patients are those who can be exposed to a disease or disease-causing condition in general or on a daily basis, or can be exposed rapidly for a limited time. Alternatively, prophylactic administration can be applied to avoid the onset of symptoms in a patient diagnosed with an underlying disorder.

  The amount of compound administered will depend, for example, on the particular indication being treated, the mode of administration, the severity of the indication being treated, regardless of whether the desired utility is prophylactic or therapeutic. As well as a variety of factors including the age and weight of the patient, the bioavailability of the particular active compound, and the like. The determination of an effective dose is well within the ability of those skilled in the art.

Effective doses can be estimated initially from in vitro assays. For example, initial dosages for use in animals are specific compounds as measured in in vitro assays, such as in vitro fungal MIC or minimum fungal concentration (MFC) and other in vitro assays described in the Examples section. In order to achieve a circulating blood or serum concentration of the active compound that is an IC ₅₀ or higher. Calculation of dosages to achieve such circulating blood or serum concentrations, taking into account the bioavailability of a particular compound, is well within the ability of the skilled worker. As a guide, Fingl & Woodbury, “General Principles”, In: Goodman and Gilman's The Pharmaceutical Basis of Therapeutics 1, Chapter, incorporated herein by reference. 1-46, 12th edition, McGraw-Hill Professional and references cited therein.

  Initial dosages can also be estimated from in vivo data such as animal models. Animal models useful for testing the effectiveness of compounds for treating or preventing the various diseases described above are well known in the art.

  The dosage is generally in the range of about 0.0001 or 0.001 or 0.01 mg / kg / day to about 100 mg / kg / day, although among other factors the activity of the compound, its bio Depending on availability, mode of administration and the various factors discussed above, it can go up and down. Dosage amount and interval may be adjusted individually to provide plasma levels of the compound which are sufficient to maintain therapeutic or prophylactic effect. In cases of local administration or selective uptake, such as local administration, the effective local concentration of the active compound may not be related to plasma concentration. The skilled worker can optimize the effective local dosage without undue experimentation.

  The compound may be administered once a day, 2 to 3 times or 5 to 6 times a day, or more than once a day, depending on, inter alia, the indication being treated and the judgment of the prescribing physician. .

  Preferably, the compound provides therapeutic or prophylactic utility without causing substantial toxicity. The toxicity of the compound can be determined using standard pharmaceutical procedures. The dose ratio between toxic and therapeutic (or prophylactic) effects is a therapeutic index. Compounds that exhibit high therapeutic indices are preferred.

  Reference to a list of chemical groups in any definition of a variable herein includes the definition of that variable as any single group or combination of listed groups. Citation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. Citation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

Agricultural Application The compounds of formula I can be formulated into agriculturally acceptable acid addition salts. By way of non-limiting example, the amine functional group can be hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, citric acid, malonic acid, salicylic acid, malic acid, fumaric acid, oxalic acid, succinic acid, tartaric acid, lactic acid. It can form salts with gluconic acid, ascorbic acid, maleic acid, aspartic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxymethanesulfonic acid and hydroxyethanesulfonic acid. Further, according to non-limiting examples, the acid functional groups can form salts, including those derived from alkali or alkaline earth metals and those derived from ammonia and amines. Examples of preferred cations include sodium, potassium and magnesium.

  The compounds of formula I can be formulated into salt derivatives. According to a non-limiting example, a salt derivative can be prepared by contacting the free base with a sufficient amount of the desired acid to form a salt. The free base can be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium hydroxide (NaOH), potassium carbonate, ammonia and sodium bicarbonate. As an example, in many cases, insecticides such as 2,4-D are rendered more water soluble by conversion to their dimethylamine salts.

Suitable salts include those derived from alkali or alkaline earth metals and those derived from ammonia and amines. Preferred cations include sodium, potassium, magnesium and the formula:
R ¹⁰ R ¹¹ R ¹² R ¹³ N ⁺
In which R ¹⁰ , R ¹¹ , R ¹² and R ¹³ each independently represent hydrogen or C ₁ -C ₁₂ alkyl, C ₃ -C ₁₂ alkenyl or C ₃ -C ₁₂ alkynyl, Are each optionally substituted by one or more hydroxy, C ₁ -C ₄ alkoxy, C ₁ -C ₄ alkylthio or phenyl groups, provided that R ¹⁰ , R ¹¹ , R ¹² and R ¹³ are steric. For example). Further, any two of R ¹⁰ , R ¹¹ , R ¹² and R ¹³ together represent an aliphatic bifunctional moiety containing 1 to 12 carbon atoms and no more than 2 oxygen or sulfur atoms. obtain. The salt of the compound of formula I is a metal hydroxide such as sodium hydroxide, such as ammonia, trimethylamine, diethanolamine, 2-methylthiopropylamine, bisallylamine, 2-butoxyethylamine, morpholine, cyclododecylamine or benzylamine. It can be prepared by treatment of a compound of formula I with an amine or with a tetraalkylammonium hydroxide such as tetramethylammonium hydroxide or choline hydroxide. Amine salts are often the preferred form of compounds of Formula I because they are water soluble and as such are useful in preparing the desired aqueous based herbicidal compositions.

  The compounds and compositions herein modulate metalloenzyme activity in microorganisms in plants, including contacting a plant (eg, seed, seedling, grass, weed, cereal) with a compound herein. Can be used in the method. The compounds and compositions herein are administered to the subject plant, field or other agricultural area (eg, contacted, sprayed, sprayed, sprayed, sprinkled, etc.) ) Can be used to treat plants, fields, or other agricultural areas (eg, as herbicides, insecticides, growth regulators, etc.). Administration can be either before germination or after germination. Administration can be either a therapeutic or a prophylactic regime.

  One aspect is a method of treating or preventing a fungal disease or disorder in or on a plant comprising contacting a compound (or composition) of any of the formulas herein with the plant. Another aspect is a method of treating or preventing fungal growth in or on a plant comprising contacting the plant with a compound (or composition) of any of the formulas herein. Another aspect is a method of inhibiting a microorganism in or on a plant comprising contacting a compound (or composition) of any of the formulas herein with the plant.

  The compounds and compositions herein include in or on plants, including contacting the compounds herein with plants (eg, seeds, seedlings, grasses, weeds, cereals) or areas adjacent to plants. It can be used in a way to prevent or modulate pathogen-induced diseases. The compounds and compositions herein are administered to the subject plant, field or other agricultural area (eg, contacted, sprayed, sprayed, sprayed, sprinkled, etc.) ) Can be used to treat plants, fields or other agricultural areas. Administration can be either before germination or after germination. Administration can be either a therapeutic or a prophylactic regime. Thus, the compounds, compositions and agricultural applications herein include turf, lawn, foliage plants, home and garden, plantation, farmland and pasture applications. The pathogen can be any on the plant, including those described herein.

  Certain embodiments of the present disclosure include the application of a plant from attack by phytopathogenic organisms, including application of a compound of Formula I or a composition comprising the compound to soil, plants, plant parts, foliage and / or seeds. Use of a compound of formula I for the protection or treatment of plants infected with phytopathogenic organisms.

  Furthermore, another embodiment of the present disclosure includes a compound of Formula I and a plant-acceptable carrier material to protect plants from attack by phytopathogenic organisms and / or infect phytopathogenic organisms It is a composition useful for the treatment of cultivated plants.

  The compounds of the present disclosure can be applied by any of a variety of known techniques, either as compounds or as formulations containing the compounds. For example, the compounds can be applied to plant roots, seeds or foliage for the control of various fungi without damaging the commercial value of the plant.

  The compounds herein can be used alone or in combination with other agriculturally active agents. The use of the compounds or compositions (and compositions) herein includes epoxiconazole, tebuconazole, fluquinconazole, flutriahol, metconazole, microbutanyl, cycproconazole, prothioconazole and propiconazole. Further active agents such as azole fungicides selected from can further be included.

  The use of the compounds or compositions (and compositions) herein includes azole fungicides selected from the group of trifloxystrobin, pyraclostrobin, orisatrobin, floxastrobin and azoxystrobin, etc. Of additional active agents.

  Preferably, the compounds of the present disclosure are applied in the form of a formulation comprising one or more of the compounds of formula I together with an agriculturally or plantally acceptable carrier. Compositions containing the compounds herein are for example directly sprayable aqueous solutions, powders, suspensions, highly concentrated aqueous, oily or other suspensions or dispersions, emulsions, oily dispersions, pastes, It can be used by spraying, spraying, sprinkling or pouring in the form of dusts, materials for diffusion or granules.

  The present disclosure contemplates all vehicles in which one or more of the compounds can be formulated for delivery and use as a fungicide. Generally, the formulation is formulated as an aqueous suspension or emulsion. Aqueous use forms can be prepared from emulsion concentrates, suspensions, pastes, wettable powders or water-dispersible granules by adding water. To prepare emulsions, pastes or oil dispersions, materials that are neat or dissolved in oil or solvent can be homogenized in water with wetting agents, tackifying materials, dispersing agents or emulsifiers. However, it is also possible to prepare concentrates composed of active substances, wetting agents, tackifiers, dispersants or emulsifiers and, if necessary, solvents or oils, these concentrates in water Suitable for dilution.

  Wettable powders that can be shaped to produce water-dispersible granules include complete mixtures of one or more compounds of formula I, an inert carrier and a surfactant. The concentration of the compound in the wettable powder can be from about 10 weight percent to about 90 weight percent, more preferably from about 25 wt% to about 75 wt%, based on the total weight of the wettable powder. In the preparation of wettable powder formulations, the compound can be used in any refinement such as prophylite, talc, chalk, gypsum, fuller earth, bentonite, attapulgite, starch, casein, gluten, montmorillonite clay, diatomaceous earth, refined silicate, etc. Can be combined with solids. In such operations, the finely divided carrier and the surfactant are generally blended with the compound and ground.

  Granules such as coated granules, impregnated granules and uniform granules can be prepared by binding the active ingredient (eg, compounds herein) to a solid carrier. Solid carrier is mineral soil, such as silica, silica gel, silicate, talc, kaolin, limestone, lime, chalk, balls, ocher, clay, dolomite, diatomaceous earth, calcium sulfate, magnesium sulfate, magnesium oxide, powdered synthetic materials, etc. Fertilizers such as ammonium sulfate, ammonium phosphate, ammonium nitrate, urea, and vegetable products such as cereal flour, bark flour, wood flour and nutshell powder, cellulose powder, and other solid carriers.

  The compounds herein can be formulated as ordinary tablets, capsules, solids, liquids, emulsions, slurries, oils, fine granules or powders, which are intended for administration to plants, fields or other agricultural areas. Is appropriate. In preferred embodiments, the formulation is 1 to 95% (eg 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25%, 75%, 80%) in a carrier or diluent. 90%, 95%) of the compounds herein. The compositions described herein are compounds of the formulas described herein in an amount effective to modulate (eg, modulate, inhibit) a metalloenzyme-mediated agricultural disease or disorder. As well as additional agricultural agents, if present.

  In one approach, the compounds herein are provided in an encapsulated formulation (liquid or powder). Specific materials suitable for use in the capsule material include porous particulates or substances such as silica, perlite, talc, clay, pyrophyllite, diatomaceous earth, gelatin and gel, such as polymers (eg polyurea, polyurethane, polyamide, Polyesters), polymeric particles or cellulose, but are not limited to these. These include, for example, hollow fibers, hollow tubes or tubing, capillaries that release the compound from the opening of the tubing, releasing the compound specified herein through the wall, various forms of polymeric properties A membrane system that releases the compound from a block, eg a polymer matrix, holds the compound in a strip, block, tablet, disk, impermeable container and releases it through an accurately measured permeable membrane and Including combinations of things. Examples of such dispensing compositions are polymer substrates, polyvinyl chloride pellets and microcapillaries.

  Encapsulation processes are generally classified as chemical or mechanical. Examples of chemical processes for encapsulation are complex coacervation, polymer-polymer incompatibility, interfacial polymerization in liquid media, in situ polymerization, drying in liquid, heat and ionic gelation in liquid medium, liquid This includes, but is not limited to, desolvation in media, chemical processes based on starch, entrapment in cyclodextrin and liposome formation. Examples of mechanical processes for encapsulation are: spray drying, spray cooling, fluidized bed, electrostatic deposition, centrifugal extrusion, rotary disk or rotational suspension separation, annular jet encapsulation, liquid-gas Or including, but not limited to, polymerization at a solid-gas interface, solvent evaporation, pressure extrusion or spraying into a solvent extraction vessel.

  Microcapsules are also suitable for extended release of the active compounds herein. Microcapsules are small particles containing a core material or active ingredient surrounded by a coating or shell. The size of microcapsules generally varies from 1 to 1000 μm, capsules smaller than 1 μm are classified as nanocapsules, and capsules larger than 1000 μm are classified as macrocapsules. The core payload typically varies from 0.1 to 98% by weight. Microcapsules can have a variety of structures (continuous core / shell, polynuclear or monolithic) and can have irregular or geometric shapes.

  In another approach, the compounds herein are provided in an oily delivery system. The oil releasing matrix includes vegetable and / or mineral oil. In certain embodiments, the substrate also contains a surfactant that makes the composition readily dispersible in water; such agents include wetting agents, emulsifying agents, dispersing agents, and the like.

  The compounds of the present invention can also be provided as emulsions. Emulsion formulations can also be found as water-in-oil (w / o) or oil-in-water (o / w). Droplet size can vary from nanometer scale (colloidal dispersion) to several hundred μm. Various surfactants and thickeners are usually incorporated into the formulation to adjust the size of the droplets, stabilize the emulsion, and change the release.

  The emulsifiable concentration of the compound of formula I may include convenient concentrations, such as from about 10 weight percent to about 50 weight percent of the compound, in a suitable liquid, relative to the total weight of the concentrate. The compounds can be dissolved in an inert carrier, either a water-miscible solvent or a mixture of water-immiscible organic solvent and emulsifier. The concentrate can be diluted with water and oil to form a spray mixture in the form of an oil-in-water emulsion. Useful organic solvents include aromatics, especially the high boiling naphthalene and olefinic portions of petroleum such as heavy aromatic naphtha. Other organic solvents such as terpene solvents, including rosin derivatives, aliphatic ketones such as cyclohexanone, and complex alcohols such as 2-ethoxyethanol can also be used.

  Emulsifiers that can be advantageously used herein can be readily determined by those skilled in the art and include various nonionic, anionic, cationic and amphoteric emulsifiers or blends of two or more emulsifiers. Examples of nonionic emulsifiers useful in preparing emulsions include polyalkylene glycol ethers and condensation products of alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or fatty acids and ethylene oxide, propylene oxide, such as polyols Or, ethoxylated alkylphenols and carboxyl esters solubilized with polyoxyalkylene. Cationic emulsifiers include quaternary ammonium compounds and fatty amine salts. Anionic emulsifiers include oil-soluble salts of alkylaryl sulfonic acids (eg calcium), oil-soluble salts or suitable salts of sulfated polyglycol ethers and phosphorylated polyglycol ethers.

  Representative organic liquids that can be used in preparing emulsions of the compounds of the present invention are aromatic liquids such as xylene, propylbenzene fractions; or mixed naphthalene fractions, mineral oils, substituted aromatic organic liquids such as phthalic acid Dioctyl, etc .; kerosene; dialkylamides of various fatty acids, especially dimethylamides and glycol derivatives of fatty glycols, such as n-butyl ether, ethyl ether or methyl ether of diethylene glycol, methyl ether of triethylene glycol, petroleum fractions or hydrocarbons, For example, mineral oil, aromatic solvent, paraffin oil, etc .; vegetable oil such as soybean oil, rapeseed oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cottonseed oil, linseed oil, coconut oil, peanut oil, safflower oil , Sesame oil, tung oil Etc.; the plant oil esters, and the like. Mixtures of two or more organic liquids can also be used in the preparation of the emulsion. Organic liquids include xylene and propylbenzene fractions, with xylene being most preferred in some cases. Surfactant dispersants may generally be used in liquid formulations in amounts of 0.1 to 20% by weight, based on the combined weight of one or more of the compounds and the dispersant. The formulation may also contain other compatible additives such as plant growth regulators and other biologically active compounds used in agriculture.

  An aqueous suspension is a suspension of one or more compounds insoluble in water of formula I dispersed in an aqueous vehicle at a concentration ranging from about 5 to about 50 weight percent based on the total weight of the aqueous suspension. Contains liquid. The suspension is obtained by finely grinding one or more of the compounds and thoroughly mixing the ground material into a vehicle composed of water and a surfactant selected from the same types as discussed above. Prepared. Other ingredients such as inorganic salts and synthetic or natural rubber can also be added to improve the density and viscosity of the aqueous vehicle. It is often most effective to prepare an aqueous mixture and grind and mix at the same time by homogenizing it in an instrument such as a sand mill, ball mill or piston type homogenizer.

  Aqueous emulsions generally include emulsions of one or more water-insoluble pesticidal active ingredients that are emulsified in an aqueous vehicle at a concentration in the range of about 5 to about 50 weight percent based on the total weight of the aqueous emulsion. . If the pesticidal active ingredient is a solid, it must be dissolved in a suitable water-immiscible solvent before preparation of the aqueous emulsion. An emulsion is typically prepared by emulsifying a liquid pesticidal active ingredient or a water-immiscible solution thereof in an aqueous medium, including a surfactant that aids in the formation and stabilization of the emulsion as described above. This is often accomplished by vigorous mixing provided by a high shear mixer or homogenizer.

  The compounds of formula I can also be applied as granule formulations, which are particularly useful for soil applications. Granule formulations generally consist of the present compound dispersed in an inert carrier consisting entirely or largely of a coarsely divided inert material such as attapulgite, bentonite, diatomite, clay or similar inexpensive materials. From about 0.5 to about 10 weight percent based on the total weight of the granule formulation. Such formulations are usually prepared by dissolving the compound in a suitable solvent and applying it to a preformed granule carrier that has a suitable particle size ranging from about 0.5 to about 3 mm. The A suitable solvent is a solvent in which the compound is substantially or completely soluble. Such formulations can also be prepared by making a soft mass or paste of the carrier and compound and solvent, crushed and dried to obtain the desired granules.

  Alternatively, the compounds of the present invention can also be formulated in solid tablets, useful for the prevention or treatment of oils, protein / carbohydrate materials (preferably vegetable), sweeteners and metalloenzyme mediated agricultural diseases or disorders. Containing (and preferably consisting essentially of) components. In certain embodiments, the present invention provides solid tablets, active ingredients useful for the prevention or treatment of oils, protein / carbohydrate materials (preferably vegetable), sweeteners and metalloenzyme mediated agricultural diseases or disorders. (Eg, a compound herein or a combination or derivative thereof) (and preferably consists essentially of). Tablets are typically about 4 to 40% (eg 5%, 10%, 20%, 30%, 40%) oil (eg vegetable oils such as corn, sunflower, peanut, Olive, grape seed, giraffe, turnip, soybean, cottonseed, walnut, palm, castor, shrimp oyster, hazelnut, avocado, sesame, haze, cacao, flaxseed, rapeseed and canola oil and their hydrogenated derivatives; petroleum Contains oil (such as paraffin and petrolatum) and other water-immiscible hydrocarbons (such as paraffin) Tablets are about 5 to 40% by weight (eg 5%, 10%, 20%, 30%, 40%) ) Vegetable protein / carbohydrate material, which comprises a carbohydrate portion (eg wheat, rye, barley, oats, corn, Derived from grains such as rice, millet, sorghum, grain, buckwheat, alfalfa, mielga, corn meal, soy flour, cereal flour, wheat middling, bran, corn gluten meal, algal flour, dry yeast, beans, rice ) And the protein portion.

  In some cases, various excipients and binders may be used to assist in the delivery of the active ingredient or to provide the tablet with the appropriate structure. Preferred excipients and binders include anhydrous lactose, microcrystalline cellulose, corn starch, magnesium esterate, calcium esterate, zinc esterate, sodium carboxymethyl cellulose, ethyl cellulose, hydroxy Mention may be made of propylmethylcellulose and mixtures thereof.

  Dust agents containing a compound of formula I can be prepared by careful mixing of one or more of the compounds in powder form with a suitable dusty agricultural carrier such as kaolin clay, volcanic rock powder and the like. The dust agent may suitably contain from about 1 to about 10 weight percent of the compound relative to the total weight of the dust agent.

The formulation may further contain a co-surfactant to promote the deposition, wetting and penetration of the compound into the target crop and organism. These co-surfactants can optionally be used as a component of the formulation or as a tank mix. The amount of co-surfactant generally varies from 0.01 to 1.0 volume percent, preferably from 0.05 to 0.5 volume percent, relative to the water spray volume. Suitable adjuvant surfactants include ethoxylated nonylphenol, ethoxylated synthetic or natural alcohols, salts of esters or sulfosuccinic acid, ethoxylated organosilicones, ethoxylated fatty amines, blends of surfactants with mineral or vegetable oils, Grain oil concentrate (mineral oil (85%) + emulsifier (15%)); nonylphenol ethoxylate; benzylcocoalkyldimethyl quaternary ammonium salt; blend of petroleum hydrocarbon, alkyl ester, organic acid and anionic surfactant C ₉ -C ₁₁ alkyl polyglycosides; phosphorylated alcohol ethoxylates; natural primary alcohol (C ₁₂ -C ₁₆ ) ethoxylates; di-sec-butylphenol EO-PO block copolymers; polysiloxane-methyl caps; Emulsified methylated seed oil; tridecyl alcohol (synthetic) ethoxylate (8 EO); tallow amine ethoxylate (15 EO); PEG (400) dioleate-99. The formulation may also include an oil-in-water emulsion, such as that described in US patent application Ser. No. 11 / 495,228, the disclosure of which is expressly incorporated herein by reference.

  The formulation may optionally include combinations containing other insecticidal compounds. Such additional insecticidal compounds are selected for application and are compatible with the compounds of the invention in a medium that does not antagonize the activity of the compounds, fungicides, insecticides, herbicides, nematicides Agent, acaricide, arthropodicide, fungicide or combinations thereof. Thus, in such embodiments, other insecticidal compounds are used as supplemental toxic substances for the same or different insecticidal applications. The compounds of formula I and pesticidal compounds in combination may generally be present in a weight ratio of 1: 100 to 100: 1.

  The compounds of the present disclosure can also be combined with other fungicides to produce fungicidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure are often applied along with one or more other fungicides to modulate a wider variety of undesirable diseases. When used with other fungicides, the claimed compounds can be formulated with other fungicides, tank mixed with other fungicides, or with other fungicides Can be applied continuously. Other such fungicides are 2- (thiocyanate methylthio) -benzothiazole, 2-phenylphenol, 8-hydroxyquinoline sulfate, amethoctrazine, amisulbrom, antimycin, Ampelomyces quisqualis, azaconazole, azoxy Strobin, Bacillus subtilis, Benalaxyl, Benomyl, Benchavalicarb-isopropyl, Benzylaminobenzene-sulfonate (BABS) salt, Bicarbonate, Biphenyl, Bismerthiazole, Vitertanol, Bixafen, Blasticidin S, borax, Bordeaux mixture, boscalid, bromconazole, bupilimate, calcium polysulfide, captaho , Captan, carbendazim, carboxin, carpropamide, carvone, chloronebu, chlorothalonil, clozolinate, Coniothyrium minitans, copper hydroxide, copper octoate, copper oxychloride, copper sulfate, copper sulfate (tribasic) , Cuprous oxide, cyazofamide, cyflufenamide, simoxanyl, cyproconazole, cyprozinyl, dazomet, debacarb, diammonium ethylenebis- (dithiocarbamate), diclofluanide, dichlorophen, diclocimet, diclomedin, dichlorane, dietofencarb, diphenoconazole, di Fenzo coat ion, diflumetrim, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinobutone, dino , Diphenylamine, dithianone, dodemorph, dodemorph acetate, dodine, dozin free base, edifenphos, enestrobine, epoxiconazole, ethaboxam, ethoxyquin, etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fenfram, fenhexamide, Phenoxanyl, Fenpiclonyl, Fenpropidin, Fenpropimorph, Fenpyrazamine, Fentine, Fentine acetate, Fentine hydroxide, Farbum, Ferimzone, Fluazinam, Fludioxonil, Flumorph, Fluopicolide, Fluopyram, Fluorimide, Fluoxastrobin, Fluquinconazole , Flusilazole, fursulfamide, fluthianyl, flutolanil, flutria Fol, floxapyroxide, folpet, formaldehyde, fosetil, fosetil-aluminum, fuberidazole, flaraxil, furamethopyl, guazatine, guazatine acetate, GY-81, hexachlorobenzene, hexaconazole, hymexazole, imazalyl, imazalyl sulfate, imi Benconazole, iminotadine, iminoctadine triacetate, iminoctadine tris (albesylate), iodocarb, ipconazole, ipfenpyrazolone, iprobenphos, iprodione, iprovaricarb, isoprothiolane, isopyrazam, isothianyl, laminarin, kasugamycin, kasugamycin hydrochloride-hydrate , Mancozeb, Mandipropamide, Maneb, Mehf Noxam, mepanipyrim, mepronil, meptyl-dinocup, mercuric chloride, mercuric oxide, mercuric chloride, metalaxyl, metalaxyl-M, metam, metam-ammonium, metam-potassium, metam-sodium, metconazole, metasulfocarb , Methyl iodide, methyl isothiocyanate, methylam, metminostrobin, metraphenone, myrdiomycin, microbutanyl, narbum, nitrotar-isopropyl, nuarimol, octyrinone, off lace, oleic acid (fatty acid), orisatrobin, oxadixyl, oxine-copper, ox Poconazole fumarate, oxycarboxin, pefazoate, penconazole, pencyclon, penflufen, pentachlorophenol, pentachlorophenyl laur , Penthiopyrad, phenylmercuric acetate, phosphonic acid, phthalide, picoxystrobin, polyoxin B, polyoxin, polyoxolim, potassium bicarbonate, potassium hydroxyquinoline sulfate, probenazole, prochloraz, prosimidone, propamocarb, propamocarb hydrochloride, propiconazole , Propinebu, proquinazide, prothioconazole, pyraclostrobin, pyramethostrobin, pyroxystrobin, pyrazophos, pyribencarb, pyributibalbu, pyrifenox, pyrimethanyl, pyriophenone, pyroxylone, quinocuramin, quinoxyphene, quintozen, leinoutria saccharinensis ( Reynoutria sachalinensis) extract, sedaxane, sylthiophanum, shi Conazole, sodium 2-phenylphenoxide, sodium bicarbonate, sodium pentachlorophenoxide, spiroxamine, sulfur, SYP-Z071, SYP-Z048, tar oil, tebuconazole, tebufloquine, technazen, tetraconazole, thiabendazole, tifluzamide, thiophanate-methyl, Thiram, thiazinyl, tolurophos-methyl, tolylfluanid, triadimethone, triadimenol, triazoxide, tricyclazole, tridemorph, trifloxystrobin, triflumizole, trifolin, triticonazole, validamycin, varifenalate, varifenal, vinclozoline, dineb , Ziram, zoxamide, Candida oleophila, Fusarium Oxysporum (Fusarium oxysporum), Gliocladium species, Phlebiopsis gigantea, Streptomyces griseovirdis3 (N)-Streptomyces griseovirdis (Tri), Chryseoviridis (N) Dichlorophenyl) -2- (methoxymethyl) -succinimide, 1,2-dichloropropane, 1,3-dichloro-1,1,3,3-tetrafluoroacetone hydrate, 1-chloro-2,4-dinitronaphthalene 1-chloro-2-nitropropane, 2- (2-heptadecyl-2-imidazolin-1-yl) ethanol, 2,3-dihydro-5-phenyl-1,4-dithioy 1,1,4,4-tetraoxide, 2-methoxyethylmercury acetate, 2-methoxyethylmercury chloride, 2-methoxyethylmercury silicate, 3- (4-chlorophenyl) -5-methylrhodanine, 4- (2 -Nitroprop-1-enyl) phenyl thiocyanate, ampropylphos, anilazine, azithylam, barium polysulfide, Bayer 32394, benodanyl, benquinox, bentalron, benzacryl, benzacryl-isobutyl, benzamorph, bis (mercury) ) Sulfate, bis (tributyltin) oxide, butiobate, cadmium calcium copper zinc chromate sulfate, carbamorph, CECA, clobenazone, chloraniformane , Chlorphenazole, Chlorquinox, Crimbazole, Cyclafamide, Cipendazole, Ciproflam, Decafentine, Dicron, Diclozoline, Diclobutrazole, Dimethylylmol, Dinoctone, Dinosulfone, Dinoterbon, Dipyrithion, Ditalimphos, Dodicine, EBP, EBP, EBP , Etem, etirim, phenaminosulf, phenapanyl, fenitropan, fluotrimazole, flucarbanil, fluconazole, fluconazole-cis, flumeciclox, furophanate, gliodin, griseofulvin, haracrinate, Hercules 3944, hexylthiophos, opa , Isovaredione, me Nil, mecarbinzide, metazoxolone, metofloxam, methylmercuric dicyandiamide, methosulfax, milnebu, mucochloric anhydride, microzoline, N-3,5-dichlorophenyl-succinimide, N-3-nitrophenylitaconimide, natamycin, N-ethylmercurio- 4-toluenesulfonanilide, nickel bis (dimethyldithiocarbamate), OCH, phenylmercury dimethyldithiocarbamate, phenylmercury nitrate, phosdiphene, picolinamide UK-2A and its derivatives, prothiocarb, prothiocarb hydrochloride, pyracarbide, pyridinitrile, pyrrolocyclol , Piroxiflu, quinacetol, quinacetol sulfate, quinazamide, quinconazole, lavenzazo , Salicylanilide, SSF-109, sultropene, tecolum, thiadifluor, thiosiophene, thiochlorfenfim, thiophanate, thioquinox, thioximide, triamifos, trialimol, triazbutyl, triculamide, urubside and zaliramide and any combination thereof obtain.

  Furthermore, the compounds of the present invention are compatible with the compounds of the present invention in media that are selected for application and do not antagonize the activity of the compounds to produce pesticidal mixtures and synergistic mixtures thereof. Can be combined with other insecticides including insecticides, nematicides, acaricides, arthropodicides, fungicides or combinations thereof. The fungicidal compounds of the present disclosure can be applied along with one or more other insecticides to control a wider variety of undesirable pests. When used with other insecticides, the claimed compounds can be formulated with other insecticides, tank mixed with other insecticides, or applied continuously with other insecticides Can be done. Typical insecticides include 1,2-dichloropropane, abamectin, acephate, acetamiprid, acethione, acetoprole, acrinathrin, acrylonitrile, alanicarb, aldicarb, aldoxycarb, aldrin, allethrin, allosamidin, alixiccarb, α-si Permethrin, α-ecdysone, α-endosulfan, amidithione, aminocarb, amiton, amiton oxalate, amitraz, anabasine, atidathione, azadirachtin, azamethiphos, azinephos-ethyl, azinephos-methyl, azotoate, barium hexafluorosilicate, bartholin, bendiocarb, Benfuracarb, bensultap, β-cyfluthrin, β-cypermethrin, bifenthrin, bioarethrin, bioethanometry , Biopermethrin, bistrifluron, borax, boric acid, bromfenvinphos, bromocyclene, bromo-DDT, bromophos, bromophos-ethyl, bufencarb, buprofezin, butacarb, butathiophos, butocarboxyme, butonate, butoxycarboxym, kazusafos , Calcium arsenate, calcium polysulfide, camfechlor, carbanolate, carbaryl, carbofuran, carbon disulfide, carbon tetrachloride, carbophenothion, carbosulfan, cartap, cartap hydrochloride, chlorantraniliprole, chlorbicyclene, chlordane, Chlordecone, chlordimeform, chlordimeform hydrochloride, chlorethoxyphos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormefos, Roloform, chloropicrin, chlorfoxime, chlorprazofos, chlorpyrifos, chlorpyrifos-methyl, chlorthiophos, chromafenozide, cinerine I, cinerine II, cinerines, cismethrin, cloetocarb, closantel, clothianidin, copper aceto arsenite, copper naphthenate, copper naphthenate Copper oleate, coumaphos, cumitoate, crotamiton, crotoxifos, kulfomate, cryolite, cyanophenphos, cyanophos, cyanatoate, cyantraniliprole, cicletrin, cycloprotorin, cyfluthrin, cyhalothrin, cypermethrin, ciphenothrin, cyromazine, cythioate, DDT, decarbofuran, deltamethrin, demefion, demefion-O, demefion-S, demeton, demet -Methyl, demeton-O, demeton-O-methyl, demeton-S, demeton-S-methyl, demeton-S-methylsulfone, diafenthiuron, diarifos, diatomite, diazinon, dicapton, diclofenthion, dichlorvos, dicresyl, dicrotophos , Dicyclanyl, dieldrin, diflubenzuron, dilol, dimethylfluthrin, dimefox, dimethane, dimethoate, dimethrin, dimethylvinphos, dimethylan, dinex, dinex-dicrexin, dinoprop, dinosum, dinotefuran, diphenolane, dioxabenzophos, dioxacarb, dioxathione, , Diticlophos, d-limonene, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium, doramectin , Ecdysterone, emamectin, emamectin benzoate, EMPC, empentrin, endosulfan, endothione, endrin, EPN, epofenonan, eprinomectin, esdepalletrine, esfenvalerate, ethafos, etiofencarb, ethione ethitoe , Ethyl-DDD, ethylene dibromide, ethylene dichloride, ethylene oxide, etofenprox, etrimphos, EXD, famfur, fenamifos, phenazafur, fenchlorfos, phenetacarb, fenfluthrin, fenitrothion, fenobucarb, phenoxacrime, phenoxycarb , Fenpyritrin, Fenpropatoline, Fensulfo ON, fenthion, fenthion-ethyl, fenvalerate, fipronil, furometokin, flonicamid, flubendiamide, flucoflon, flucycloxuron, flucitrinate, fluphenimine, flufenoxuron, flufenprox, flufiprolol, flupiradifuron, fluvarinate, Phonophos, formethanate, formatenate hydrochloride, formotione, formparanate, formparanate hydrochloride, phosmethylan, hospirate, phostietane, furthiocarb, fretrine, gamma-cyhalothrin, gamma-HCH, halfenprox, halophenozide, HCH, HEOD, heptachlor, Heptenophos, heterophos, oxaflumuron, HHDN, hydramethylnon, hydrogen cyanide, hydroprene, hydr Ncarb, imidacloprid, imiprothrin, indoxacarb, iodomethane, IPSP, isazophos, isobenzan, isocarbophos, isodoline, isofenphos, isofenphos-methyl, isoprocarb, isoprothiolane, isothioate, isoxathione, ivermectin, jasmolin I, jasmoline II, iodofenphos Hormone I, juvenile hormone II, juvenile hormone III, kerebane, quinoprene, lambda-cyhalothrin, lead arsenate, lepimectin, leptophos, linden, lirimfos, lufenuron, ritidathione, malathion, malonoben, majidox, mecarbam, mecalphone, menazone, Meperfluthrin, mephospholane, mercuric chloride, mesulfenphos, metaflumizone, methacrifos, meta Midofos, methidathion, methiocarb, methocrothos, mesomil, metoprene, methoxychlor, methoxyphenozide, methyl bromide, methyl isothiocyanate, methyl chloroform, methylene chloride, methofurthrin, metorcarb, methoxadiazone, mevinphos, mexacarbate, milbemectin, milbemycin oxime, rex , Morsultap, monocrotofos, monomehypo, monosultap, morphothion, moxidectin, naphthalophos, nared, naphthalene, nicotine, niflulidide, nitenpyram, nithiazine, nitriracarb, nobarulonate, oxydeflumerone, Hos, Oki Disulfotone, para-dichlorobenzene, parathion, parathion-methyl, penflurone, pentachlorophenol, permethrin, fencapton, phenothrin, phentoate, folate, hosalon, phospholane, phosmet, phosnichlor, phosphamidone, phosphine, oxime, oxime-methyl, pyrimethaphos, Pirimicarb, pyrimiphos-ethyl, pyrimiphos-methyl, potassium arsenite, potassium thiocyanate, pp'-DDT, praletrin, plecocene I, plecocene II, plecocene III, primidophos, propofenophos, profluralin, promasil, promecarb, propaphos, propetumphos, propoxl , Protidathione, prothiophos, protoate, protrifenbut, pyracrofos, pilaf Prolol, pyrazophos, pyrethmethrin, pyrethrin I, pyrethrin II, pyrethrins, pyridaben, pyridalyl, pyridafenthione, pyrifuraquinazone, pyrimidifene, pyrimidate, pyriprole, pyriproxyfen, quasia, quinalphos, quinalphos-methyl, quinothione, rafoxanilide, resmetrianthrone, resmetrione , Sabadilla, shuradan, selamectin, silafluophene, silica gel, sodium arsenite, sodium fluoride, sodium hexafluorosilicate, sodium thiocyanate, sofamid, spinetoram, spinosad, spiromesifen, spirotetramat, sulcoflon, sulcofuron-sodium, Sulfluramide, Sulfotep, Sulfoxafurol, Sulfuryl fluoride, Sulprofo , Tau-fulvalinate, tajimcarb, TDE, tebufenozide, tebufenpyrad, tebupyrimphos, teflubenzuron, tefluthrin, temefos, TEPP, teraretrin, terbufos, tetrachloroethane, tetrachlorobinphos, tetramethrin, tetramethylfluthrin, theta-cypermethrin, thiacloprid , Thiamethoxam, ticlofos, thiocarboxyme, thiocyclam, thiocyclam oxalate, thiodicarb, thiophanox, thiomethone, thiosultap, thiosultap-disodium, thiosultap-monosodium, thuringiensine, tolfenpyrad, tralomethrin, transfluthrin, transpermethrin, trialatin, Triazamate, triazophos, trichlorfone, trichlorme Phosphite -3, trichloromethyl isocyanate, Torifenohosu, triflumuron, trimethacarb, triprene, vamidothion, vaniliprole, XMC, xylylcarb, zeta - cypermethrin, including but Zorapurohosu and some combination thereof, without limitation.

  Furthermore, the compounds of the present invention are selected for application to produce pesticidal mixtures and synergistic mixtures thereof and are compatible with the compounds of the present invention in media that do not antagonize the activity of the compounds. Can be combined with herbicides. The fungicidal compounds of the present disclosure can be applied together with one or more herbicides to regulate a wide variety of undesirable plants. When used with herbicides, the compounds claimed herein can be formulated with herbicides, tank mixed with herbicides, or applied continuously with herbicides. Typical herbicides include 4-CPA; 4-CPB; 4-CPP; 2,4-D; 3,4-DA; 2,4-DB; 3,4-DB; 2,4-DEP; 3,4-DP; 2,3,6-TBA; 2,4,5-T; 2,4,5-TB; acetochlor, acifluorfen, acronifene, acrolein, alachlor, aridoclor, Aloxidim, allyl alcohol, aralac, ametridione, ametrine, amyvudine, amicarbazone, amidosulfuron, aminocyclopyrochlor, aminopyralide, aminoprophos-methyl, amitrolol, ammonium sulfamate, anilophos, anisulone, aslam, atlaton, atrazine, azaphenidine, azimusulfuron , Adiprotrin, barban, BCPC, beflubutami , Benazoline, Bencarbazone, Benfluralin, Benfresate, Bensulfuron, Benthuride, Bentazone, Benzadox, Benzfendizone, Benzipram, benzobicyclon, benzophenap, benzzofluor, benzoylprop, benzthiazuron, bicyclopyrone, bifenox, vilanfos, sand Bromasil, bromobonyl, bromobutide, bromophenoxime, bromoxynil, brompyrazone, butachlor, butaphenacyl, butamifos, butenachlor, butidazol, butyuron, butralin, butroxydim, buturon, butyrate, cacodylic acid, fenfentrol, calcium chlorate, calcium cyanamide, cambendichlor Carbaslam, carbetamid, carboxazole black Procarb, carfentrazone, CDEA, CEPC, chloromethoxyphen, chloramben, chloranoclyl, chlorazihop, chlorazine, chlorbromulone, chlorbufam, chloretulone, chlorfenac, chlorfenprop, chlorflurazole, chlorflurenol, chloridazon, chlorimuron , Chloropon, chlorotoluron, chloroxuron, chloroxinyl, chlorpropham, chlorsulfuron, chlortar, chlorthiamid, sinidone-ethyl, cinmethyrin, sinosulfurone, cisanilide, cretodim, cryogenate, clodinahop, clofop, clomazone, clomeprop, clopropidium, Clopyralide, chloranthram, CMA, copper sulfate, CPMF, CP PC, credazine, cresol, cumyluron, cyanatoline, cyananadine, cycloate, cyclosulfamuron, cycloxydim, cyclulone, cyhalohop, cypercoat, cyprazine, cyprazole, cypromide, dimrone, darapon, dazomet, delachlor, desmedifam, desmethrin, dialate, dicamba, dicamba , Dichlorurea, Dichlormate, Dichlorprop, Dichlorprop-P, Diclohop, Diclosram, Dietamcote, Dietatil, Diphenopentene, Diphenoxuron, Difenzocote, Diflufenican, Diflufenzopyr, Dimeflon, Dimepimetherate, Dimethametrimide, Dimethametrimide P, dimexano, dimidazone, dinitramine, dinov Nate, dinoprop, dinosum, dinocebu, dinoterb, diphenamide, dipropetrin, diquat, disulfur, dithiopyr, diuron, DMPA, DNOC, DSMA, EBEP, eglinazine, endtal, epronaz, EPTC, elbon, esprocarb, etalfluralurin, ethatrasulfuron , Etizimuron, etiolate, etofumesate, ethoxyphen, ethoxysulfuron, ethinophene, etonipromide, ettobenzanide, EXD, phenathram, phenoprop, phenoxaprop, phenoxaprop-P, phenoxasulfone, fenteracol, fenthiaprop, fentrazamide, Phenuron, ferrous sulfate, flamprop, flamprop-M, flazasulfuron, flora slam, fluazi , Fluazifop-P, fluazolate, flucarbazone, flucetosulfuron, fluchlorarine, flufenacet, flufenican, flufenpyr, flumethoslam, flumedin, fluromicrolac, flumioxazin, flumipropine, fluometuron, fluorodiphen, fluoroglycophene, fluoromidine Nitrophen, fluothiuron, flupoxam, flupropacil, flupropanate, flupirsulfuron, fluridone, flurochloridone, fluroxypyr, flurtamone, fluthiaset, fomesafen, holamsulfuron, fosamine, fluroxifene, glufosinate, glufosinate-P, glyphosate, halosafene , Halosulfuron, haloxidine, haloxyhop, haloxyhop-P, Hexachloroacetone, hexaflurate, hexazinone, imazametabenz, imazamox, imazapic, imazapyr, imazaquin, imazetapyr, imazosulfuron, indanophan, indafram, iodobonyl, iodomethane, iodosulfuron, iofensulfuron, ioxonyl fenisorpy Carbamide, isosyl, isomethiodine, isonorulone, isopolynate, isoproparin, isoproturon, isouron, isoxaben, isoxachlortol, isoxaflutol, isoxapyrihop, carbbutylate, ketospiradox, lactofen, lenacyl, linuron, MAA, MAMA, MCPA, MCPA-thioethyl, MCPB, mecoprop, mecoprop-P Medinoterb, Mefenacet, Mefluidide, Mesoprazine, Mesosulfuron, Mesotrione, Metam, Metamihop, Metamitron, Metazachlor, Metazosulfuron, Metoflulazone, Metabenzthiazulone, Metalproparin, Methazole, Methiobencarb, Methiozoline, Methiurone, Methiuron, Promethometone , Methyl isothiocyanate, Methyldimuron, Metobenzuron, Metobromulone, Metrachlor, Methoslam, Metoxuron, Metrivudine, Methosulfuron, Molinate, Monalid, Monisouron, Monochloroacetic acid, Monolinuron, Monuron, Morphamcote, MSMA, Naproanilide, Napropanebona Luflon, Nipiraclofen, Nitraline, Nitrof , Nitrofluorfen, norflurazon, norlon, OCH, olbencarb, ortho-dichlorobenzene, orthosulfamlone, oryzalin, oxadiargyl, oxadiazone, oxapyrazone, oxasulfuron, oxadichromemephone, oxyfluorfen, parafluron, paraquat, pebrate, pelargonic acid, Pendimethalin, penoxyslam, pentachlorophenol, pentanochlor, pentoxazone, perfluidone, petoxamide, phenichamum, phenmedifam, fenmedifam-ethyl, phenobenzuron, phenylmercuric acetate, picroram, picolinaphene, pinoxaden, piperophos, potassium arsenite, azide Potassium halide, potassium cyanate, pretilachlor, primisulflon, procyanine, Prodiamine, Profluazole, Profluralin, Proxoxime, Proglinazine, Prometon, Promethrin, Propachlor, Propanyl, Propaquizahop, Propadin, Profam, Propisochlor, Propoxycarbazone, Propyrisulfuron, Propizzamid, Prosulfarin, Prosulfocarb, Prosulfuron, Proxan, Pyrinachlor, Pidanone, Pyraclonyl, Pyraflufen, Pyrazosulfol, Pyrazolinate, Pyrazosulfuron, Pyrazoxifene, Pyribenzoxime, Pyributicalbu, Pyrichlor, Pyridahol, Pyridate, Pyriphthalide, Pyriminobac, Pyrisulfane, Pyrithiobac, Piroxasulfone, Pyloxulphone Lac, kimmerak, quinoclamin, quinonamide, quizalofop Quizalofop-P, rodetanyl, rimsulfuron, saflufenacil, S-metolachlor, cebutyrazine, sectbumethone, cetoxidim, shizuron, simazine, simeton, simethrin, SMA, sodium arsenite, sodium azide, sodium chlorate, sulcotrione, sulphate , Sulfentrazone, sulfometuron, sulfosulfuron, sulfuric acid, sulglycapine, swep, TCA, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraxidim, terbacil, terbucarb, terbuchlor, terbumetone, terbutyrazine, terbutrin, tetraflulone, tenylchlor Thiazaflulone, thiazopyr, thiazimine, thiazulone, thiencarbazone-methyl, thifensulfuron, thiobencarb Thiocarbazyl, thiochlorim, topramezone, tolalkoxydim, triafamon, tri-arate, trisulfuron, triadifram, tribenuron, tricamba, triclopyr, tridiphan, trietadine, trifloxysulfuron, trifluralin, triflusulfuron, trihop, trihopsime, trihydroxytriazine, trimetron Examples include, but are not limited to, tripropindane, tritactic tritosulfuron, vernolate and xylachlor.

  Another embodiment of the present disclosure is a method for controlling or preventing fungal attack. This method applies a fungicidally effective amount of one or more of the compounds of formula I to soil, plants, roots, foliage, seeds or fungal sites or where infection is to be prevented (eg cereal plants To apply). The compounds are suitable for the treatment of various plants at a fungicidal level while exhibiting low phytotoxicity. The present compounds may be useful in both protective and / or eradication mode.

  The compounds have been found to have a significant fungicidal effect, especially for agricultural applications. Many of the compounds are particularly effective for use with crops and horticultural plants. Further benefits include improved plant health; improved plant yield (eg increased biomass and / or increased content of valuable components); improved plant viability (eg improved plant growth and / or leaf growth) Darkening); improving plant quality (eg, improving the content and composition of certain ingredients); and improving tolerance of plants to abiotic and / or biological stresses, but are not limited to these.

  The composition of formula I may be effective against pathogen-induced diseases, and the phytofungal pathogens are: Blumeria, Podosphaera, Sphaerotheca, Uncinula, Erysiphe, Psychia (Puccinia), Phakopsora, Gymnosporangium, Hemelia, Uromyces, Alternaria, Cercosporch, Cercosporch Colletotrichum, Magnaporte Magnaporthe, Mycosphaerella, Phaeosphaeria, Pirenophora, Ramularia, Rhyncosporium, Septoria (U), Sepia (V) ), Penicillium, Drechslera, Fusarium, Botrytis, Gibberella, Rhizotonia, Pseudoscosporel c Sclerotinia (Sclerotinia), Helminthosporium (Helminthosporium), belonging to at least one genus chosen from Sutagunosupora (Stagonospora), Exserohilum (Exserohilum) and Pyricularia (Pyricularia). Venturia-Inakuarisu (Venturia inaequalis), Septoria tritici (Septoria tritici), Cercospora Bechikora (Cercospora beticola), peanut leaf spot (Cercospora Arakijikora (Cercospora arachidicola)), Colletotrichum-Ragenariumu (Colletotrichum lagenarium), Pukushinia graminis (Puccinia graminis) f. sp. Tritici, Puccinia recondita tritici, Pichia recondita tritici, Unchinula necator, pharmeria i Can be controlled by In addition, the composition of formula I comprises apple black spot, wheat leaf blight, sugar beet spot disease, peanut spot disease, cucumber anthracnose disease, wheat rust disease, grape powdery mildew, wheat powdery mildew and banana leaf spot It can be effective in preventing or controlling diseases including diseases.

  The present invention provides kits for the treatment or prevention of agricultural or plant diseases or disorders. In certain embodiments, the kit comprises a composition containing an effective amount of a compound herein in a form suitable for delivery to a site plant. In some embodiments, the kit comprises a container containing a compound as described herein (eg, of any formula herein); such container comprises a box, It can be ampoules, bottles, vials, tubes, bags, pouches, blister packs or other suitable container forms known in the art. Such containers can be made from plastic, glass, laminated paper, metal foil or other material suitable to hold the compound.

  If desired, the compounds of the invention are provided with instructions for administering them to plants, fields or other agricultural areas. The instructions generally include information regarding the use of the composition for the treatment or prevention of metalloenzyme mediated agricultural diseases or disorders. In other embodiments, the instructions include the following: description of the compound; administration schedule and administration for treatment or prevention of metalloenzyme mediated agricultural diseases or disorders; precautions; warnings; And / or at least one of the references. The instructions can be printed directly on the container (if present) or as a label attached to the container or as a separate sheet, brochure, card or holder supplied in or with the container. .

The compounds of the present disclosure can be effective in use with plants in a plant-acceptable amount that inhibits disease. The term “inhibiting disease and a plant acceptable amount” refers to the amount of a compound that kills or inhibits a plant disease for which control is desired, but is not significantly toxic to the plant. . This amount is generally from about 0.1 to about 1000 ppm (parts per million), with 1 to 500 ppm being preferred. The exact amount of compound required will vary with the fungal disease to be controlled, the type of formulation used, the method of application, the particular plant species, climatic conditions, etc. Suitable application rates are generally in the range of about 0.10 to about 4 pounds / acre (about 0.01 to 0.45 grams / square meter, g / m ² ).

  Any range or desired value given herein may be expanded or changed without losing the desired effect, as will be apparent to those skilled in the art for an understanding of the teachings herein.

EXAMPLES The invention will now be clarified using specific examples which should not be construed as limiting.

General Experimental Procedures The definitions of variables in the structures in the schemes herein are equivalent to those in the corresponding positions in the formulas described herein.

下記で示される（スキーム１）例となる合成を使用して、アゾール標的（式Ｉ）の合成を遂行し得る。官能性ハロ芳香族出発物質（例えばＡ）から出発して、下記の２−ピリジンの例（Ｄ）に加えて、幅広い範囲のアレーンおよび複素環を調製し得る。この例の目的に対して、式Ｉ中のＲ_４はハロゲン化ベンゼン部分である。 Synthesis of azole targets

The exemplary synthesis shown below (Scheme 1) can be used to accomplish the synthesis of the azole target (Formula I). Starting from functional haloaromatic starting materials (eg A), in addition to the 2-pyridine example (D) below, a wide range of arenes and heterocycles can be prepared. For purposes of this example, R _{4 in} Formula I is a halogenated benzene moiety.

An exemplary synthesis of a target of formula I begins with condensation of A with copper activated ethyl-bromo-acetate followed by condensation of the initial ethyl ester product with lithiated bromodifluorobenzene to give ketone B. (Scheme 1). This ketone is epoxidized with diazomethane to give C. Ringing epoxide C with n-butyllithium / trimethylborate to obtain the corresponding boronic acid during aqueous processing gives alcohol product D; this intermediate is converted to alcohol via oxidation with oxone. Convert. Alcohol intermediate D to the corresponding ether (X═O) via alkylation with the required benzyl bromide (R ₅ —Br; substituted benzyl ether) or aryl-boronic acid coupling (substituted phenyl ether) Can be converted. The epoxide is then opened with an azole to give the final product of formula I.

２−（５−ブロモピリジン−２−イル）−１−（２，４−ジフルオロフェニル）−２，２−ジフルオロエタノン（Ｂ）の合成
ジメチルスルホキシド（ＤＭＳＯ；３５ミリリットル（ｍＬ））中の銅粉末（２．６８グラム（ｇ）、４２．２ミリモル（ｍｍｏｌ））の縣濁液に、エチル２−ブロモ−２，２−ジフルオロアセテート（２．７０ｍＬ、２１．１０ｍｍｏｌ）を添加し、混合物を室温（ＲＴ）で１時間撹拌した。次いで、２，５−ジブロモピリジン（２．５０ｇ、１０．５５ｍｍｏｌ）を添加し、ＲＴで１５時間撹拌を継続した。反応混合物を水性（ａｑ）塩化アンモニウム（ＮＨ_４Ｃｌ）で不活性化し、ジクロロメタン（ＣＨ_２Ｃｌ_２；３ｘ２５ｍＬ）で抽出した。合わせた有機層を水（Ｈ_２Ｏ）で洗浄し、塩水で洗浄し、無水硫酸ナトリウム（Ｎａ_２ＳＯ_４）上で乾燥させ、減圧下で濃縮して粗製生成混合物を得た。カラムクロマトグラフィーによる精製（酢酸エチル（ＥｔＯＡｃ）／ヘキサンで溶出）によって、エチルエステル中間体（２．４０ｇ、８．５７ｍｍｏｌ、８１％）を薄黄色の油状物質として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７１（ｓ，１Ｈ）、８．００（ｄ，Ｊ＝９．０Ｈｚ，１Ｈ）、７．６４（ｄ，Ｊ＝９．０Ｈｚ，１Ｈ）、４．４２−４．３５（ｍ，２Ｈ）、１．３９−１．３１（ｍ，３Ｈ）。 Scheme 1

Synthesis of 2- (5-bromopyridin-2-yl) -1- (2,4-difluorophenyl) -2,2-difluoroethanone (B) Copper in dimethyl sulfoxide (DMSO; 35 milliliters (mL)) To a suspension of the powder (2.68 grams (g), 42.2 mmol (mmol)), ethyl 2-bromo-2,2-difluoroacetate (2.70 mL, 21.10 mmol) was added and the mixture was Stir at room temperature (RT) for 1 hour. Then 2,5-dibromopyridine (2.50 g, 10.55 mmol) was added and stirring was continued at RT for 15 hours. The reaction mixture was inactivated with aqueous (aq) ammonium chloride (NH ₄ Cl) and extracted with dichloromethane (CH ₂ Cl ₂ ; 3 × 25 mL). The combined organic layers were washed with water (H ₂ O), washed with brine, dried over anhydrous sodium sulfate (Na ₂ SO ₄ ) and concentrated under reduced pressure to give a crude product mixture. Purification by column chromatography (eluting with ethyl acetate (EtOAc) / hexane) afforded the ethyl ester intermediate (2.40 g, 8.57 mmol, 81%) as a pale yellow oil. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.71 (s, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 4 .42-4.35 (m, 2H), 1.39-1.31 (m, 3H).

To a stirred solution of 1-bromo-2,4-difluorobenzene (1.65 g, 8.57 mmol) in diethyl ether (Et ₂ O; 10 mL) was continuously added n-butyllithium (n-BuLi at −70 ° C.). 2.3 molr (M) in hexane; 3.70 mL, 8.57 mmol) and 15 min later the above ester (2.40 g, 8.57 mmol) in Et ₂ O (5 mL) was added. The reaction mixture was stirred at −70 ° C. for 1 hour, warmed to RT and stirred for an additional 2 hours. The reaction mixture was inactivated with aqNH ₄ Cl solution and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with H ₂ O, washed with brine, dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (eluted with EtOAc / hexanes) to give ketone B (1.30 g, 3.73 mmol, 43%) as a yellow liquid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.62 (s, 1H), 8.08-8.04 (m, 2H), 7.74-7.70 (m, 1H), 7.05-6 .95 (m, 1H), 6.88-6.78 (m, 1H). MS (ESI): m / z 347, 349 [(M ⁺⁺ 1) +2].

5-Bromo-2-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) pyridine (C)
To a stirred solution of ketone B (1.30 g, 3.73 mmol) in Et ₂ O (300 mL) was added freshly prepared diazomethane at 0 ° C. and the mixture was warmed to RT. The reaction mixture was stirred for 2 hours. Volatiles were removed under reduced pressure to give a crude product mixture. Column chromatography (eluting with EtOAc / hexanes) gave oxirane C (800 mg, 2.20 mmol, 59%) as a pale yellow solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.72 (s, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.39-7.35 (m, 2H), 6.86 -6.83 (m, 1H), 6.77-6.74 (m, 1H), 3.44 (s, 1H), 2.98 (s, 1H). MS (ESI): m / z 362, 364 [(M ⁺⁺ 1) +2].

6-((2- (2,4-Difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-ol (D)
To a stirred solution of n-BuLi (1.5 M in hexane; 21 mL, 33.13 mmol) in anhydrous Et ₂ O (250 mL) was added compound C (8 g, 22.09 mmol) in Et ₂ O (50 mL) at −78 ° C. ) Was added. After stirring for 30 minutes, trimethyl borate (5 mL, 44.19 mmol) was added to the reaction mixture at −78 ° C. and stirring was continued for an additional 10 minutes. The reaction mixture was warmed to RT and stirred for 30 minutes. The reaction mixture was inactivated with acetic acid (HOAc; 40 mL), diluted with H ₂ O (120 mL) and stirred at RT for 1 h. The reaction mixture was basified by addition of 2N (N) sodium hydroxide (NaOH) (pH˜12), the organic layer was separated and the aqueous layer was acidified with 1N hydrochloric acid (HCl) (pH˜6). The aqueous layer was extracted with CH ₂ Cl ₂ ( ₂ × 500 mL). The combined organic layers were dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the corresponding boronic acid (7 g, 21.4 mmol, 97%) as a brown solid. ¹ H NMR (500 MHz, CD ₃ OD): δ 8.81 (s, 1H), 8.15 (d, J = 7.5 Hz, 1H), 7.47 (d, J = 8 Hz, 1H), 7. 36-7.35 (m, 1H), 6.93-6.87 (m, 2H), 3.42 (d, J = 5.5 Hz, 1H), 2.99-2.98 (m, 1H) ). MS (ESI): m / z 328.1 [M ⁺⁺ 1].

To a stirred solution of boronic acid (0.6 g, 1.83 mmol) in acetone (5 mL) was added potassium persulfate (K ₂ S ₂ O ₈ ; 1.12 g, 1.83 mmol) in H ₂ O (5 mL) at RT. ) Was added and the mixture was stirred for 16 hours. After consumption of the starting material (by thin layer chromatography (TLC)), the volatiles were evaporated under reduced pressure and the residue was extracted with CH ₂ Cl ₂ (2 × 30 mL). The combined organic layers were washed with satd sodium bicarbonate (NaHCO ₃ ) solution (5 mL) and brine (5 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. . Purification by column chromatography; by _(SiO 2, 100-200 mesh eluting with 10% EtOAc / hexanes) to afford alcohol D (0.3g, 1.0mmol, 54.6% ) as a white solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.81 (s, 1H), 7.36-7.35 (m, 2H), 7.25 (d, J = 8 Hz, 1H), 6.84 (t , J = 8.5 Hz, 1H), 6.73 (t, J = 8.5 Hz, 1H), 3.39 (d, J = 5.5 Hz, 1H), 2.99 (d, J = 4. 5Hz, 1H). MS (ESI): m / z 299 [M ⁺⁺ 1].

１−（５−（４−クロロ−２−フルオロベンジルオキシ）ピリジン−２−イル）−２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（１）
次の２段階の手順を使用して、１−（ブロモメチル）−４−クロロ−２−フルオロベンゼンを調製した。メチルアルコール（ＣＨ_３ＯＨ；１５ｍＬ）中の４−クロロ−２−フルオロベンズアルデヒド（１．０ｇ、６．３１ｍｍｏｌ）の撹拌溶液に、０℃で水素化ホウ素ナトリウム（ＮａＢＨ_４；０．４７ｇ、１２．６ｍｍｏｌ）を添加した。反応混合物をＲＴで１時間撹拌した。出発物質の消費（ＴＬＣによる。）後、反応混合物を氷片で不活性化し、揮発性物質を減圧下で蒸発させた。残渣をＨ_２Ｏ（２５ｍＬ）で希釈し、ＥｔＯＡｃ（２ｘ５０ｍＬ）で抽出した。合わせた有機層を無水Ｎａ_２ＳＯ_４上で乾燥させ、ろ過し、減圧下で濃縮した。得られた粗製物質をカラムクロマトグラフィーにより精製し（ＳｉＯ_２、１００−２００メッシュ）、対応するアルコール（０．８ｇ、５．０ｍｍｏｌ、７８．７％）を半固形物として得た。^１Ｈ ＮＭＲ（２００ＭＨｚ，ＣＤＣｌ_３）：δ７．４１（ｑ，Ｊ＝８．０、１５．６Ｈｚ，１Ｈ）、７．１７−７．０５（ｍ，２Ｈ）、４．７３（ｄ，Ｊ＝６．２Ｈｚ，２Ｈ）、１．８３（ｔ，Ｊ＝６．２Ｈｚ，１Ｈ）。 Example 1

1- (5- (4-Chloro-2-fluorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (1)
1- (Bromomethyl) -4-chloro-2-fluorobenzene was prepared using the following two-step procedure. To a stirred solution of 4-chloro-2-fluorobenzaldehyde (1.0 g, 6.31 mmol) in methyl alcohol (CH ₃ OH; 15 mL) at 0 ° C. sodium borohydride (NaBH ₄ ; 0.47 g, 12. 6 mmol) was added. The reaction mixture was stirred at RT for 1 hour. After consumption of the starting material (by TLC), the reaction mixture was inactivated with ice chips and the volatiles were evaporated under reduced pressure. The residue was diluted with H ₂ O (25 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over anhydrous Na ₂ SO ₄ , filtered and concentrated under reduced pressure. The resulting crude material was purified by column chromatography _(SiO 2, 100-200 mesh) to give the corresponding alcohol (0.8 g, 5.0 mmol, 78.7%) as a semi-solid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 7.41 (q, J = 8.0, 15.6 Hz, 1H), 7.17-7.05 (m, 2H), 4.73 (d, J = 6.2 Hz, 2H), 1.83 (t, J = 6.2 Hz, 1H).

To a stirred solution of alcohol (0.8 g, 5.0 mol) in anhydrous Et ₂ O (10 mL) was added phosphorus tribromide (PBr ₃ ; 0.33 mL, 3.5 mmol) at 0 ° C. The reaction mixture was stirred at RT for 3 hours. After consumption of the starting material (by TLC), the reaction mixture was inactivated with ice chips and the aqueous layer was extracted with EtOAc (2 × 75 mL). The combined organic layers were washed with satd NaHCO ₃ solution, dried over anhydrous Na ₂ SO ₄ , filtered, concentrated under reduced pressure and 1- (bromomethyl) -4-chloro-2-fluorobenzene (0.6 g, 2.7 mmol, 54%) was obtained as a pale yellow liquid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 7.41 (q, J = 14.5, 16.6 Hz, 1H), 7.15-7.07 (m, 2H), 4.46 (s, 2H) .

To a stirred solution of alcohol D (0.2 g, 0.66 mmol) in N, N-dimethylformamide (DMF; 3 mL) was added 1- (bromomethyl) -4-chloro-2-fluorobenzene (0.14 g, RT) at RT. 0.66 mmol) and potassium carbonate (K ₂ CO ₃ ; 0.09 g, 0.66 mmol) were added. The reaction mixture was gradually heated to 70 ° C. and stirred for 2 hours. After consumption of starting material (by TLC), the reaction mixture was inactivated with H ₂ O and extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure. The resulting crude material was purified by column chromatography _(SiO 2, 100-200 mesh; eluting with EtOAc / hexanes) to give compound E (0.25g, 0.56mmol, 85% ) as a white solid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 8.39 (d, J = 2.8 Hz, 1H), 7.46-7.27 (m, 4H), 7.25-7.17 (m, 2H) 6.88-6.68 (m, 2H), 5.14 (s, 2H), 3.43 (d, J = 5.2 Hz, 1H), 2.96 (d, J = 5.2 Hz, 1H).

Compound E (0.25 g, 0.56 mmol) in DMF (4 mL) to a stirred solution of, 1H-tetrazole (0.05 g, 0.85 mmol) and followed by _K 2 _CO 3 (0.07g, 0.56mmol ) At RT under an inert atmosphere. The reaction mixture was gradually heated to 65 ° C. and stirred for 24 hours. The reaction mixture was inactivated with H ₂ O and extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over Na ₂ SO ₄ and concentrated under reduced pressure. The resulting crude material was purified by column chromatography _(SiO 2, 100-200 mesh; eluting with EtOAc / hexanes) to give 1 (0.07g, 0.15mmol, 26% ) as an off-white solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.25 (d, J = 2.0 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7 .49 (s, 1H), 7.41-7.30 (m, 3H), 7.20-7.16 (m, 2H), 6.77-6.73 (m, 1H), 6.67 (T, J = 3.4 Hz, 1H), 5.56 (d, J = 14 Hz, 1H), 5.14 (s, 2H), 5.08 (d, J = 14 Hz, 1H). MS (ESI): m / z 512.1 [M ⁺⁺ 1]. HPLC: 98.07%.

  Using the same conditions as intermediate D and commercially available or prepared benzyl or alkyl halides (see Table 1, starting materials) and compound 1 from commercial azoles (Example 1), compounds 19 to 74 of Table 1, 83 and 113-118 were prepared.

１−（５−（２，４−ジフルオロベンジルオキシ）ピリジン−２−イル）−２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（２）
ＤＭＦ（５ｍＬ）中のアルコールＤ（０．３ｇ、１．０ｍｍｏｌ）の撹拌溶液に、ＲＴでＫ_２ＣＯ_３（０．２７ｇ、２．０ｍｍｏｌ）および１−（ブロモメチル）−２，４−ジフルオロベンゼン（実施例１３において調製したときのＩ−１；０．２ｇ、１．０ｍｍｏｌ）を添加した。反応混合物を７０℃まで徐々に加熱し、５時間撹拌した。出発物質の消費後（ＴＬＣによる。）、揮発性物質を減圧下で蒸発させた。残渣をＨ_２Ｏ（５ｍＬ）で希釈し、ＥｔＯＡｃ（２ｘ２５ｍＬ）で抽出した。合わせた有機層を無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮した。得られた粗製物質をカラムクロマトグラフィーにより精製し（ＳｉＯ_２、１００−２００メッシュ）、７％ＥｔＯＡｃ／ヘキサンで溶出して、エーテル生成物（０．２５ｇ、０．５９ｍｍｏｌ、５８．６％）を半固形物として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．３８（ｄ，Ｊ＝２．５Ｈｚ，１Ｈ）、７．４８−７．３５（ｍ，３Ｈ）、７．２７（ｄ，Ｊ＝２．５Ｈｚ，１Ｈ）、６．９３−６．８１（ｍ，３Ｈ）、６．７５（ｔ，Ｊ＝２．０Ｈｚ，１Ｈ）、５．１４（ｓ，２Ｈ）、３．４２（ｄ，Ｊ＝５．５Ｈｚ，１Ｈ）、２．９６（ｄ，Ｊ＝５．５Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４２５［Ｍ^＋＋１］。 Example 2

1- (5- (2,4-Difluorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane -2-ol (2)
To a stirred solution of alcohol D (0.3 g, 1.0 mmol) in DMF (5 mL) was added K ₂ CO ₃ (0.27 g, 2.0 mmol) and 1- (bromomethyl) -2,4-difluorobenzene at RT. (I-1 as prepared in Example 13; 0.2 g, 1.0 mmol) was added. The reaction mixture was gradually heated to 70 ° C. and stirred for 5 hours. After consumption of starting material (by TLC), volatiles were evaporated under reduced pressure. The residue was diluted with H ₂ O (5 mL) and extracted with EtOAc (2 × 25 mL). The combined organic layers were dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure. The resulting crude material was purified by column chromatography _(SiO 2, 100-200 mesh), eluting with 7% EtOAc / hexanes, ether product (0.25 g, 0.59 mmol, 58.6%) Obtained as a semi-solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.38 (d, J = 2.5 Hz, 1H), 7.48-7.35 (m, 3H), 7.27 (d, J = 2.5 Hz, 1H), 6.93-6.81 (m, 3H), 6.75 (t, J = 2.0 Hz, 1H), 5.14 (s, 2H), 3.42 (d, J = 5. 5 Hz, 1H), 2.96 (d, J = 5.5 Hz, 1H). MS (ESI): m / z 425 [M ⁺⁺ 1].

Ether product in DMF (5mL) (0.25g, 0.58mmol ) to a stirred solution of, RT in under an inert atmosphere 1H- tetrazole (0.06g, 0.88mmol), followed by _K 2 CO ₃ (0.08 g, 0.58 mmol) was added. The reaction mixture was gradually heated to 65 ° C. and stirred for 7 hours. Volatiles were removed under reduced pressure; the residue was diluted with H ₂ O (5 mL) and extracted with EtOAc (2 × 25 mL). The combined organic layers were dried over Na ₂ SO ₄ and concentrated under reduced pressure. The resulting crude material was purified by column chromatography _(SiO 2, 100-200 mesh), eluting with 20% EtOAc / hexane, 2 (0.11g, 0.22mmol, 38 %) of an off-white solid Got as. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.74 (s, 1H), 8.25 (d, J = 3.0 Hz, 1H), 7.52 (d, J = 11.0 Hz, 2H), 7 .45-7.41 (m, 1H), 7.36-7.31 (m, 2H), 6.95-6.90 (m, 1H), 6.90-6.86 (m, 1H) 6.77-6.73 (m, 1H), 6.88-6.85 (m, 1H), 5.57 (d, J = 14.5 Hz, 1H), 5.12 (s, 2H) , 5.08 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 495 [M ⁺⁺ 1]. HPLC: 98.89%.

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−（３−フルオロベンジルオキシ）ピリジン−２−イル）−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（３）
化合物１と同様の方式で１−（ブロモメチル）−３−フルオロベンゼン化合物から３を調製し、シロップ（０．０２ｇ、０．０４ｍｍｏｌ、１５．５％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．２５（ｄ，Ｊ＝２．５Ｈｚ，１Ｈ）、７．５２（ｔ，Ｊ＝３．５Ｈｚ，２Ｈ）、７．４０−７．２６（ｍ，３Ｈ）、７．１７（ｄ，Ｊ＝９．５Ｈｚ，１Ｈ）、７．１２−７．０４（ｍ，２Ｈ）、６．７７−７．６．７５（ｍ，１Ｈ）、６．６６（ｔ，Ｊ＝９．０Ｈｚ，１Ｈ）、５．５６（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）、５．１２（ｓ，２Ｈ）、５．０６（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４７８．２［Ｍ^＋＋１］．ＨＰＬＣ：９９．４９％。 Example 3

2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (3-fluorobenzyloxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (3)
3 was prepared from the 1- (bromomethyl) -3-fluorobenzene compound in the same manner as compound 1 to give syrup (0.02 g, 0.04 mmol, 15.5%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.25 (d, J = 2.5 Hz, 1H), 7.52 (t, J = 3.5 Hz, 2H), 7 .40-7.26 (m, 3H), 7.17 (d, J = 9.5 Hz, 1H), 7.12-7.04 (m, 2H), 6.77-7.7.65 ( m, 1H), 6.66 (t, J = 9.0 Hz, 1H), 5.56 (d, J = 14.0 Hz, 1H), 5.12 (s, 2H), 5.06 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 478.2 [M ⁺⁺ 1]. HPLC: 99.49%.

１−（５−（４−クロロベンジルオキシ）ピリジン−２−イル）−２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（４）
化合物１と同様の方式で１−（ブロモメチル）−４−クロロベンゼンから化合物４を調製し、シロップ（０．０４ｇ、０．０８ｍｍｏｌ、２８．７％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．２３（ｄ，Ｊ＝２．０Ｈｚ，１Ｈ）、７．５１（ｄ，Ｊ＝８．５Ｈｚ，２Ｈ）、７．４０（ｄ，Ｊ＝８．５Ｈｚ，２Ｈ）、７．３４−７．２９（ｍ，２Ｈ）、７．２８（ｄｄ，Ｊ＝９．０、３．０Ｈｚ，１Ｈ）、６．７７−６．７３（ｍ，１Ｈ）、６．６７（ｔ，Ｊ＝７．０Ｈｚ，１Ｈ）、５．５５（ｄ，Ｊ＝１４Ｈｚ，１Ｈ）、５．０９（ｓ，２Ｈ）、５．０８（ｄ，Ｊ＝１４．５Ｈｚ，２Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４９４．１［Ｍ^＋＋１］．ＨＰＬＣ：９９．４３％。 Example 4

1- (5- (4-Chlorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane-2 -All (4)
Compound 4 was prepared from 1- (bromomethyl) -4-chlorobenzene in the same manner as Compound 1 to give syrup (0.04 g, 0.08 mmol, 28.7%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.23 (d, J = 2.0 Hz, 1H), 7.51 (d, J = 8.5 Hz, 2H), 7 .40 (d, J = 8.5 Hz, 2H), 7.34-7.29 (m, 2H), 7.28 (dd, J = 9.0, 3.0 Hz, 1H), 6.77- 6.73 (m, 1H), 6.67 (t, J = 7.0 Hz, 1H), 5.55 (d, J = 14 Hz, 1H), 5.09 (s, 2H), 5.08 ( d, J = 14.5 Hz, 2H). MS (ESI): m / z 494.1 [M ⁺⁺ 1]. HPLC: 99.43%.

４−（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イルオキシ）ベンゾニトリル（５）
ＣＨ_２Ｃｌ_２（１０ｍＬ）中の分子ふるい（０．５ｇ、４Å）の撹拌縣濁液に、ＲＴで４−（シアノフェニル）ボロン酸（０．２４ｇ、１．６ｍｍｏｌ）、アルコールＤ（０．５ｇ、１．６ｍｍｏｌ）、酢酸銅（ＩＩ）（Ｃｕ（ＯＡｃ）_２；０．３１ｇ、１．６ｍｍｏｌ）およびピリジン（０．６５ｍＬ、８．０ｍｍｏｌ）を連続的に添加した。反応混合物をＲＴで２４時間撹拌した。出発物質の消費後（ＴＬＣによる。）、反応混合物をＣｅｌｉｔｅ（登録商標）のパッドに通してろ過し、Ｃｅｌｉｔｅ（登録商標）ベッドをＣＨ_２Ｃｌ_２（１０ｍＬ）で洗浄した。ろ液をｓａｔｄ硫酸銅（ＩＩ）（ＣｕＳＯ_４）溶液（２５ｍＬ）で洗浄し、ＣＨ_２Ｃｌ_２（３ｘ５０ｍＬ）で抽出した。合わせた有機層を無水Ｎａ_２ＳＯ_４上で乾燥させた。ろ過および蒸発後、粗製物質をカラムクロマトグラフィー（ＳｉＯ_２、１００−２００メッシュ；ＥｔＯＡｃ／ヘキサンで溶出）に供し、Ｆ（０．１ｇ、０．２５ｍｍｏｌ、１５％）を液体として得た。^１Ｈ ＮＭＲ（２００ＭＨｚ，ＣＤＣｌ_３）：δ８．４７（ｄ，Ｊ＝６．５Ｈｚ，１Ｈ）、７．７２（ｄ，Ｊ＝６．５Ｈｚ，２Ｈ）、７．５５−７．３６（ｍ，３Ｈ）、７．１４−７．０４（ｍ，２Ｈ）、６．９１−６．７０（ｍ，３Ｈ）、３．４６（ｄ，Ｊ＝１３．０Ｈｚ，１Ｈ）、３．０１（ｄ，Ｊ＝５．０Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４０１．５［Ｍ^＋＋１］。 Example 5

4- (6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yloxy) benzonitrile (5 )
To a stirred suspension of molecular sieves (0.5 g, 4Å) in CH ₂ Cl ₂ (10 mL) was added 4- (cyanophenyl) boronic acid (0.24 g, 1.6 mmol), alcohol D (0. 5 g, 1.6 mmol), copper (II) acetate (Cu (OAc) ₂ ; 0.31 g, 1.6 mmol) and pyridine (0.65 mL, 8.0 mmol) were added sequentially. The reaction mixture was stirred at RT for 24 hours. After consumption of the starting material (by TLC), the reaction mixture was filtered through a pad of Celite® and the Celite® bed was washed with CH ₂ Cl ₂ (10 mL). The filtrate was washed with satd copper (II) sulfate (CuSO ₄ ) solution (25 mL) and extracted with CH ₂ Cl ₂ (3 × 50 mL). The combined organic layers were dried over anhydrous Na ₂ SO ₄ . After filtration and evaporation, the crude material was purified by column chromatography; subjecting the _(SiO 2, 100-200 mesh eluting with EtOAc / hexanes) to give F (0.1g, 0.25mmol, 15% ) as a liquid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 8.47 (d, J = 6.5 Hz, 1H), 7.72 (d, J = 6.5 Hz, 2H), 7.55-7.36 (m, 3H), 7.14-7.04 (m, 2H), 6.91-6.70 (m, 3H), 3.46 (d, J = 13.0 Hz, 1H), 3.01 (d, J = 5.0 Hz, 1H). MS (ESI): m / z 401.5 [M ⁺⁺ 1].

To a stirred solution of compound F (0.12 g, 0.3 mmol) in DMF (2 mL) was added 1 H-tetrazole (0.03 g, 0.45 mmol) and then K ₂ CO ₃ (0.03 g) under an inert atmosphere at RT. 0.04 g, 0.3 mmol) was added. The reaction mixture was heated at 60 ° C. for 16 hours. The reaction mixture was diluted with H ₂ O (20 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were dried over Na ₂ SO ₄ and concentrated under reduced pressure. The resulting crude material was purified by column chromatography _(SiO 2, 100-200 mesh; eluting with EtOAc / hexanes), 5 (0.03g, 0.06mmol, 21%) was obtained as a yellowish liquid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.25 (d, J = 2.5 Hz, 1H), 7.73 (d, J = 9.0 Hz, 2H), 7 .64 (d, J = 9.0 Hz, 1H), 7.49-7.42 (m, 2H), 7.18 (s, 1H), 7.13 (d, J = 8.5 Hz, 2H) 6.83-6.74 (m, 2H), 5.40 (d, J = 14.0 Hz, 1H), 5.27 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 471.1 [M ⁺⁺ 1]. HPLC: 99.33%.

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−（４−フルオロフェノキシ）ピリジン−２−イル）−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（６）
（４−フルオロフェニル）ボロン酸から化合物５と同様にして化合物６を調製し、固形物６（０．１ｇ、０．２２ｍｍｏｌ、４２．４％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．２０（ｄ，Ｊ＝２．５Ｈｚ，１Ｈ）、７．５３（ｄ，Ｊ＝９．０Ｈｚ，１Ｈ）、７．４３−７．３８（ｍ，２Ｈ）、７．２７（ｄ，Ｊ＝２．５Ｈｚ，１Ｈ）、７．２６−７．０３（ｍ，４Ｈ）、６．７９−６．７０（ｍ，２Ｈ）、５．４９（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）、５．１５（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４９４．１［Ｍ^＋＋１］。ＨＰＬＣ：９９．４３％。 Compounds 75 to 82 in Table 1 were prepared from Intermediate D and commercially available boronic acid (see Table 1, starting material) and commercially available azoles using the same conditions as Compound 5 (Example 5).
Example 6

2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (4-fluorophenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (6)
Compound 6 was prepared in the same manner as Compound 5 from (4-fluorophenyl) boronic acid to obtain Solid 6 (0.1 g, 0.22 mmol, 42.4%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.20 (d, J = 2.5 Hz, 1H), 7.53 (d, J = 9.0 Hz, 1H), 7 .43-7.38 (m, 2H), 7.27 (d, J = 2.5 Hz, 1H), 7.26-7.03 (m, 4H), 6.79-6.70 (m, 2H), 5.49 (d, J = 14.5 Hz, 1H), 5.15 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 494.1 [M ⁺⁺ 1]. HPLC: 99.43%.

１−（５−（４−クロロフェノキシ）ピリジン−２−イル）−２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（７）
（４−クロロフェニル）ボロン酸から化合物５と同様にして化合物７を調製し、固形物（５０ｍｇ、０．１ｍｍｏｌ、３５．７％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．２２（ｄ，Ｊ＝２．５Ｈｚ，１Ｈ）、７．５４（ｄ，Ｊ＝８．５Ｈｚ，１Ｈ）、７．４６−７．３７（ｍ，３Ｈ）、７．３０（ｄｄ，Ｊ＝３．０、９．０Ｈｚ，１Ｈ）、７．０４−７．００（ｍ，２Ｈ）、６．８０−６．７７（ｍ，１Ｈ）、６．７６−６．７１（ｍ，１Ｈ）、５．４９（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）、５．１６（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４７９［Ｍ^＋＋１］．ＨＰＬＣ：９８．４３％。 Example 7

1- (5- (4-Chlorophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2- All (7)
Compound 7 was prepared in the same manner as Compound 5 from (4-chlorophenyl) boronic acid to obtain a solid (50 mg, 0.1 mmol, 35.7%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.22 (d, J = 2.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7 .46-7.37 (m, 3H), 7.30 (dd, J = 3.0, 9.0 Hz, 1H), 7.04-7.00 (m, 2H), 6.80-6. 77 (m, 1H), 6.76-6.71 (m, 1H), 5.49 (d, J = 14.5 Hz, 1H), 5.16 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 479 [M ⁺⁺ 1]. HPLC: 98.43%.

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−メトキシピリジン−２−イル）−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（８）：
２−ブロモ−５−メトキシピリジンから化合物１と同様の方式で化合物８を調製し、黄褐色の固形物（２８ｍｇ、１０％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７４（ｓ，１Ｈ）、８．１９（ｓ，１Ｈ）、７．６３（ｂｒ ｓ，１Ｈ）、７．５１（ｄ，Ｊ＝８．５Ｈｚ，１Ｈ）、７．３４−７．３３（ｍ，１Ｈ）、７．２４−７．２３（ｍ，１Ｈ）、６．７５−６．７４（ｍ，１Ｈ）、６．６７−６．６６（ｍ，１Ｈ）、５．５８（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）、５．０７（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）、３．８８（ｓ，３Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ３８２［Ｍ^＋−１］．ＨＰＬＣ：９２．３７％。 Example 8

2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-methoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (8):
Compound 8 was prepared from 2-bromo-5-methoxypyridine in the same manner as Compound 1 to give a tan solid (28 mg, 10%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.74 (s, 1H), 8.19 (s, 1H), 7.63 (br s, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.34-7.33 (m, 1H), 7.24-7.23 (m, 1H), 6.75-6.74 (m, 1H), 6.67-6.66 ( m, 1H), 5.58 (d, J = 14.0 Hz, 1H), 5.07 (d, J = 14.0 Hz, 1H), 3.88 (s, 3H). MS (ESI): m / z 382 [M ⁺ -1]. HPLC: 92.37%.

４−（（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）メチル）ベンゾニトリル（９）
４−（ブロモメチル）ベンゾニトリルから化合物１と同様の方式で化合物９を調製し、白色固形物（８０ｍｇ、３３％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．２４（ｓ，１Ｈ）、７．７２（ｄ，Ｊ＝７．５Ｈｚ，２Ｈ）、７．７５−７．５２（ｍ，３Ｈ）、７．４３（ｂｒ ｓ，１Ｈ）、７．３９−７．３５（ｍ，１Ｈ）、７．３１−７．２９（ｍ，１Ｈ）、６．７８−６．７４（ｍ，１Ｈ）、６．７０−６．６７（ｍ，１Ｈ）、５．５１（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）、５．１８（ｓ，２Ｈ）、５．１３（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４８５［Ｍ^＋＋１］．ＨＰＬＣ：９７．１２％。 Example 9

4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (9)
Compound 9 was prepared from 4- (bromomethyl) benzonitrile in the same manner as Compound 1 to give a white solid (80 mg, 33%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.24 (s, 1H), 7.72 (d, J = 7.5 Hz, 2H), 7.75-7.52 (M, 3H), 7.43 (brs, 1H), 7.39-7.35 (m, 1H), 7.31-7.29 (m, 1H), 6.78-6.74 ( m, 1H), 6.70-6.67 (m, 1H), 5.51 (d, J = 14.0 Hz, 1H), 5.18 (s, 2H), 5.13 (d, J = 14.0 Hz, 1H). MS (ESI): m / z 485 [M ⁺⁺ 1]. HPLC: 97.12%.

  Compound 83 of Table 1 was prepared from Intermediate D using the same conditions as Compound 9 (Example 9).

４−（（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）メチル）−２−フルオロベンゾニトリル（１０）
４−（ブロモメチル）−２−フルオロベンゾニトリルから、化合物１と同様の方式で化合物１０を調製し、白色固形物（９０ｍｇ、３６％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．２３（ｓ，１Ｈ）、 ７．７０−７．６７（ｍ，１Ｈ）、７．５６（ｄ，Ｊ＝８．５Ｈｚ，１Ｈ）、７．３８−７．３６（ｍ，２Ｈ）、７．３２−７．２９（ｍ，３Ｈ）、６．７８−６．７４（ｍ，１Ｈ）、６．７１−６．６８（ｍ，１Ｈ）、５．５０（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）、５．１７（ｓ，２Ｈ）、５．１５（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ５０３［Ｍ^＋＋１］．ＨＰＬＣ：９５．８４％。 Example 10

4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (10)
Compound 10 was prepared from 4- (bromomethyl) -2-fluorobenzonitrile in the same manner as Compound 1 to give a white solid (90 mg, 36%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.23 (s, 1H), 7.70-7.67 (m, 1H), 7.56 (d, J = 8 .5Hz, 1H), 7.38-7.36 (m, 2H), 7.32-7.29 (m, 3H), 6.78-6.74 (m, 1H), 6.71-6 .68 (m, 1H), 5.50 (d, J = 14.5 Hz, 1H), 5.17 (s, 2H), 5.15 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 503 [M ⁺⁺ 1]. HPLC: 95.84%.

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−フェノキシピリジン−２−イル）−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（１１）
フェニルボロン酸から化合物５と同様の方式で化合物１１を調製し、固形物（３０ｍｇ、８．７％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７４（ｓ，１Ｈ）、８．２５（ｓ，１Ｈ）、７．５２（ｄ，Ｊ＝８．５Ｈｚ，１Ｈ）、７．４９（ｂｒ ｓ，１Ｈ）、７．４５−７．３５（ｍ，３Ｈ）、７．３０−７．２９（ｍ，１Ｈ）、７．２８−７．２７（ｍ，１Ｈ）、７．０６（ｄ，Ｊ＝７．５Ｈｚ，２Ｈ）、６．７９−６．７４（ｍ，１Ｈ）、６．７２−６．６９（ｍ，１Ｈ）、５．５４（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）、５．１２（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４４６．８［Ｍ^＋＋１］．ＨＰＬＣ：９９．５％。 Example 11

2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-phenoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (11)
Compound 11 was prepared in the same manner as Compound 5 from phenylboronic acid to obtain a solid (30 mg, 8.7%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.74 (s, 1H), 8.25 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.49 (br s, 1H), 7.45-7.35 (m, 3H), 7.30-7.29 (m, 1H), 7.28-7.27 (m, 1H), 7.06 (d, J = 7.5 Hz, 2H), 6.79-6.74 (m, 1H), 6.72-6.69 (m, 1H), 5.54 (d, J = 14.0 Hz, 1H), 5. 12 (d, J = 14.0 Hz, 1H). MS (ESI): m / z 446.8 [M ⁺⁺ 1]. HPLC: 99.5%.

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）−１−（５−（２，２，２−トリフルオロエトキシ）ピリジン−２−イル）プロパン−２−オール（１２）
１，１，１−トリフルオロ−２−ヨードエタンから化合物１と同様の方式で化合物１２を調製し、薄黄色の固形物（２３．０ｍｇ、５０％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．２７（ｓ，１Ｈ）、７．５６（ｄ，Ｊ＝９．０Ｈｚ，１Ｈ）、７．３５−７．３０（ｍ，２Ｈ）、７．２１（ｂｒ ｓ，１Ｈ）、６．７８−６．７３（ｍ，１Ｈ）、６．６９−６．６６（ｍ，１Ｈ）、５．５５（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）、５．１２（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）、４．４３（ｑ，Ｊ＝８．０Ｈｚ，２Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４５２．１［Ｍ^＋＋１］。ＨＰＬＣ：９８．０５％。 Example 12

2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (2,2,2-trifluoroethoxy) pyridin-2-yl ) Propan-2-ol (12)
Compound 12 was prepared from 1,1,1-trifluoro-2-iodoethane in the same manner as Compound 1 to obtain a pale yellow solid (23.0 mg, 50%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.27 (s, 1H), 7.56 (d, J = 9.0 Hz, 1H), 7.35-7.30. (M, 2H), 7.21 (brs, 1H), 6.78-6.73 (m, 1H), 6.69-6.66 (m, 1H), 5.55 (d, J = 14.5 Hz, 1H), 5.12 (d, J = 14.5 Hz, 1H), 4.43 (q, J = 8.0 Hz, 2H). MS (ESI): m / z 452.1 [M ⁺⁺ 1]. HPLC: 98.05%.

（１−（ブロモメチル）−２，４−ジフルオロベンゼン）（Ｉ−１）
ＣＨ_３ＯＨ（８ｍＬ）中の２，４−ジフルオロベンズアルデヒド（５００ｍｇ、３．５２ｍｍｏｌ）の撹拌溶液に、０℃でＮａＢＨ_４（２６６ｍｇ、７．０４ｍｍｏｌ）を分割して添加し、反応混合物を０℃で１時間撹拌した。反応完了後（ＴＬＣによる。）、ＣＨ_３ＯＨを減圧下で除去し、氷冷Ｈ_２Ｏ（４０ｍＬ）で希釈し、ＥｔＯＡｃ（２ｘ２０ｍＬ）で抽出した。合わせた有機層をＨ_２Ｏ（４０ｍＬ）および塩水（４０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、粗製物質を得た。１０％ＥｔＯＡｃ／ヘキサンで溶出するシリカゲルカラムクロマトグラフィーによる精製によって、アルコールＧ（４５０ｍｇ、３．１２ｍｍｏｌ、８８％）を無色の液体として得た。^１Ｈ ＮＭＲ（２００ＭＨｚ，ＣＤＣｌ_３）：δ７．４５−７．３３（ｍ，１Ｈ）、６．８３−６．７５（ｍ，２Ｈ）、４．７２（ｓ，２Ｈ）、１．７９（ｂｒ ｓ、ＯＨ）。 Example 13-Preparation of Intermediate

(1- (Bromomethyl) -2,4-difluorobenzene) (I-1)
To a stirred solution of 2,4-difluorobenzaldehyde (500 mg, 3.52 mmol) in CH ₃ OH (8 mL) was added NaBH ₄ (266 mg, 7.04 mmol) in portions at 0 ° C. and the reaction mixture was added at 0 ° C. For 1 hour. After the reaction was complete (by TLC), CH ₃ OH was removed under reduced pressure, diluted with ice cold H ₂ O (40 mL) and extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with H ₂ O (40 mL) and brine (40 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 10% EtOAc / hexanes afforded alcohol G (450 mg, 3.12 mmol, 88%) as a colorless liquid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 7.45-7.33 (m, 1H), 6.83-6.75 (m, 2H), 4.72 (s, 2H), 1.79 (br s, OH).

To a solution of compound G (450 mg, 3.12 mmol) in Et ₂ O (10 mL) was added PBr ₃ (0.2 mL, 2.18 mmol) at 0 ° C. and the mixture was stirred at RT for 2 h. After completion of the reaction (by TLC), the reaction mixture was inactivated with ice cold H ₂ O (20 mL) and extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with H ₂ O (40 mL) and brine (40 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 5% EtOAc / hexanes afforded bromide I-1 (420 mg, 2.02 mmol, 65%) as a colorless liquid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 7.43-7.31 (m, 1H), 6.92-6.77 (m, 2H), 4.48 (s, 2H).

３−フルオロ−４−（メルカプトメチル）ベンゾニトリル（Ｉ−２）
エチルアルコール（ＥｔＯＨ；２０ｍＬ）中の４−（ブロモメチル）−３−フルオロベンゾニトリル（０．８ｇ、３．７ｍｍｏｌ）およびチオ尿素（０．５７ｇ、７．４ｍｍｏｌ）の混合物を１時間加熱還流した。ＴＬＣによって反応進行を監視し、反応混合物をＲＴに冷却し、減圧下で濃縮した。残渣をＥｔＯＡｃ（５０ｍＬ）で洗浄し、１．６Ｎ ＮａＯＨで処理し、ＲＴで２０時間撹拌した。反応混合物を濃ＨＣｌでｐＨ〜４に調整し、Ｅｔ_２Ｏ（５０ｍＬ）で希釈した。有機層をＨ_２Ｏ（２５ｍＬ）および塩水（２５ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、粗製Ｉ−２（３００ｍｇ）を得た。さらなる精製を行わずに粗製物質を使用した。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ７．４５（ｄｄ，Ｊ＝９．５Ｈｚ，１．５Ｈｚ，１Ｈ）、７．４０−７．３７（ｍ，２Ｈ）、３．７６（ｓ，２Ｈ）。

3-Fluoro-4- (mercaptomethyl) benzonitrile (I-2)
A mixture of 4- (bromomethyl) -3-fluorobenzonitrile (0.8 g, 3.7 mmol) and thiourea (0.57 g, 7.4 mmol) in ethyl alcohol (EtOH; 20 mL) was heated to reflux for 1 hour. The reaction progress was monitored by TLC and the reaction mixture was cooled to RT and concentrated under reduced pressure. The residue was washed with EtOAc (50 mL), treated with 1.6 N NaOH and stirred at RT for 20 hours. The reaction mixture was adjusted to pH˜4 with concentrated HCl and diluted with Et ₂ O (50 mL). The organic layer was washed with H ₂ O (25 mL) and brine (25 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give crude I-2 (300 mg). The crude material was used without further purification. ¹ H NMR (500 MHz, CDCl ₃ ): δ 7.45 (dd, J = 9.5 Hz, 1.5 Hz, 1H), 7.40-7.37 (m, 2H), 3.76 (s, 2H) .

１−（ブロモメチル）−４−（２，２，２−トリフルオロエトキシ）ベンゼン（Ｉ−３）
ＣＨ_２Ｃｌ_２（１００ｍＬ）中の２，２，２−トリフルオロエタノール（１０．０ｇ、１００ｍｍｏｌ）の撹拌溶液に、０℃で不活性雰囲気下にてトリエチルアミン（Ｅｔ_３Ｎ；２７．８ｍＬ、２００ｍｍｏｌ）、ｐ−トルエンスルホニルクロリド（１９．１ｇ、１００ｍｍｏｌ）および触媒量の４−ジメチルアミノピリジン（ＤＭＡＰ；１０ｍｇ）を添加した。反応混合物をＲＴに温め、撹拌をさらに５時間継続した。反応混合物をＨ_２Ｏ（１００ｍＬ）で希釈し、ＣＨ_２Ｃｌ_２（３ｘ２００ｍＬ）で抽出した。合わせた有機抽出物をＨ_２Ｏ（５０ｍＬ）および塩水（５０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、化合物Ｈ（２５．０ｇ、９８．４２ｍｍｏｌ；粗製）を半固形物として得た。^１Ｈ ＮＭＲ（２００ＭＨｚ，ＣＤＣｌ_３）：δ７．８１（ｄ，Ｊ＝８．０Ｈｚ，２Ｈ）、７．３８（ｄ，Ｊ＝８．０Ｈｚ，２Ｈ）、４．３５（ｑ，Ｊ＝８．０Ｈｚ，２Ｈ）、２．４７（ｓ，３Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ２５６［Ｍ＋２］^＋。

1- (Bromomethyl) -4- (2,2,2-trifluoroethoxy) benzene (I-3)
To a stirred solution of 2,2,2-trifluoroethanol (10.0 g, 100 mmol) in CH ₂ Cl ₂ (100 mL) at 0 ° C. under an inert atmosphere, triethylamine (Et ₃ N; 27.8 mL, 200 mmol). ), P-toluenesulfonyl chloride (19.1 g, 100 mmol) and a catalytic amount of 4-dimethylaminopyridine (DMAP; 10 mg). The reaction mixture was warmed to RT and stirring was continued for another 5 hours. The reaction mixture was diluted with H ₂ O (100 mL) and extracted with CH ₂ Cl ₂ (3 × 200 mL). The combined organic extracts were washed with H ₂ O (50 mL) and brine (50 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give compound H (25.0 g, 98.42 mmol; crude) Was obtained as a semi-solid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 7.81 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 4.35 (q, J = 8. 0 Hz, 2H), 2.47 (s, 3H). MS (ESI): m / z 256 [M + 2] ^< +>.

To a stirred suspension of 4-hydroxybenzaldehyde (0.24 g, 1.97 mmol) and K ₂ CO ₃ (1.36 g, 9.84 mmol) in DMF (5 mL) was added Compound H ( 0.5 g, 1.97 mmol) was added. The reaction mixture was heated to 80 ° C. and stirred for 18 hours. After the reaction was complete (by TLC), the reaction mixture was inactivated with ice cold H ₂ O (25 mL) and extracted with EtOAc (4 × 25 mL). The combined organic extracts were washed with H ₂ O (25 mL) and brine (25 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 10% EtOAc / hexanes afforded compound I (0.4 g, 1.8 mmol, 93%) as a pale yellow oil. ¹ H NMR (200 MHz, CDCl ₃ ): δ 9.93 (s, 1H), 7.90 (d, J = 9.0 Hz, 2H), 7.06 (d, J = 9.0 Hz, 2H), 4 .44 (q, J = 8.0 Hz, 2H).

To a stirred solution of I (0.4 g, 1.8 mmol) in CH ₃ OH (10 mL) at 0 ° C. was added NaBH ₄ (0.14 g, 3.6 mmol) and the mixture was stirred for 1 hour. After completion of the reaction (by TLC), volatiles were removed under reduced pressure. The reaction mixture was then diluted with ice cold H ₂ O (40 mL) and extracted with EtOAc (2 × 40 mL). The combined organic extracts were washed with H ₂ O (40 mL) and brine (40 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 20% EtOAc / hexane) afforded J (0.3 g, 1.35 mmol, 75%) as a colorless liquid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 7.33 (d, J = 9.0 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 4.64 (d, J = 6. 0 Hz, 2H), 4.35 (q, J = 8.0 Hz, 2H), 1.58 (t, J = 6.0 Hz, OH),

To a stirred solution of compound J (0.3 g, 1.35 mmol) in Et ₂ O (10 mL) was added PBr ₃ (0.25 g, 0.95 mmol) at 0 ° C. and the reaction mixture was stirred at RT for 1 h. did. After complete consumption of starting material (by TLC), the reaction mixture was inactivated with ice cold H ₂ O (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed with H ₂ O (30 mL) and brine (30 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 10% EtOAc / hexanes afforded compound I-3 (0.25 g, 0.87 mmol, 65%) as a colorless liquid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 7.36 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 4.49 (s, 2H), 4 .35 (q, J = 8.0 Hz, 2H).

６−（ブロモメチル）ニコチノニトリル（Ｉ−４）
１，２−ジクロロエタン（３０ｍＬ）中の６−メチルニコチノニトリル（１．０ｇ、８．４７ｍｍｏｌ）の撹拌溶液に、ＲＴでＮ−ブロモスクシンイミド（ＮＢＳ；１．５２ｇ、８．５４ｍｍｏｌ）および次いで２，２’−アゾビス（イソブチロニトリル）（ＡＩＢＮ；０．１４ｇ、０．８５ｍｍｏｌ）を添加した。次に反応混合物を８０℃に加熱し、１４時間撹拌した。出発物質の完全消費後（ＴＬＣによる。）、反応混合物をＲＴに冷却し、揮発性物質を減圧下で除去し、粗製物質を得た。１０％ＥｔＯＡｃ／ヘキサン）で溶出するシリカゲルカラムクロマトグラフィーによる精製によって、化合物Ｉ−４（０．６ｇ、３．０５ｍｍｏｌ、３６％）を無色の液体として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ７．６７−７．６２（ｍ，２Ｈ）、７．２１（ｄｄ，Ｊ＝９．０，２．０Ｈｚ，１Ｈ）、４．４４（ｓ，２Ｈ）。

6- (Bromomethyl) nicotinonitrile (I-4)
To a stirred solution of 6-methylnicotinonitrile (1.0 g, 8.47 mmol) in 1,2-dichloroethane (30 mL) at RT N-bromosuccinimide (NBS; 1.52 g, 8.54 mmol) and then 2 , 2′-Azobis (isobutyronitrile) (AIBN; 0.14 g, 0.85 mmol) was added. The reaction mixture was then heated to 80 ° C. and stirred for 14 hours. After complete consumption of starting material (by TLC), the reaction mixture was cooled to RT and volatiles were removed under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 10% EtOAc / hexane) afforded compound I-4 (0.6 g, 3.05 mmol, 36%) as a colorless liquid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 7.67-7.62 (m, 2H), 7.21 (dd, J = 9.0, 2.0 Hz, 1H), 4.44 (s, 2H) .

（３，５−ジフルオロピリジン−２−イル）メチル４−メチルベンゼンスルホネート（Ｉ−５）
テトラヒドロフラン（ＴＨＦ；１０ｍＬ）中の（３，５−ジフルオロピリジン−２−イル）メタノール（０．２５ｇ、０．７ｍｍｏｌ）の溶液に、ＲＴで水酸化カリウム（ＫＯＨ；０．１４ｇ、２．５５ｍｍｏｌ）を添加し、混合物を１５分間撹拌した。ｐ−トルエンスルホニルクロリド（０．４２ｇ、２．２１ｍｍｏｌ）をＲＴでゆっくりと添加し、反応混合物をさらに１８時間撹拌した。出発物質の完全消費後（ＴＬＣによる。）、反応混合物をＨ_２Ｏ（５０ｍＬ）で希釈し、ＥｔＯＡｃ（２ｘ２５ｍＬ）で抽出した。合わせた有機抽出物をＨ_２Ｏ（２５ｍＬ）および塩水（２５ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、粗製物質を得た。１５％ＥｔＯＡｃ／ヘキサンで溶出するシリカゲルカラムクロマトグラフィーによる精製によって、化合物Ｉ−５（０．１８ｇ、０．２５ｍｍｏｌ、３５％）を無色の液体として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．２９（ｓ，１Ｈ）、７．８２（ｄ，Ｊ＝８．５Ｈｚ，２Ｈ）、７．３４（ｄ，Ｊ＝８．５Ｈｚ，２Ｈ）、７．２０−７．１６（ｍ，１Ｈ）、５．２０（ｓ，２Ｈ）、２．４５（ｓ，３Ｈ）

(3,5-Difluoropyridin-2-yl) methyl 4-methylbenzenesulfonate (I-5)
To a solution of (3,5-difluoropyridin-2-yl) methanol (0.25 g, 0.7 mmol) in tetrahydrofuran (THF; 10 mL) at RT potassium hydroxide (KOH; 0.14 g, 2.55 mmol) Was added and the mixture was stirred for 15 minutes. p-Toluenesulfonyl chloride (0.42 g, 2.21 mmol) was added slowly at RT and the reaction mixture was stirred for an additional 18 hours. After complete consumption of starting material (by TLC), the reaction mixture was diluted with H ₂ O (50 mL) and extracted with EtOAc (2 × 25 mL). The combined organic extracts were washed with H ₂ O (25 mL) and brine (25 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 15% EtOAc / hexanes afforded compound I-5 (0.18 g, 0.25 mmol, 35%) as a colorless liquid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.29 (s, 1H), 7.82 (d, J = 8.5 Hz, 2H), 7.34 (d, J = 8.5 Hz, 2H), 7 20-7.16 (m, 1H), 5.20 (s, 2H), 2.45 (s, 3H)

３−（ブロモメチル）−２−フルオロベンゾニトリル（Ｉ−６）
１，２−ジクロロエタン（３０ｍＬ）中の２−フルオロ−３−メチルベンゾニトリル（２００ｍｇ、１．５ｍｍｏｌ）の撹拌溶液に、ＲＴでＮＢＳ（２６６ｍｇ、１．４９ｍｍｏｌ）およびＡＩＢＮ（２９ｍｇ、０．１５ｍｍｏｌ）を添加した。次いで反応混合物を８０℃に加熱し、反応混合物を２時間撹拌した。出発物質の完全消費後（ＴＬＣによる。）、反応混合物をＲＴに冷却した。揮発性物質を減圧下で除去し、粗製物質を得た。２−３％ＥｔＯＡｃ／ヘキサンで溶出するシリカゲルカラムクロマトグラフィーによる精製によって、化合物Ｉ−６（２５０ｍｇ、１．１５ｍｍｏｌ、７８％）を無色の液体として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ７．６９−７．６５（ｍ，１Ｈ）、７．６２−７．５８（ｍ，１Ｈ）、７．２８−７．２５（ｍ，１Ｈ）、４．５０（ｓ，２Ｈ）。

3- (Bromomethyl) -2-fluorobenzonitrile (I-6)
To a stirred solution of 2-fluoro-3-methylbenzonitrile (200 mg, 1.5 mmol) in 1,2-dichloroethane (30 mL) was added NBS (266 mg, 1.49 mmol) and AIBN (29 mg, 0.15 mmol) at RT. Was added. The reaction mixture was then heated to 80 ° C. and the reaction mixture was stirred for 2 hours. After complete consumption of starting material (by TLC), the reaction mixture was cooled to RT. Volatiles were removed under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 2-3% EtOAc / hexanes afforded compound I-6 (250 mg, 1.15 mmol, 78%) as a colorless liquid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 7.69-7.65 (m, 1H), 7.62-7.58 (m, 1H), 7.28-7.25 (m, 1H), 4 .50 (s, 2H).

１−（４−（（２，４−ジフルオロベンジル）オキシ）ピリジン−２−イル）−２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（１３）
ＤＭＦ（４ｍＬ）中の２−ブロモピリジン−４−オール（８４ｍｇ、０．４８ｍｍｏｌ）の撹拌溶液に、ＲＴでＫ_２ＣＯ_３（１３３ｍｇ、０．９６ｍｍｏｌ）および化合物Ｉ−１（１００ｍｇ、０．４８ｍｍｏｌ）を連続的に添加した。混合物を７０℃まで徐々に加熱し、３時間撹拌した。反応完了後（ＴＬＣによる。）、反応混合物を氷冷Ｈ_２Ｏ（３０ｍＬ）で不活性化し、ＥｔＯＡｃ（２ｘ２０ｍＬ）で抽出した。合わせた有機層をＨ_２Ｏ（３０ｍＬ）および塩水（３０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、粗製物質を得た。１５％ＥｔＯＡｃ／ヘキサンで溶出するシリカゲルカラムクロマトグラフィーによる精製によって、化合物Ｋ（７０ｍｇ、０．２３ｍｍｏｌ、４８％）を黄色の固形物として得た。^１Ｈ ＮＭＲ（２００ＭＨｚ，ＣＤＣｌ_３）：δ８．２０（ｄ，Ｊ＝５．６Ｈｚ，１Ｈ）、７．４４−７．３６（ｍ，１Ｈ）、７．０９（ｄ，Ｊ＝２．２Ｈｚ，１Ｈ）、６．９８−６．８２（ｍ，３Ｈ）、５．１０（ｓ，２Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ３０２［Ｍ＋２］^＋。 Example 14

1- (4-((2,4-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (13)
To a stirred solution of 2-bromopyridin-4-ol (84 mg, 0.48 mmol) in DMF (4 mL) at RT was K ₂ CO ₃ (133 mg, 0.96 mmol) and compound I-1 (100 mg, 0.48 mmol). ) Was added continuously. The mixture was gradually heated to 70 ° C. and stirred for 3 hours. After the reaction was complete (by TLC), the reaction mixture was inactivated with ice cold H ₂ O (30 mL) and extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with H ₂ O (30 mL) and brine (30 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 15% EtOAc / hexanes afforded compound K (70 mg, 0.23 mmol, 48%) as a yellow solid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 8.20 (d, J = 5.6 Hz, 1H), 7.44-7.36 (m, 1H), 7.09 (d, J = 2.2 Hz, 1H), 6.98-6.82 (m, 3H), 5.10 (s, 2H). MS (ESI): m / z 302 [M + 2] ^< +>.

To a suspension of copper powder (60 mg, 0.93 mmol) in DMSO (5 mL), ethyl 2-bromo-2,2-difluoroacetate (0.06 mL, 0.46 mmol) is added and the mixture is dissolved at RT. Stir for 1 hour under active atmosphere. Compound K (70 mg, 0.23 mmol) was added to the resulting solution and stirring was continued at RT for 10 hours. After completion of the reaction (by TLC), the reaction mixture was inactivated with saturated NH ₄ Cl solution (30 mL) and extracted with CH ₂ Cl ₂ (3 × 50 mL). The combined organic layers were washed with H ₂ O (30 mL) and brine (30 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 10% EtOAc / hexanes afforded ester L (30 mg, 0.09 mmol, 37%) as a semi-solid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 8.48 (d, J = 5.8 Hz, 1H), 7.51-7.39 (m, 1H), 7.30 (d, J = 2.2 Hz, 1H), 6.98-6.83 (m, 3H), 5.16 (s, 2H), 4.37 (q, J = 7.2 Hz, 2H), 1.33 (t, J = 7. 2Hz, 3H). MS (ESI): m / z 344 [M + H] ^< +>.

To a stirred solution of 1-bromo-2,4-difluorobenzene (0.01 mL, 0.09 mmol) in Et ₂ O (3 mL) at −78 ° C. n-BuLi (1.6 M in hexane; 0.06 mL, 0.09 mmol) was added and the mixture was stirred under an inert atmosphere for 30 minutes. A solution of ester L (30 mg, 0.09 mmol) in Et ₂ O (2 mL) was added to the reaction mixture at −78 ° C. and stirring was continued for another 2 hours. After completion of the reaction (by TLC), the reaction mixture was inactivated with saturated NH ₄ Cl solution (15 mL) and extracted with EtOAc (2 × 15 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 20% EtOAc / hexane) afforded ketone M (10 mg, 0.02 mmol, 27%) as a colorless semi-solid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 8.38 (d, J = 5.8 Hz, 1H), 8.10-8.02 (m, 1H), 7.50-7.42 (m, 2H) 7.00-6.83 (m, 5H), 5.18 (s, 2H). MS (ESI): m / z 412 [M + H] ^< +>.

To a stirred solution of ketone M (350 mg, 0.85 mmol) in Et ₂ O (10 mL) was added freshly prepared diazomethane [10% KOH solution (20 mL) and Et ₂ O (20 mL) 1: 1 at −5 ° C.]. NMU (439 mg, 4.26 mmol) was dissolved in the mixture at 0 ° C., then the organic layer was separated using KOH pellets and prepared by drying] was added and the mixture was stirred for 2 h. The resulting reaction mixture was warmed to RT and stirring was continued for an additional 16 hours. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 25% EtOAc / hexanes afforded epoxide N (120 mg, 0.28 mmol, 33%) as a semi-solid. ¹ H NMR (200 MHz, CDCl ₃ ): δ 8.50 (d, J = 5.6 Hz, 1H), 7.47-7.32 (m, 2H), 7.10-7.07 (m, 1H) 6.97-6.69 (m, 5H), 5.10 (s, 2H), 3.46 (d, J = 5.2 Hz, 1H), 2.98-2.95 (m, 1H) . MS (ESI): m / z 426 [M + H] ^< +>.

To a stirred solution of epoxide N (120 mg, 0.28 mmol) in anhydrous DMF (5 mL), 1H-tetrazole (30 mg, 0.42 mmol) and K ₂ CO ₃ (39 mg, 0.28 mmol) in an inert atmosphere at RT. Was added continuously. The resulting reaction mixture was gradually heated to 65 ° C. and stirred for 8 hours. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice cold H ₂ O (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 45% EtOAc / hexanes afforded 13 (35 mg, 0.07 mmol, 25%) as a light yellow semi-solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.78 (s, 1H), 8.32 (s, 1H) 8.06 (s, 1H) 7.41-7.32 (m, 2H), 7. 18 (s, 1H), 6.94-6.80 (m, 3H), 6.76-6.72 (m, 1H), 6.68-6.60 (m, 1H), 5.58 ( d, J = 14.5 Hz, 1H), 5.14 (s, 2H) 5.10 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 496 [M + H] ⁺ . HPLC: 96%.

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）−１−（５−（ビニルオキシ）ピリジン−２−イル）プロパン−２−オール（１４）
アセトン−Ｈ_２Ｏ（１：１；３００ｍＬ）中の化合物Ｏ（１０．０ｇ、３０．５ｍｍｏｌ）の溶液に分割してオキソン（９３．９ｇ、１５３ｍｍｏｌ）を添加し、反応混合物をＲＴで１８時間撹拌した。出発物質の完全消費後（ＴＬＣによる。）、揮発性物質を減圧下で濃縮した。反応混合物をＨ_２Ｏ（１５０ｍＬ）で希釈し、ＥｔＯＡｃ（２ｘ１５０ｍＬ）で抽出した。合わせた有機抽出物をＨ_２Ｏ（１５０ｍＬ）および塩水（１５０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、粗製物質を得た。３０％ＥｔＯＡｃ／ヘキサンで溶出するシリカゲルカラムクロマトグラフィーによる精製によって、化合物Ｄ（５．５ｇ、１８．４ｍｍｏｌ、６０％）を灰白色の固形物として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．２８（ｓ，１Ｈ）、７．４０−７．３８（ｍ，２Ｈ）、７．１９（ｄ，Ｊ＝８．０Ｈｚ，１Ｈ）、６．８３−６．８１（ｍ，１Ｈ）、６．７６−６．７４（ｍ，１Ｈ）、５．９１（ｂｒ ｓ，ＯＨ）、３．４２（ｄ，Ｊ＝５．０Ｈｚ，１Ｈ）、２．９９（ｄ，Ｊ＝５．０Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ３００［Ｍ＋Ｈ］^＋。 Example 15

2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (vinyloxy) pyridin-2-yl) propan-2-ol (14 )
Oxone (93.9 g, 153 mmol) was added in portions to a solution of compound O (10.0 g, 30.5 mmol) in acetone-H ₂ O (1: 1; 300 mL) and the reaction mixture was stirred at RT for 18 h. Stir. After complete consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. The reaction mixture was diluted with H ₂ O (150 mL) and extracted with EtOAc (2 × 150 mL). The combined organic extracts were washed with H ₂ O (150 mL) and brine (150 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 30% EtOAc / hexanes afforded compound D (5.5 g, 18.4 mmol, 60%) as an off-white solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.28 (s, 1H), 7.40-7.38 (m, 2H), 7.19 (d, J = 8.0 Hz, 1H), 6.83 −6.81 (m, 1H), 6.76-6.74 (m, 1H), 5.91 (brs, OH), 3.42 (d, J = 5.0 Hz, 1H), 2. 99 (d, J = 5.0 Hz, 1H). MS (ESI): m / z 300 [M + H] ^< +>.

Mixture of compound D (100 mg, 0.33 mmol), 1,2-dibromoethane (310 mg, 1.67 mmol) and K ₂ CO ₃ (460 mg, 3.34 mmol) in DMF (10 mL) at 70 ° C. for 16 hours. Stir. After complete consumption of starting material (by TLC), the reaction mixture was cooled to RT, diluted with H ₂ O (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic extracts were washed with H ₂ O (50 mL) and brine (50 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 30% EtOAc / hexanes afforded compound P (30 mg, 0.07 mmol, 22%) as an off-white solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.35 (d, J = 2.5 Hz, 1H), 7.43-7.35 (m, 2H), 7.21 (dd, J = 9.0, 2.5 Hz, 1H), 6.85-6.82 (m, 1H), 6.76-6.72 (m, 1H), 4.36 (t, J = 6.0 Hz, 2H), 3. 67 (t, J = 6.0 Hz, 2H), 3.43 (d, J = 5.0 Hz, 1H), 2.95 (d, J = 5.0 Hz, 1H).

To a stirred solution of compound P (30 mg, 0.07 mmol) in t-butyl alcohol (t-BuOH; 10 mL) was added potassium tert-butoxide (KO ^t Bu; 28 mg, 0.25 mmol) and the mixture at RT. Stir for 16 hours. After complete consumption of the starting material (by TLC), the volatile material was evaporated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 20% EtOAc / hexanes afforded compound Q (15 mg, 0.05 mmol, 62%) as an off-white solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.41 (d, J = 3.0 Hz, 1H), 7.44 (d, J = 9.0 Hz, 1H), 7.38-7.34 (m, 1H), 7.33 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 6.85-6.83 (m, 1H), 6.76-6.72 (m, 1H), 6. 65 (dd, J = 13.5 Hz, 6.0 Hz, 1H), 4.92 (dd, J = 13.5 Hz, 1.0 Hz, 1H), 4.64 (dd, J = 6.0 Hz, 1.H). 0 Hz, 1H), 3.44 (d, J = 4.5 Hz, 1H), 2.97 (d, J = 4.5 Hz, 1H).

To a stirred solution of epoxide Q (150 mg, 0.46 mmol) in anhydrous DMF (10 mL), 1H-tetrazole (48 mg, 0.69 mmol) and K ₂ CO ₃ (63 mg, 0.46 mmol) in an inert atmosphere at RT. Was added continuously. The resulting reaction mixture was gradually heated to 65 ° C. and stirred for 16 hours. After complete consumption of starting material (by TLC), the reaction mixture was diluted with ice-cold H ₂ O (30 mL) and extracted with EtOAc (2 × 30 mL). The combined organic extracts were washed with H ₂ O (30 mL) and brine (30 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 40% EtOAc / hexanes afforded 14 (25.5 mg, 0.06 mmol, 14%) as a colorless thick syrup. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.74 (s, 1H), 8.27 (s, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.38-7.31. (M, 3H), 6.77-6.74 (m, 1H), 6.69-6.66 (m, 1H), 6.63-6.60 (m, 1H), 5.57 (d , J = 14.0 Hz, 1H), 5.11 (d, J = 14.0 Hz, 1H), 4.96 (d, J = 14.0 Hz, 1H), 4.71 (d, J = 4. 5Hz, 1H). MS (ESI): m / z 396 [M + H] ⁺ . HPLC: 99%.

４−（（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）チオ）メチル）−３−フルオロベンゾニトリル（１５）および４−（（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（２Ｈ−テトラゾール−２−イル）プロピル）ピリジン−３−イル）チオ）メチル）−３−フルオロベンゾニトリル（１６）
ＤＭＦ（１５ｍＬ）中のエポキシドＣ（５ｇ、１３．８ｍｍｏｌ）の撹拌溶液に、ＲＴでＫ_２ＣＯ_３（１．９ｇ、１３．８７ｍｍｏｌ）および１Ｈ−テトラゾール（１．５５ｇ、２０．７２ｍｍｏｌ）を連続的に添加した。得られた反応混合物を６５℃に加熱し、１６時間撹拌した。ＴＬＣによって反応進行を監視した。反応物を氷冷Ｈ_２Ｏ（５０ｍＬ）で希釈し、ＥｔＯＡｃ（３ｘ５０ｍＬ）で抽出した。合わせた有機層をＨ_２Ｏ（３０ｍＬ）および塩水（３０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、粗製生成物を得た。３５％ＥｔＯＡｃ／ヘキサンで溶出するシリカゲルカラムクロマトグラフィーによる精製によって、化合物Ｓ（１．０ｇ、２．３１ｍｍｏｌ、１７％）を無色のシロップとして得て、４０％ＥｔＯＡｃ／ヘキサンで溶出し、化合物Ｒ（２．７ｇ、６．２４ｍｍｏｌ、４５％）を灰白色の固形物として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．６２（ｓ，１Ｈ）、７．９３（ｄｄ，Ｊ＝８．０，２．０Ｈｚ，１Ｈ）、７．４６（ｄ，Ｊ＝８．０Ｈｚ，１Ｈ）、７．３１−７．２８（ｍ，１Ｈ）、６．７８−６．７３（ｍ，１Ｈ）、６．７０−６．６６（ｍ，１Ｈ）、５．６０（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）、５．１４（ｄ，Ｊ＝１４．５Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４３３［Ｍ＋Ｈ］^＋。 Example 16

4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) thio) Methyl) -3-fluorobenzonitrile (15) and 4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazole-2- Yl) propyl) pyridin-3-yl) thio) methyl) -3-fluorobenzonitrile (16)
To a stirred solution of epoxide C (5 g, 13.8 mmol) in DMF (15 mL) was added K ₂ CO _{3 (} 1.9 g, 13.87 mmol) and 1H-tetrazole (1.55 g, 20.72 mmol) at RT. Was added. The resulting reaction mixture was heated to 65 ° C. and stirred for 16 hours. The reaction progress was monitored by TLC. The reaction was diluted with ice cold H ₂ O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with H ₂ O (30 mL) and brine (30 mL) and dried over anhydrous Na ₂ SO ₄ to give the crude product. Purification by silica gel column chromatography eluting with 35% EtOAc / hexanes afforded compound S (1.0 g, 2.31 mmol, 17%) as a colorless syrup, eluting with 40% EtOAc / hexanes, compound R ( 2.7 g, 6.24 mmol, 45%) was obtained as an off-white solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.62 (s, 1H), 7.93 (dd, J = 8.0, 2.0 Hz, 1H), 7.46 (D, J = 8.0 Hz, 1H), 7.31-7.28 (m, 1H), 6.78-6.73 (m, 1H), 6.70-6.66 (m, 1H) 5.60 (d, J = 14.5 Hz, 1H), 5.14 (d, J = 14.5 Hz, 1H). MS (ESI): m / z 433 [M + H] ^< +>.

R (100 mg, 0.23 mmol), I-2 (38 mg, crude), diisopropylethylamine (DIEA; 0.07 mL, 0.57 mmol), tris (dibenzylideneacetone) dipalladium (0) in toluene (1 mL) ( A stirred solution of Pd ₂ (dba) ₃ ; (11 mg, 0.011 mmol) and xanthophos (13 mg, 0.023 mmol) was heated under microwave conditions to 100 ° C. for 1 hour LC-MS (for further confirmation) The reaction progress was monitored by: The reaction mixture was filtered through a Celite® pad and the pad was washed with EtOAc (3 × 15 mL) The filtrate was washed with H ₂ O (50 mL) and brine (50 mL), dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure to give the crude material. preparative high performance liquid Purification by chromatography (HPLC), 15 (15mg, 0.03mmol, 11%) as a colorless liquid _{1 H NMR (400MHz, CDCl 3} ):. Δ8.73 (s, 1H), 8.38 (S, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.42-7.28 (m, 4H), 6 79-6.67 (m, 2H), 5.50 (d, J = 14.0 Hz, 1H), 5.16 (d, J = 14.0 Hz, 1H), 4.19 (s, 2H) MS (ESI): m / z 519 [M + H] ⁺ HPLC: 98%.

S (300 mg, 0.69 mmol), I-2 (116 mg, crude), DIEA (0.22 mL, 1.7 mmol), Pd ₂ (dba) ₃ (31 mg, 0.03 mmol) and xanthophos in toluene (3 mL) A stirred solution of (39 mg, 0.069 mmol) was heated at 100 ° C. for 1 hour under microwave conditions. The reaction progress was monitored by LC-MS. The reaction mixture was filtered through a Celite® pad and the pad was washed with EtOAc (3 × 15 mL). The filtrate was washed with H ₂ O (50 mL) and brine (50 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by preparative HPLC gave 16 (50 mg, 0.09 mmol, 14%) as a colorless liquid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.43 (s, 1H), 8.33 (s, 1H), 7.66 (dd, J = 8.5 Hz, 2.0 Hz, 1H), 7.46 (D, J = 8.5 Hz, 2H), 7.41-7.33 (m, 4H), 6.81-6.78 (m, 1H), 6.71-6.68 (m, 1H) 5.82 (d, J = 14.5 Hz, 1H), 5.36 (d, J = 14.5 Hz, 1H), 4.19 (s, 2H). MS (ESI): 519 [M + H] ^< +>. HPLC: 96%.

Preparative HPLC method for purification of 15 and 16 Column: Sunfire C-18 (250 × 19 mm, 10 μ)
Mobile phase: A) Acetonitrile; B) 0.1% (aq) Trifluoroacetic acid (TFA)
Flow rate: 15 mL / min Time (min) /% B: 0.01 / 55, 3/55, 20/45, 26/40, 26.1 / 0, 35/0

４−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）−２−フルオロベンゾニトリル（１７）
Ｅｔ_２Ｏ（２５０ｍＬ）中の化合物Ｃ（２５．０ｇ、６９．０ｍｍｏｌ）の撹拌溶液に、−７８℃でｎ−ＢｕＬｉ（ヘキサン中２．３Ｍ；８６ｍＬ、１３８ｍｍｏｌ）を添加した。４５分間撹拌した後、７８℃でＥｔ_２Ｏ（５０ｍＬ）中のホウ酸トリメチル（１５．６ｍＬ、１３８ｍｍｏｌ）の溶液を反応混合物に添加し、撹拌をさらに３０分間継続した。得られた反応混合物をＲＴに温め、２時間撹拌した。反応混合物をＨＯＡｃ−Ｈ_２Ｏ（１：２．５；２４０ｍＬ）で不活性化し、ＲＴでさらに１時間、撹拌を継続した。ＰＨを２Ｎ ＮａＯＨ溶液で〜１４に調整した。有機層を分離した。水性層を１Ｎ ＨＣｌでｐＨ〜６に調整し、ＣＨ_２Ｃｌ_２（２ｘ２５０ｍＬ）で抽出した。合わせた有機層をＨ_２Ｏ（２５０ｍＬ）および塩水（２５０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、化合物Ｏ（１．２ｇ、３．６７ｍｍｏｌ、６６％）を褐色固形物として得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤ_３ＯＤ）：δ８．８１（ｓ，１Ｈ）、８．２０（ｄ，Ｊ＝８．０Ｈｚ，１Ｈ）、７．４７（ｄ，Ｊ＝８．０Ｈｚ，１Ｈ）、７．３６−７．３５（ｍ，１Ｈ）、６．９３−６．８７（ｍ，２Ｈ）、３．４２（ｄ，Ｊ＝５．５Ｈｚ，１Ｈ）、２．９９−２．９８（ｍ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ３２８．１［Ｍ＋Ｈ］^＋。 Example 17

4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy)- 2-Fluorobenzonitrile (17)
To a stirred solution of compound C (25.0 g, 69.0 mmol) in Et ₂ O (250 mL) was added n-BuLi (2.3 M in hexane; 86 mL, 138 mmol) at −78 ° C. After stirring for 45 minutes, a solution of trimethyl borate (15.6 mL, 138 mmol) in Et ₂ O (50 mL) at 78 ° C. was added to the reaction mixture and stirring was continued for another 30 minutes. The resulting reaction mixture was warmed to RT and stirred for 2 hours. The reaction mixture was inactivated with HOAc-H ₂ O (1: 2.5; 240 mL) and stirring was continued for an additional hour at RT. The pH was adjusted to ˜14 with 2N NaOH solution. The organic layer was separated. The aqueous layer was adjusted to pH˜6 with 1N HCl and extracted with CH ₂ Cl ₂ ( ₂ × 250 mL). The combined organic layers were washed with H ₂ O (250 mL) and brine (250 mL), dried over anhydrous Na ₂ SO ₄ , concentrated under reduced pressure and compound O (1.2 g, 3.67 mmol, 66%) Was obtained as a brown solid. ¹ H NMR (500 MHz, CD ₃ OD): δ 8.81 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.36-7.35 (m, 1H), 6.93-6.87 (m, 2H), 3.42 (d, J = 5.5 Hz, 1H), 2.99-2.98 (m , 1H). MS (ESI): m / z 328.1 [M + H] &lt; ⁺ &gt;.

To a suspension of 2-fluoro-4-hydroxybenzonitrile (270 mg, 1.99 mmol) in CH ₂ Cl ₂ (20 mL) was added (6-((2- (2,4-difluorophenyl) oxirane-2- Yl) difluoromethyl) pyridin-3-yl) boronic acid (O; 500 mg, 1.53 mmol), Cu (OAc) ₂ (276 mg, 1.53 mmol), pyridine (0.6 mL, 7.65 mmol), powder 4 molecule Sieve was added and the reaction mixture was stirred at RT for 16 h under oxygen atmosphere. After consumption of the starting material (by TLC), the reaction mixture was filtered through a pad of Celite® to remove the molecular sieve and the pad was washed with CH ₂ Cl ₂ ( ₂ × 25 mL). The filtrate was washed with H ₂ O (25 mL) and brine (25 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 30% EtOAc / hexanes afforded compound T (100 mg, crude) as a colorless thick syrup. (Note: All characteristic protons were found in the ¹ H NMR spectrum.)

To a stirred solution of epoxide T (120 mg, crude) in anhydrous DMF (10 mL) was added 1H-tetrazole (56 mg, 0.81 mmol) and K ₂ CO ₃ (74 mg, 0.53 mmol) in an inert atmosphere at RT. Was added. The resulting reaction mixture was gradually heated to 65 ° C. and stirred for 16 hours. After complete consumption of starting material (by TLC), the reaction mixture was diluted with ice-cold H ₂ O (30 mL) and extracted with EtOAc (2 × 30 mL). The combined organic extracts were washed with H ₂ O (30 mL) and brine (30 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography eluting with 40% EtOAc / hexanes afforded 17 (25 mg, 0.04 mmol, 3% over 2 steps) as a colorless thick syrup. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.26 (d, J = 2.0 Hz, 1H), 7.69-7.66 (m, 2H), 7.50 -7.47 (m, 2H), 7.04 (s, OH), 6.93-6.88 (m, 2H), 6.83-6.76 (m, 2H), 5.37 (d , J = 15.0 Hz, 1H), 5.32 (d, J = 15.0 Hz, 1H). MS (ESI): m / z 487 [M−H] ⁻ . HPLC: 98%.

  Compounds 84 to 90 in Table 1 were prepared from Intermediate D and commercially available phenol (see Table 1 starting material) and commercially available azoles using the same conditions as Compound 17 (Example 17).

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）−１−（５−（（２，２，２−トリフルオロエチル）チオ）ピリジン−２−イル）プロパン−２−オール（１８）
０℃で，２，２−トリフルオロエタンチオール（０．１７ｍＬ、１．９０ｍｍｏｌ）にナトリウム金属（５０ｍｇ、２．１７ｍｍｏｌ）を分割して添加し、混合物をＲＴで２時間撹拌した。ＤＭＦ（２．０ｍＬ）中の化合物Ｒ（２００ｍｇ、０．４６ｍｍｏｌ）の溶液を０℃で上記化合物に添加した。得られた反応混合物を８０℃まで徐々に加熱し、１６時間撹拌した。出発物質の完全な消費後（ＴＬＣによる。）、反応混合物を氷冷Ｈ_２Ｏ（３０ｍＬ）で不活性化し、ＥｔＯＡｃ（２ｘ３０ｍＬ）で抽出した。合わせた有機層をＨ_２Ｏ（３０ｍＬ）および塩水（３０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、粗製物質を得た。分取ＨＰＬＣによる精製によって、１８（１５ｍｇ、０．０３２ｍｍｏｌ、６．９４％）半固形物としてを得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７３（ｓ，１Ｈ）、８．５８（ｓ，１Ｈ）、７．８９−７．８７（ｍ，１Ｈ）、７．５２（ｄ，Ｊ＝８．０Ｈｚ，１Ｈ）、７．３３−７．２８（ｍ，１Ｈ）、７．０３（ｓ，ＯＨ）、６．７８−６．７４（ｍ，１Ｈ）、６．６９−６．６５（ｍ，１Ｈ）、５．５５（ｄ，Ｊ＝１５．０Ｈｚ，１Ｈ）、５．１４（ｄ，Ｊ＝１５．０Ｈｚ，１Ｈ）、３．４９（ｑ，Ｊ＝９．５Ｈｚ，２Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４６８［Ｍ＋Ｈ］^＋．ＨＰＬＣ：９８％。 Example 18

2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((2,2,2-trifluoroethyl) thio) pyridine- 2-yl) propan-2-ol (18)
At 0 ° C., sodium metal (50 mg, 2.17 mmol) was added in portions to 2,2-trifluoroethanethiol (0.17 mL, 1.90 mmol) and the mixture was stirred at RT for 2 h. A solution of compound R (200 mg, 0.46 mmol) in DMF (2.0 mL) was added to the above compound at 0 ° C. The resulting reaction mixture was gradually heated to 80 ° C. and stirred for 16 hours. After complete consumption of starting material (by TLC), the reaction mixture was inactivated with ice cold H ₂ O (30 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were washed with H ₂ O (30 mL) and brine (30 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by preparative HPLC gave 18 (15 mg, 0.032 mmol, 6.94%) as a semi-solid. ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.73 (s, 1H), 8.58 (s, 1H), 7.89-7.87 (m, 1H), 7.52 (d, J = 8 0.0 Hz, 1H), 7.33-7.28 (m, 1H), 7.03 (s, OH), 6.78-6.74 (m, 1H), 6.69-6.65 (m) , 1H), 5.55 (d, J = 15.0 Hz, 1H), 5.14 (d, J = 15.0 Hz, 1H), 3.49 (q, J = 9.5 Hz, 2H). MS (ESI): m / z 468 [M + H] ⁺ . HPLC: 98%.

Preparative HPLC method for purification of 18 Column: Deltapak C-4 (300 × 19 mm, 15μ)
Mobile phase: A) Acetonitrile; B) 0.1% (aq) Trifluoroacetic acid (TFA)
Flow rate: 15 mL / min Time (min) /% B: 0.01 / 80, 4/80, 15/30, 20/30

メチル−２−（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）チオ）アセテート（９１）：
ＴＨＦ（１０ｍＬ）中のメチル２−メルカプトアセテート（２０６ｍｇ、２．３１ｍｍｏｌ）の撹拌溶液に、ＲＴで不活性雰囲気にて炭酸セシウム（Ｃｓ_２ＣＯ_３；７５２ｍｇ、２．３１ｍｍｏｌ）および次いで化合物Ｒ（２００ｍｇ、０．４６ｍｍｏｌ）を添加した。得られた反応混合物を６５℃に加熱し、４８時間撹拌した。出発物質の完全消費後（ＴＬＣによる。）、反応混合物をＥｔＯＡｃ（１００ｍＬ）で希釈した。有機層をｓａｔｄ ＮａＨＣＯ_３溶液（５０ｍＬ）、水（５０ｍＬ）および塩水（５０ｍＬ）で洗浄し、無水Ｎａ_２ＳＯ_４上で乾燥させ、減圧下で濃縮し、粗製物質を得た。シリカゲルカラムクロマトグラフィー（４５％ＥｔＯＡｃ／ヘキサンで溶出）による精製によって、９１（３０ｍｇ、０．０６ｍｍｏｌ、１４％）を得た。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）：δ８．７５（ｓ，１Ｈ）、８．５０（ｓ，１Ｈ）、７．８０（ｄ，Ｊ＝８．０Ｈｚ，１Ｈ）、７．４７（ｄ，Ｊ＝８．０Ｈｚ，１Ｈ）、７．３４−７．２７（ｍ，２Ｈ）、６．７８−６．７３（ｍ，１Ｈ）、６．６９−６．６６（ｍ，１Ｈ）、５．５８（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）、５．１０（ｄ，Ｊ＝１４．０Ｈｚ，１Ｈ）、３．７４（ｓ，２Ｈ）、３．７０（ｓ，３Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４５８［Ｍ＋Ｈ］^＋．ＨＰＬＣ：９３％。 Example 19

Methyl-2- (6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) thio) Acetate (91):
To a stirred solution of methyl 2-mercaptoacetate (206 mg, 2.31 mmol) in THF (10 mL) was added cesium carbonate (Cs ₂ CO ₃ ; 752 mg, 2.31 mmol) and then compound R (200 mg) in an inert atmosphere at RT. 0.46 mmol). The resulting reaction mixture was heated to 65 ° C. and stirred for 48 hours. After complete consumption of starting material (by TLC), the reaction mixture was diluted with EtOAc (100 mL). The organic layer was washed with satd NaHCO ₃ solution (50 mL), water (50 mL) and brine (50 mL), dried over anhydrous Na ₂ SO ₄ and concentrated under reduced pressure to give the crude material. Purification by silica gel column chromatography (eluting with 45% EtOAc / hexanes) gave 91 (30 mg, 0.06 mmol, 14%). ¹ H NMR (500 MHz, CDCl ₃ ): δ 8.75 (s, 1H), 8.50 (s, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.34-7.27 (m, 2H), 6.78-6.73 (m, 1H), 6.69-6.66 (m, 1H), 5.58 (D, J = 14.0 Hz, 1H), 5.10 (d, J = 14.0 Hz, 1H), 3.74 (s, 2H), 3.70 (s, 3H). MS (ESI): m / z 458 [M + H] ^< +>. HPLC: 93%.

１−（５−（（３−クロロ−５−（トリフルオロメチル）ピリジン−２−イル）オキシ）ピリジン−２−イル）−２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（９２）
無水ＤＭＳＯ（４．１７８ｍＬ）中の６−（（２−（２，４−ジフルオロフェニル）オキシラン−２−イル）ジフルオロメチル）ピリジン−３−オール（Ｄ）（２５０ｍｇ、０．８３６ｍｍｏｌ）および炭酸セシウム（２７２ｍｇ、０．８３６ｍｍｏｌ）の磁気撹拌混合物に、Ｎ_２雰囲気下の乾燥した２５ｍＬバイアル中で２，３−ジクロロ−５−（トリフルオロメチル）ピリジン（０．１１７ｍＬ、０．８３６ｍｍｏｌ）を添加した。反応混合物を５５℃で１時間撹拌し、次いで氷水および２Ｎ ＨＣｌで希釈し、ＤＣＭ（２ｘ）で抽出した。合わせた有機抽出物を蒸発させ、粗製残渣をシリカ上で精製し（ＩＳＣＯ、４０グラムカラム、２０分間にわたり２０％ＥｔＯＡｃ／ヘキサンへの勾配）、化合物Ｕを得た。収率＝３８６ｍｇ（９２％）の透明な油状物質。１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）δ８．５８（ｓ，１Ｈ）、８．２７（ｄ，Ｊ＝１．０Ｈｚ，１Ｈ）、８．０４（ｓ，１Ｈ）、７．６２（ｄｄ，Ｊ＝８．４，２．１Ｈｚ，１Ｈ）、７．５８（ｄ，Ｊ＝８．５Ｈｚ，１Ｈ）、７．４０（ｄｄ，Ｊ＝１４．８，８．０Ｈｚ，１Ｈ）、６．９０−６．８２（ｍ，１Ｈ）、６．７７（ｔｄ，Ｊ＝９．３，２．４Ｈｚ，１Ｈ）、３．４８（ｄ，Ｊ＝５．０Ｈｚ，１Ｈ）、３．１０−２．９２（ｍ，１Ｈ）．^１Ｈ−ｄｅｃｏｕｐｌｅｄ^１９Ｆ ＮＭＲ（３７６ＭＨｚ，ＣＤＣｌ_３）δ−６１．７０（ｓ）、−１０６．７０（ｄ，Ｊ＝８．２Ｈｚ）、−１０７．４５（ｄｄ，Ｊ＝４８．４，８．９Ｈｚ）、−１０７．７２（ｄ，Ｊ＝８．２Ｈｚ）、−１０８．４１（ｄ，Ｊ＝９．５Ｈｚ）、−１０９．２６（ｄｄ，Ｊ＝１７．７，９．５Ｈｚ）．ＭＳ（ＥＳＩ）：ｍ／ｚ４７９．０（Ｍ＋Ｈ）^＋。 Example 20

1- (5-((3-chloro-5- (trifluoromethyl) pyridin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro- 3- (1H-tetrazol-1-yl) propan-2-ol (92)
6-((2- (2,4-Difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-ol (D) (250 mg, 0.836 mmol) and cesium carbonate in anhydrous DMSO (4.178 mL) To a magnetically stirred mixture of (272 mg, 0.836 mmol) was added 2,3-dichloro-5- (trifluoromethyl) pyridine (0.117 mL, 0.836 mmol) in a dry 25 mL vial under N ₂ atmosphere. . The reaction mixture was stirred at 55 ° C. for 1 h, then diluted with ice water and 2N HCl and extracted with DCM (2 ×). The combined organic extracts were evaporated and the crude residue was purified on silica (ISCO, 40 gram column, gradient to 20% EtOAc / hexanes over 20 minutes) to give compound U. Yield = 386 mg (92%) clear oil. 1H NMR (400 MHz, CDCl ₃ ) δ 8.58 (s, 1H), 8.27 (d, J = 1.0 Hz, 1H), 8.04 (s, 1H), 7.62 (dd, J = 8 .4, 2.1 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.40 (dd, J = 14.8, 8.0 Hz, 1H), 6.90-6. 82 (m, 1H), 6.77 (td, J = 9.3, 2.4 Hz, 1H), 3.48 (d, J = 5.0 Hz, 1H), 3.10-2.92 (m , 1H). ¹ H-decoupled ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-61.70 (s), −106.70 (d, J = 8.2 Hz), −107.45 (dd, J = 48.4, 8 .9 Hz), −107.72 (d, J = 8.2 Hz), −108.41 (d, J = 9.5 Hz), −109.26 (dd, J = 17.7, 9.5 Hz). MS (ESI): m / z 479.0 (M + H) ^<+> .

3-chloro-2-((6-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-yl) oxy) -5 in anhydrous DMSO (3.718 mL) To a magnetically stirred mixture of-(trifluoromethyl) pyridine (U) (356 mg, 0.744 mmol) and 1H-tetrazole (62.5 mg, 0.892 mmol) was added potassium carbonate (N ₂ atmosphere) in a dry 25 mL vial. 206 mg, 1.487 mmol) was added. The reaction mixture was stirred at 60 ° C. overnight, cooled to RT, diluted with ice cold water / 2N HCl and DCM, and the layers were separated on a phase separator. The aqueous layer was extracted again with DCM and the combined organic extracts were evaporated. The crude residue was purified on silica (ISCO, 40 gram column, gradient to 40% EtOAc / hexanes over 20 minutes) to give the title compound. Yield = 119 mg (27.7%) brown glassy material. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.76 (s, 1H), 8.50 (d, J = 2.3 Hz, 1H), 8.27 (dd, J = 2.1, 0.9 Hz, 1H ), 8.05 (d, J = 2.0 Hz, 1H), 7.74-7.63 (m, 2H), 7.34 (td, J = 8.9, 6.4 Hz, 1H), 7 .21 (s, 1H), 6.83-6.72 (m, 1H), 6.72-6.64 (m, 1H), 5.64 (d, J = 14.3 Hz, 1H), 5 .13 (d, J = 14.1 Hz, 1H). ¹ H-decoupled ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-61.74 (s), −103.20 (d, J = 15.0 Hz), −103.72 to −104.09 (m), − 107.86 (d, J = 10.9 Hz), -11.78 (d, J = 45.0 Hz), -11.48 (d, J = 45.0 Hz). MS (ESI): m / z 549.1 (M + H) ^<+> .

  From intermediate D and commercially available aryl halides (see Table 1, starting materials) and commercially available azoles using the same conditions as compound 92 (Example 20), compounds 93 to 101, 104 to 106 of Table 1 and 108 to 112 were prepared.

（Ｅ）−６−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）ニコチンアルデヒドＯ−メチルオキシム（１０２）
無水ＥｔＯＨ（１．２６５ｍＬ）中の６−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）ニコチンアルデヒド（１０１）（６０ｍｇ、０．１２６ｍｍｏｌ）の磁気撹拌混合物に、Ｎ_２雰囲気下で５ｍＬバイアル中でＯ−メチルヒドロキシルアミン塩酸塩（２１．１３ｍｇ、０．２５３ｍｍｏｌ）を添加した。反応混合物をＲＴで一晩撹拌した。反応混合物を蒸発させ、粗製残渣をシリカ上で精製し（ＩＳＣＯ、１２グラムカラム、２５分間にわたる７５％ＥｔＯＡｃ／ヘキサンへの勾配）、表題化合物を得た。収率＝１８ｍｇ（２６．９％）の白色泡状物質。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）δ８．７６（ｓ，１Ｈ）、８．４７（ｄ，Ｊ＝２．５Ｈｚ，１Ｈ）、８．１９（ｄ，Ｊ＝２．３Ｈｚ，１Ｈ）、８．１１（ｄｄ，Ｊ＝８．７，２．４Ｈｚ，１Ｈ）、８．０４（ｓ，１Ｈ）、７．６７（ｄｄ，Ｊ＝８．７，２．６Ｈｚ，１Ｈ）、７．６３（ｄ，Ｊ＝８．８Ｈｚ，１Ｈ）、７．４５（ｓ，１Ｈ）、７．３６（ｔｄ，Ｊ＝８．８，６．４Ｈｚ，１Ｈ）、７．０５（ｄ，Ｊ＝８．５Ｈｚ，１Ｈ）、６．８３−６．７３（ｍ，１Ｈ）、６．７３−６．６４（ｍ，１Ｈ）、５．６３（ｄ，Ｊ＝１４．３Ｈｚ，１Ｈ）、５．１０（ｄ，Ｊ＝１４．３Ｈｚ，１Ｈ）、３．９９（ｓ，３Ｈ）．^１Ｈ−ｄｅｃｏｕｐｌｅｄ^１９Ｆ ＮＭＲ（３７６ＭＨｚ，ＣＤＣｌ_３）δ−１０３．２０（ｄ，Ｊ＝１７．７Ｈｚ）、−１０３．８９（ｄｄｄ，Ｊ＝３１．３，２１．１，１３．６Ｈｚ）、−１０８．１１（ｄ，Ｊ＝９．５Ｈｚ）、−１１０．２１（ｄ，Ｊ＝４５．０Ｈｚ）、−１１０．９０（ｄ，Ｊ＝４５．０Ｈｚ）．ＭＳ（ＥＳＩ）：ｍ／ｚ５０４．２（Ｍ＋Ｈ）^＋。 Example 21

(E) -6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl ) Oxy) nicotinaldehyde O-methyloxime (102)
6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) in absolute EtOH (1.265 mL) To a magnetically stirred mixture of pyridin-3-yl) oxy) nicotinaldehyde (101) (60 mg, 0.126 mmol) was added O-methylhydroxylamine hydrochloride (21.13 mg, 0.253 mmol) in a 5 mL vial under N ₂ atmosphere. ) Was added. The reaction mixture was stirred at RT overnight. The reaction mixture was evaporated and the crude residue was purified on silica (ISCO, 12 gram column, gradient to 75% EtOAc / hexanes over 25 minutes) to give the title compound. Yield = 18 mg (26.9%) white foam. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.76 (s, 1H), 8.47 (d, J = 2.5 Hz, 1H), 8.19 (d, J = 2.3 Hz, 1H), 8. 11 (dd, J = 8.7, 2.4 Hz, 1H), 8.04 (s, 1H), 7.67 (dd, J = 8.7, 2.6 Hz, 1H), 7.63 (d , J = 8.8 Hz, 1H), 7.45 (s, 1H), 7.36 (td, J = 8.8, 6.4 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.83-6.73 (m, 1H), 6.73-6.64 (m, 1H), 5.63 (d, J = 14.3 Hz, 1H), 5.10 (d, J = 14.3 Hz, 1H), 3.99 (s, 3H). ¹ H-decoupled ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-103.20 (d, J = 17.7 Hz), −103.89 (ddd, J = 31.3, 21.1, 13.6 Hz), −108.11 (d, J = 9.5 Hz), −11.21 (d, J = 45.0 Hz), −110.90 (d, J = 45.0 Hz). MS (ESI): m / z 504.2 (M + H) ^<+> .

  Compound 103 of Table 1 was prepared from 101 and commercially available O-benzylhydroxylamine (see Table 1, starting material) using the same conditions as Compound 102 (Example 21).

２−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１Ｈ−テトラゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）チアゾール−５−カルボニトリル（１０７）
Ｎ_２雰囲気下で乾燥した２５ｍＬバイアル中、無水ＤＭＳＯ（６．１２７ｍＬ）中の６−（（２−（２，４−ジフルオロフェニル）オキシラン−２−イル）ジフルオロメチル）ピリジン−３−オール（Ｄ）（５５０ｍｇ、１．８３８ｍｍｏｌ）およびジイソプロピルアンモニウムテトラゾール−１−イド（６３０ｍｇ、３．６８ｍｍｏｌ）の磁気撹拌混合物を７０℃で一晩加熱した。粗製反応混合物をＲＴに冷却し、ろ過し、シリカ上で精製し（ＩＳＣＯ、４０グラムカラム、２０分間にわたる７０％ＥｔＯＡｃ／ヘキサンへの勾配）、化合物Ｖを得た。収率＝５２ｍｇ（３．８３％）の褐色油状物質。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）δ８．７６（ｓ，１Ｈ）、８．１３（ｄ，Ｊ＝３．０Ｈｚ，１Ｈ）、７．９３（ｓ，１Ｈ）、７．４１（ｄ，Ｊ＝８．９Ｈｚ，１Ｈ）、７．３４（ｄｄ，Ｊ＝８．９，２．３Ｈｚ，１Ｈ）、７．２２（ｄｄ，Ｊ＝８．７，２．８Ｈｚ，１Ｈ）、６．７８−６．７０（ｍ，１Ｈ）、６．６９−６．６３（ｍ，１Ｈ）、５．５６（ｄ，Ｊ＝１４．２Ｈｚ，１Ｈ）、５．０６（ｄ，Ｊ＝１５．５Ｈｚ，１Ｈ）．ＭＳ（ＥＳＩ）：ｍ／ｚ３７０．１（Ｍ＋Ｈ）^＋。 Example 22

2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) thiazole -5-carbonitrile (107)
6-((2- (2,4-Difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-ol (D) in anhydrous DMSO (6.127 mL) in a 25 mL vial dried under N ₂ atmosphere. ) (550 mg, 1.838 mmol) and diisopropylammonium tetrazol-1-id (630 mg, 3.68 mmol) were heated at 70 ° C. overnight. The crude reaction mixture was cooled to RT, filtered and purified on silica (ISCO, 40 gram column, gradient to 70% EtOAc / hexanes over 20 minutes) to give compound V. Yield = 52 mg (3.83%) brown oil. ¹ H NMR (300 MHz, CDCl ₃ ) δ 8.76 (s, 1H), 8.13 (d, J = 3.0 Hz, 1H), 7.93 (s, 1H), 7.41 (d, J = 8.9 Hz, 1H), 7.34 (dd, J = 8.9, 2.3 Hz, 1H), 7.22 (dd, J = 8.7, 2.8 Hz, 1H), 6.78-6. .70 (m, 1H), 6.69-6.63 (m, 1H), 5.56 (d, J = 14.2 Hz, 1H), 5.06 (d, J = 15.5 Hz, 1H) . MS (ESI): m / z 370.1 (M + H) ^<+> .

2-chlorothiazole-5-carbonitrile (14.68 mg, 0.102 mmol) and 6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy- in anhydrous DMSO (1 mL) To a magnetically stirred mixture of 3- (1H-tetrazol-1-yl) propyl) pyridin-3-ol (V) (25 mg, 0.068 mmol) was added potassium carbonate (18.71 mg in a dry 25 mL vial under N ₂ atmosphere. 0.135 mmol) was added. The reaction mixture was stirred at RT for 4 h, then diluted with DCM and washed with 2N HCl / water. The organic extract was evaporated and purified on silica (ISCO, 12 gram column, gradient to 50% EtOAc / hexanes over 15 minutes) to give the title compound. Yield = 18 mg (52.9%) of pale yellow foam. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.75 (s, 1H), 8.63 (d, J = 2.5 Hz, 1H), 7.92 (dd, J = 8.8, 2.8 Hz, 1H) ), 7.75 (s, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.34 (td, J = 8.9, 6.4 Hz, 1H), 6.90 (s). , 1H), 6.82-6.73 (m, 1H), 6.73-6.64 (m, 1H), 5.59 (d, J = 14.3 Hz, 1H), 5.16 (d , J = 15.3 Hz, 1H). ¹ H-decoupled ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-103.63 (d, J = 16.3 Hz), −104.07 (dd, J = 56.5, 10.2 Hz), −104.33 (D, J = 16.3 Hz), −107.58 (t, J = 6.8 Hz), −11.27 (d, J = 39.5 Hz), −11.97 (d, J = 40.9 Hz) ). MS (ESI): m / z 478.1 (M + H) ^<+> .

１−（５−（２，２−ジフルオロ−２−フェニルエトキシ）ピリジン−２−イル）−２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（１１９）
無水アセトン（１６７１μＬ）中の６−（（２−（２，４−ジフルオロフェニル）オキシラン−２−イル）ジフルオロメチル）ピリジン−３−オール（１００ｍｇ、０．３３４ｍｍｏｌ、化合物Ｄ）および２−ブロモ−１−フェニルエタノン（１００ｍｇ、０．５０１ｍｍｏｌ）の磁気撹拌混合物に大気雰囲気下、１０ｍＬバイアル中でＫ_２ＣＯ_３（５０．８ｍｇ、０．３６８ｍｍｏｌ）を添加した。反応混合物をｒｔで３日間撹拌した。反応完了したら、穏やかなＮ_２流下で揮発性物質を除去した。得られた残渣をＣＨ_２Ｃｌ_２およびＨ_２Ｏの混合液中で吸収させ、ＣＨ_２Ｃｌ_２で３回抽出した。相分離装置を通過させることによって、合わせた有機層を乾燥させ、揮発性物質を穏やかなＮ_２流下で除去し、ＳｉＯ_２のパッド上に置き、精製して（ＩＳＣＯ、１２ｇ ＳｉＯ_２、１０分間にわたりヘキサンに対して５−２５％酢酸エチル、２５％で５分間）、化合物Ｗを得た。収率＝１４４ｍｇ（９８％）の、静置時に凝固する無色油状物質。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）δ８．３９（ｄ，Ｊ＝２．９Ｈｚ，１Ｈ）、７．９８（ｄｄ，Ｊ＝５．２，３．３Ｈｚ，２Ｈ）、７．７１−７．６２（ｍ，１Ｈ）、７．５４（ｔ，Ｊ＝７．７Ｈｚ，２Ｈ）、７．４０（ｄ，Ｊ＝８．７Ｈｚ，１Ｈ）、７．３９−７．３３（ｍ，１Ｈ）、７．２０（ｄｄ，Ｊ＝８．７，２．９Ｈｚ，１Ｈ）、６．８３（ｄｄｄ，Ｊ＝１１．２，５．６，１．７Ｈｚ，１Ｈ）、６．７８−６．６９（ｍ，１Ｈ）、５．３９（ｓ，２Ｈ）、３．４２（ｄ，Ｊ＝５．１Ｈｚ，１Ｈ）、３．００−２．９３（ｍ，１Ｈ）．^１Ｈ ｄｅｃｏｕｐｌｅｄ−^１９Ｆ ＮＭＲ（３７６ＭＨｚ，ＣＤＣｌ_３）δ−１０６．９０（ｄｄ，Ｊ＝２５６．８，８．４Ｈｚ，１Ｆ）、−１０７．４１−−１０８．３６（ｍ，２Ｆ）、−１０９．３３（ｑ，Ｊ＝８．３Ｈｚ，１Ｆ）．ＭＳ（ＥＳＩ）：ｍ／ｚ Ｃ_２２Ｈ_１５Ｆ_４ＮＯ_３に対して計算：４１７．３５３；実測：４１８．８（Ｍ＋Ｈ）^＋、４１６．４（Ｍ−Ｈ）⁻。 Example 23

1- (5- (2,2-difluoro-2-phenylethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1- Yl) propan-2-ol (119)
6-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-ol (100 mg, 0.334 mmol, compound D) and 2-bromo- in anhydrous acetone (1671 μL) To a magnetically stirred mixture of 1-phenylethanone (100 mg, 0.501 mmol) was added K ₂ CO ₃ (50.8 mg, 0.368 mmol) in a 10 mL vial under atmospheric atmosphere. The reaction mixture was stirred at rt for 3 days. When the reaction was complete, the volatiles were removed under a gentle stream of N _2. The resulting residue was taken up in a mixture of CH ₂ Cl ₂ and H ₂ O and extracted 3 times with CH ₂ Cl ₂ . The combined organic layers are dried by passing through a phase separator and the volatiles are removed under a gentle stream of N ₂ , placed on a pad of SiO ₂ and purified (ISCO, 12 g SiO ₂ , 10 min. 5-25% ethyl acetate over hexane, 25% for 5 minutes) to give compound W. Yield = 144 mg (98%), colorless oil that solidifies upon standing. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.39 (d, J = 2.9 Hz, 1H), 7.98 (dd, J = 5.2, 3.3 Hz, 2H), 7.71-7.62 (M, 1H), 7.54 (t, J = 7.7 Hz, 2H), 7.40 (d, J = 8.7 Hz, 1H), 7.39-7.33 (m, 1H), 7 .20 (dd, J = 8.7, 2.9 Hz, 1H), 6.83 (ddd, J = 11.2, 5.6, 1.7 Hz, 1H), 6.78-6.69 (m , 1H), 5.39 (s, 2H), 3.42 (d, J = 5.1 Hz, 1H), 3.00-2.93 (m, 1H). ¹ H decoupled- ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-106.90 (dd, J = 256.8, 8.4 Hz, 1F), −107.41—108.36 (m, 2F), − 109.33 (q, J = 8.3 Hz, 1F). MS _(ESI): calculated for _{m / z C 22 H 15 F} 4 NO 3: 417.353; ^{Found: 418.8 (M + H) +} , 416.4 (M-H) -.

2-((6-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-yl) oxy) -1-phenyl eta in anhydrous CH ₂ Cl ₂ (1679 μL) To a magnetically stirred mixture of non (140 mg, 0.335 mmol, Compound W) was added Deoxofluor® 50% (284 μL, 0.772 mmol) in toluene in a 20 mL vial under N ₂ atmosphere. The reaction mixture was stirred at 0 ° C. for 30 minutes, then the temperature was raised to rt and stirred overnight. The reaction was stopped by dropwise addition of a saturated aqueous NaHCO ₃ solution (caution for gas evolution). The aqueous layer was extracted 3 times with CH ₂ Cl ₂ . The combined organic layers were dried by passing through a phase separator and volatiles were removed by rotary evaporation. Place the resulting residue on a pad of SiO ₂ and purify (ISCO, 12 g SiO ₂ , 0-20% ethyl acetate against hexane over 10 minutes, 20% up to 60% over 3 minutes over 3 minutes. Compound X was obtained. Yield = 81 mg (55.0%) colorless oil. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.32 (d, J = 2.8 Hz, 1H), 7.63-7.44 (m, 5H), 7.43-7.32 (m, 2H), 7.20 (dd, J = 8.7, 2.9 Hz, 1H), 6.87-6.79 (m, 1H), 6.73 (ddd, J = 9.8, 9.0, 2. 5 Hz, 1H), 4.44 (t, J = 11.9 Hz, 2H), 3.41 (d, J = 5.1 Hz, 1H), 2.99-2.92 (m, 1H). ¹ H decoupled- ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-104.01 (s, 2F), -106.92 (dd, J = 256.9, 8.4 Hz, 1F), -107.46-- 108.33 (m, 2F), −109.36 (q, J = 8.5 Hz, 1F). MS _(ESI): Calcd 439.350 for _{m / zC 22 H 15 F 6} NO 2; ^{Found: 440.9 (M + H) +} .

5- (2,2-difluoro-2-phenylethoxy) -2-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) pyridine (81 mg, 0 in anhydrous DMSO (1229 μL) To a magnetically stirred mixture of .184 mmol, compound X) and 1H-tetrazole (19.37 mg, 0.277 mmol) was added K ₂ CO ₃ (28.0 mg, 0.203 mmol) in a 20 mL vial under N ₂ atmosphere. . The reaction mixture was stirred at 60 ° C. overnight. The reaction was cooled to rt, diluted with CH ₂ Cl ₂ and poured into a separatory funnel containing saturated aqueous NH ₄ Cl. The organic layer was washed and then the aqueous layer was back extracted twice with CH ₂ Cl ₂ . The combined organic layers were then washed 3 times with water and dried by passing through a phase separator. Volatiles were removed by rotary evaporation and the resulting residue was placed on a pad of SiO ₂ and purified (ISCO, 12 g SiO ₂ , 20-60% ethyl acetate against hexane over 7 minutes, then 60% 7 minutes), the title compound 119 was obtained. Yield = 56 mg (59.6%) pale yellow viscous oil. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.74 (s, 1H), 8.21 (d, J = 2.8 Hz, 1H), 7.57-7.45 (m, 6H), 7.41 ( s, 1H), 7.33-7.24 (m, 2H), 6.80-6.70 (m, 1H), 6.70-6.62 (m, 1H), 5.58 (d, J = 14.3 Hz, 1H), 5.07 (d, J = 15.1 Hz, 1H), 4.42 (t, J = 11.9 Hz, 2H). ¹ H coupled- ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-102.97 (dd, J = 261.4, 15.2 Hz, 1F), −103.88 (ddd, J = 43.5, 14.9) , 9.8 Hz, 1F), −104.07 (s, 2F), −108.15 (d, J = 9.7 Hz, 1F), −11.87 (dd, J = 261.4, 43.2 Hz). , 1F). _{MS (ESI): m / zC} 23 H 17 F 6 N 5 O 2 Calculated for: 509.404; ^{found: 510.2 (M + H) +} , 508.6 (M-H) -.

  Compounds 120-122 of Table 1 were prepared from Intermediate D and commercially available α-haloketones (see Table 1, starting materials) and commercially available azoles using the same conditions as Compound 119 (Example 23).

２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−（２−フルオロ−２−フェニルエトキシ）ピリジン−２−イル）−３−（１Ｈ−テトラゾール−１−イル）プロパン−２−オール（化合物１２３）
メタノール（１．５ｍＬ）およびＣＨ_２Ｃｌ_２（１ｍＬ）中の２−（（６−（（２−（２，４−ジフルオロフェニル）オキシラン−２−イル）ジフルオロメチル）ピリジン−３−イル）オキシ）−１−フェニルエタノン（５９ｍｇ、０．１４１ｍｍｏｌ、化合物Ｗ）の磁気撹拌混合物にＮ_２雰囲気下、２０ｍＬバイアル中でＮａＢＨ_４（５．３５ｍｇ、０．１４１ｍｍｏｌ）を添加した。反応混合物を０℃で１０分間撹拌し、その時点で水およびＮＨ_４Ｃｌ飽和水溶液で反応停止させ、次いでｒｔまで温度を上昇させた。反応混合物をＥｔ_２Ｏで３回抽出した。相分離装置を通過させることによって、合わせた有機層を乾燥させ、揮発性物質を回転蒸発によって除去した。粗製反応混合物をＳｉＯ_２のパッド上に置き、精製し（ＩＳＣＯ、４ｇ ＳｉＯ_２、５分間にわたりヘキサンに対して１５−３５％酢酸へ、３５％で５分間）、化合物Ｙをジアステレオマーの１：１混合物として得た。収率＝４９ｍｇ（８３％）の無色油状物質。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）δ８．３５（ｓ，１Ｈ）、７．５０−７．３２（ｍ，７Ｈ）、７．２０（ｄｄ，Ｊ＝８．７，２．８Ｈｚ，１Ｈ）、６．８３（ｔｄ，Ｊ＝８．３，２．３Ｈｚ，１Ｈ）、６．７３（ｔｄ，Ｊ＝９．４，２．５Ｈｚ，１Ｈ）、５．１６（ｄｄ，Ｊ＝７．９，３．３Ｈｚ，１Ｈ）、４．１９−４．０８（ｍ，２Ｈ）、３．４２（ｄ，Ｊ＝５．１Ｈｚ，１Ｈ）、２．９９−２．９３（ｍ，１Ｈ）．^１Ｈ ｄｅｃｏｕｐｌｅｄ−^１９Ｆ ＮＭＲ（３７６ＭＨｚ，ＣＤＣｌ_３）δ−１０６．５８−−１０７．４５（ｍ，１Ｆ）、−１０７．５２−−１０８．３８（ｍ，２Ｆ）、−１０９．３８（ｐ，Ｊ＝８．３Ｈｚ，１Ｆ）．ＭＳ（ＥＳＩ）：ｍ／ｚ Ｃ_２２Ｈ_１７Ｆ_４ＮＯ_３に対する計算値：４１９．３６９；実測値：４２０．２（Ｍ＋Ｈ）^＋。 Example 24

2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (2-fluoro-2-phenylethoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) Propan-2-ol (Compound 123)
2-((6-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-yl) oxy in methanol (1.5 mL) and CH ₂ Cl ₂ (1 mL) ) -1-Phenylethanone (59 mg, 0.141 mmol, Compound W) was added NaBH ₄ (5.35 mg, 0.141 mmol) in a 20 mL vial under N ₂ atmosphere. The reaction mixture was stirred at 0 ° C. for 10 min, at which point it was quenched with water and saturated aqueous NH ₄ Cl, then the temperature was allowed to rise to rt. The reaction mixture was extracted 3 times with Et ₂ O. The combined organic layers were dried by passing through a phase separator and volatiles were removed by rotary evaporation. The crude reaction mixture was placed on a pad of SiO ₂ and purified (ISCO, 4 g SiO ₂ , 15-35% acetic acid to hexane over 5 minutes, 35% for 5 minutes) and compound Y was converted to the diastereomeric 1 1 obtained as a mixture. Yield = 49 mg (83%) of colorless oil. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.35 (s, 1H), 7.50-7.32 (m, 7H), 7.20 (dd, J = 8.7, 2.8 Hz, 1H), 6.83 (td, J = 8.3, 2.3 Hz, 1H), 6.73 (td, J = 9.4, 2.5 Hz, 1H), 5.16 (dd, J = 7.9, 3.3 Hz, 1H), 4.19-4.08 (m, 2H), 3.42 (d, J = 5.1 Hz, 1H), 2.99-2.93 (m, 1H). ¹ H decoupled- ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-106.58--107.45 (m, 1F), -107.52--108.38 (m, 2F), -109.38 (p , J = 8.3 Hz, 1F). MS _(ESI): Calcd for _{m / z C 22 H 17 F} 4 NO 3: 419.369; ^{Found: 420.2 (M + H) +} .

2-((6-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) pyridin-3-yl) oxy) -1-phenylethanol in anhydrous CH ₂ Cl ₂ (1168 μL) To a magnetically stirred mixture of (49 mg, 0.117 mmol, Compound Y) was added Deoxofluor® (86 μL, 0.234 mmol) in a 20 mL vial under N ₂ atmosphere. The reaction mixture was stirred at RT for 1.5 h, at which point sat. aq. It was inactivated by the dropwise addition of NaHCO ₃ (gas evolution is observed). The reaction mixture was extracted 3 times with CH ₂ Cl ₂ . The combined organic layers were dried by passing through a phase separator and then the volatiles were removed by rotary evaporation. The resulting residue was placed on a pad of SiO ₂ and purified (ISCO, 4 g SiO ₂ , 5-20% ethyl acetate against hexane for 8 minutes, 20% for 4 minutes) and diastereomeric 1: 1. Compound Z was obtained as a mixture. Yield = 39 mg (79%) colorless oil. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.37 (d, J = 2.8 Hz, 1H), 7.49-7.32 (m, 7H), 7.22 (dd, J = 8.7, 2 .9 Hz, 1H), 6.83 (td, J = 8.3, 2.2 Hz, 1H), 6.77-6.70 (m, 1H), 5.85 (ddd, J = 48.1) 7.8, 2.7 Hz, 1H), 4.46-4.17 (m, 2H), 3.43 (dd, J = 5.1, 2.3 Hz, 1H), 3.01-2.92 (M, 1H). ¹ H decoupled- ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-106.60--107.40 (m, 1F), −107.48--108.39 (m, 2F), −109.36 (dq , J = 11.9, 8.4 Hz, 1F), -183.74 (d, J = 5.4 Hz, 1F). _{MS (ESI): m / z} C 22 H 16 F Calcd for 5 NO _2: 421.360; ^{Found: 422.1 (M + H) +} .

2-((2- (2,4-difluorophenyl) oxiran-2-yl) difluoromethyl) -5- (2-fluoro-2-phenylethoxy) pyridine (37 mg, 0.088 mmol) in anhydrous DMSO (878 μL) , Compound Z) and 1H-tetrazole (12.30 mg, 0.176 mmol) were added K ₂ CO ₃ (24.27 mg, 0.176 mmol) in a 15 mL vial under N ₂ atmosphere. The reaction mixture was stirred at 60 ° C. for 3 days. The reaction was cooled to rt, then diluted with water, extracted 3 times with CH ₂ Cl ₂ and passed through a phase separator to dry the combined organic layers and volatiles were removed by rotary evaporation. The resulting residue was placed on a pad of SiO ₂ and purified (ISCO, 4 g SiO ₂ , 20-60% ethyl acetate against hexane over 6 minutes, 60% for 3 minutes) and diastereomeric 1: The title compound 123 was obtained as a mixture. Yield = 28 mg (64.9%) white foamy solid. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.75 (s, 1H), 8.24 (t, J = 2.8 Hz, 1H), 7.54 (d, J = 4.0 Hz, 1H), 7. 51 (d, J = 8.8 Hz, 1H), 7.48-7.38 (m, 5H), 7.35-7.24 (m, 2H), 6.79-6.71 (m, 1H) ), 6.66 (ddd, J = 9.0, 5.1, 2.0 Hz, 1H), 5.83 (ddt, J = 48.1, 7.7, 2.4 Hz, 1H), 5. 58 (dd, J = 14.3, 3.1 Hz, 1H), 5.12-5.04 (m, 1H), 4.36 (dddd, J = 17.6, 11.0, 7.8, 5.4 Hz, 1H), 4.24 (dddd, J = 28.1, 11.0, 2.7, 1.3 Hz, 1H). ¹ H coupled- ¹⁹ F NMR (376 MHz, CDCl ₃ ) δ-103.02 (ddd, J = 261.2, 15.2, 10.0 Hz, 1F), −103.62—104.04 (m, 1F), −108.26 (dd, J = 9.6, 4.2 Hz, 1F), −10.69 (ddd, J = 261.2, 42.8, 11.9 Hz, 1F), −183. 73 (s, 1F). _{MS (ESI): m / z} C 23 H 18 F 5 N 5 O 2 Calculated for: 491.413; ^{found: 493.2 (M + H) +} , 491.2 (M-H) -.

  Compound 124 of Table 1 was prepared from D and commercially available 2-bromo-1- (4-difluoromethoxy) phenyl) ethanone (see Table 1, starting material) using the same conditions as for compound 123 (Example 24). Prepared.

HPLC Method Method A Specifications Column: Aquity BEH C-18 (50 × 2.1 mm, 1.7 μ)
Mobile phase: A) Acetonitrile; B) 0.025% (aq) Trifluoroacetic acid (TFA)
Flow rate: 0.50 mL / min Time (min) /% B: 0.01 / 90, 0.5 / 90, 3/10, 6/10
Method B Specifications:
Column: Eclipse XDB C-18 (150 × 4.6 mm, 5.0 μ)
Mobile phase: A) Acetonitrile; B) 5 mM acetic acid Flow rate: 1.0 mL / min Time (min) /% B: 0.01 / 80, 2/80, 15/10, 15.01 / Stop Method C Specifications:
Column: Eclipse XDB C-18 (150 × 4.6 mm, 5.0 μ)
Mobile phase: A) Acetonitrile; B) 5 mM NH ₄ OAc
Flow rate: 1.0 mL / min Time (min) /% B: 0.01 / 80, 3/80, 10/10, 20/10
Method D Specification:
Column: Develosil ODS-HG-3 (50 × 4.6 mm)
Mobile phase: A) Acetonitrile; B) 10 mM NH ₄ OAc
Flow rate: 1.0 mL / min Time (min) /% B: 0.01 / 90, 1/90, 4/10, 10/10
Method E Specification:
Column: X-Bridge, C ₁₈ , 3.5 μm, 4.6 × 75 mm
Mobile phase: A) 0.1% TFA in acetonitrile; B) 0.1% aq. In H ₂ O. TFA
Flow rate: 0.8 mL / min Time (min) /% B: 0/98, 2.2 / 55, 3.0 / 10, 7.5 / 10, 7.8 / 98
Method F Specification:
Column: Acquity UPLC ™ BEH, C ₁₈ , 1.7 μm, 2.1 × 50 mm
Mobile phase: A) 0.1% TFA in acetonitrile; B) 0.1% aq. In H ₂ O. TFA
Flow rate: 0.4 mL / min F (1) Time (min) /% B: 0/100, 1.8 / 100, 3.8 / 25, 4.5 / 5, 6/5, 6.01 / 100
F (2) Time (min) /% B: 0/95, 1/95, 3/20, 6/20, 6.01 / 95
Method G Specification:
Column: Acquity UPLC ™ BEH, C18, 1.7 μm, 2.1 × 30 mm
Mobile phase: A) 0.03% aq. AcOH; B) 0.03% AcOH in acetonitrile
Flow rate: 1.3 mL / min Time (min) /% B: 0/5 to 0.8 / 95 gradient, held at 1.5 / 95 Method H Specifications Column: Symmetry, C-18, 3.5 μm, 4 .6x50mm
Mobile phase: A) Acetonitrile; B) 0.1% aq. In H ₂ O. TFA
Flow rate: 0.8 mL / min Time (min) /% B: 0/98, 2/98, 4/10, 6/10, 6.5 / 2, 8/2, 8.01 / 98
Method I Specifications Column: X-Bridge, C ₁₈ , 3.5 μm, 4.6 × 75 mm
Mobile phase: A) Acetonitrile; B) 5 mM NH ₄ OAc
Flow rate: 0.8 mL / min I (1) Time (min) /% B: 0/100, 2/55, 2.8 / 5, 6.8 / 5, 7.5 / 100
I (2) Time (min) /% B: 0/98, 1.5 / 98, 3/10, 7/10, 8.01 / 98
Method J Specifications Column: Sunfire ™ C18 OBD ™ 5 μm 4.5 × 50 mm column Mobile phase: A) 0.1% AcOH in H ₂ O, 5% MeCN B) 0.1% AcOH in MeCN
Flow rate: 3.0 mL / min I (1) Time (min) /% B: 0/5, 5/95

Example 25: Metalloenzyme activity Minimum inhibitory concentration (MIC) (C. albicans)
Using the standardization procedure (CLSI M27-A2), fungi C.I. The compounds of the present disclosure were evaluated for their ability to inhibit the growth of common strains of C. albicans.
Stock solutions of test compounds and standards were prepared at 1,600 μg / mL (C. albicans) in DMSO. Eleven serial 2-fold dilutions of the compound were prepared in 96 well plates in RPMI + MOPS. The assay concentration range was 8 to 0.001 μg / mL (C. albicans). C. A cell suspension of C. albicans was prepared and added to each well at a concentration of approximately 3.7 × 10 ³ colony forming units / mL (cfu / mL). All tests were performed in duplicate. Inoculated plates were incubated at 35 ± 1 ° C. for approximately 48 hours. When incubation was complete, the wells of each plate were visually assessed for the presence or absence of fungal growth.

In the case of fluconazole and test compounds, the MIC was the concentration at which proliferation was significantly reduced (approximately 50% reduction). In the case of voriconazole, the MIC is C.I. C. albicans growth was reduced by 50% (relative to CLSI M27-A2). For QC purposes, C.I. C. krusei isolate ATCC 6258 (4.0 × 10 ³ cfu / mL) was included in the VOR assay. This isolate showed no trailing development for voriconazole and therefore the MIC was at the concentration at which growth was completely inhibited.

B. Inhibition of liver cytochrome P450 enzymes Solutions of each test compound were prepared individually at concentrations of 20000, 6000, 2000, 600, 200 and 60 μM by serial dilution in DMSO: acetonitrile (MeCN) (50:50 v / v). Next, individual test compound solutions are diluted 20-fold with DMSO: MeCN: deionized water (5: 5: 180 v / v / v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. did. Mixtures of isozyme inhibitors containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6 and 2 μM by serial dilution with DMSO: MeCN (50:50 v / v) (respectively isozyme 2C9, As specific inhibitors of 2C19 and 3A4, sulfaphenazole, tranylcypromine and ketoconazole) were prepared. Next, the inhibitor solution mixed to a concentration of 300, 100, 30, 10, 3, 1, 0.3 and 0.1 μM was added with DMSO: MeCN: deionized water (5: 5: 180 v / v / v). Diluted 20 times. The percentage of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v / v.

To obtain a 5 mg / mL suspension, pooled human liver microsome suspension (20 mg / mL) was diluted with phosphate buffer. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. DMSO: MeCN (50: 50v / v) individual stock solutions of each substrate were prepared in, mixed and diluted with phosphate buffer, at 5 times the experimentally determined _{K m} concentration One solution containing each substrate was obtained. The percentage of organic solvent due to the substrate mixture in the final reaction mixture was 1% v / v.

  The substrate solution and microsome suspension were combined in a 1: 1 volume ratio, mixed and distributed to the reaction wells of the PCR plate. Each concentration of individual test compound or combined inhibitor solution was added to the wells and mixed by repeated aspiration-drain cycles. For real controls, a blank phosphate buffer solution was added instead of the test compound solution. The reaction mixture was allowed to equilibrate at 37 ° C. for approximately 2 minutes before addition of the NADPH solution to initiate the reaction, and then the reaction mixture was pipetted. Ten minutes after the addition of NADPH, the reaction mixture was inactivated with cold acetonitrile. Samples were mixed for approximately 1 minute by orbital shaking and centrifuged at 2900 RCF for 10 minutes. A portion of the supernatant was analyzed by gradient reverse phase HPLC, detected by electrospray ionization triple quadrupole mass spectrometry in positive ion mode.

Data was fitted to a sigmoidal dose response curve and the inhibitory potency of each test compound was determined as its IC ₅₀ value.

result

  C. Minimum inhibitory concentration (MIC) against Septoria tritici

  Inhibiting the growth of a common strain of the fungal phytopathogen Septoria tritici (ATCC26517) using a procedure based on the Clinical and Laboratory Standards Institute (CLSI) Microdilution Assay Protocol for filamentous fungi The compounds were evaluated for their ability to

  Stock solutions of test compounds and standards were prepared at 6400 μg / mL in DMSO. 2-fold dilution series ranging from 16 to 0.016 μg / mL in RPMI-1640 (Rosell Park Memory Institute) medium containing 3- (N-morpholino) propanesulfonic acid (MOPS) buffer and 2% DMSO (all Each stock solution was used to prepare 11 compound concentrations). A 100 μL aliquot of the dilution was added to column 1 (16 μg / mL compound) to 11 (0.016 μg / mL compound) of a 96-well microtiter plate. This format was repeated in the second row of the microtiter plate. Thus, each microtiter plate could be replicated twice and contained 11 concentrations of 4 test or control compounds. A 100 μL aliquot of RPMI-1640 / MOPS / 2% DMSO medium was added to column 12 (no compound control) of the microtiter plate.

To prepare a solution of approximately 5 × 10 ⁴ colony forming units / mL (cfu / mL) in RPMI / MOPS medium without DMSO. A fresh culture of S. tritici was used. A 100 μL aliquot of this solution was added to all 96 wells in a microtiter plate. This resulted in 1% DMSO and approximately 2.5 × 10 ⁴ cfu / mL S.D. Final concentrations of each test or control compound from 8 μg / mL to 0.008 μg / mL in 200 μL RPMI / MOPS medium containing S. tritici are obtained. The assay plate was incubated for 7 days at 22 ° C. in the dark without shaking. Compared to the control (column 12) The MIC for each compound was determined visually as the concentration that resulted in a 50% reduction in S. tritici growth. The results can be seen in Table 3.

In each example in Table 3, the Septoria rating scale is as follows:

D. Evaluation of fungicidal activity against leaf rust (pathogen Puccinia recondita tritici = Puccinia triticina; Bayer code PUCCRT) in soilless peat-based potting mixture (Metrox) Wheat plants (Yuma variety) were grown from the seeds until the true leaves were fully opened. Each pot contained 3 to 8 seedlings. Formulated test compounds were sprayed onto these plants until wet. 10 vol. % Acetone + 90 vol. The compound was formulated at 50 ppm in% Triton X water (deionized water 99.99 wt% + 0.01 wt% Triton X100) to obtain a “prescription test compound”. The formulated test compounds were applied to the plants using a turntable sprayer fitted with two oppositely directed air spray nozzles delivering a spray volume of approximately 1500 L / ha. The next day, the leaves were inoculated with an aqueous spore suspension of Puccinia recondita tritici to allow the spores to germinate and maintain the plants overnight in high humidity to infect the leaves. The plants were then transferred to the greenhouse until disease developed in the untreated control plants. The severity of the disease was assessed after 7 to 9 days depending on the rate of disease development.

In each example of Table 3, the Puxinia rating scale is as follows:

INCORPORATION BY REFERENCE The contents of all references cited throughout this application, including literature references, issued patents, published patent applications and co-pending patent applications, are hereby incorporated by reference herein in their entirety. Clearly incorporated into the

Equivalents Those skilled in the art will recognize, and be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims (39)

Compounds of formula I or their salts:

(Wherein MBG is optionally substituted tetrazolyl, optionally substituted triazolyl, optionally substituted oxazolyl, optionally substituted pyrimidinyl, optionally substituted. Thiazolyl or optionally substituted pyrazolyl;
R ₁ is H, halo, alkyl or haloalkyl;
R ₂ is H, halo, alkyl or haloalkyl;
R ₃ is independently H, alkyl, nitro, cyano, haloalkyl, alkoxy, halo, haloalkoxy, alkenyl, haloalkenyl, cycloalkyl, halocycloalkyl, alkynyl, haloalkynyl, thioalkyl, SF ₃ , SF ₆ , SCN , SO ₂ R ₆ , —C (O) -alkyl, —C (O) OH, —C (O) O-alkyl, C (O) H, CH═N—O-alkyl, —CH═N—O. -Arylalkyl;
R ₄ is aryl, heteroaryl or cycloalkyl, optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
R ₅ is alkyl, haloalkyl, cycloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl, aryl, each optionally substituted with 0, 1, 2, or 3 independent R ₃ , Heteroaryl, arylalkyl or heteroarylalkyl;
R ₆ is alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R ₇ is substituted with H, alkyl, —Si (R ₈ ) ₃ , —P (O) (OH) ₂ , —CH ₂ —O—P (O) (OH) ₂ or optionally amino. -C (O) -alkyl;
R ₈ is independently alkyl or aryl;
R ₉ is independently H, alkyl, halo or haloalkyl;
X is O or S. ). The compound of claim 1, wherein R ₁ is fluoro. The compound of claim 1, wherein R ₂ is fluoro. The compound of claim 1, wherein R ₁ and R ₂ are fluoro. The compound of claim 1, wherein R ₄ is phenyl optionally substituted with 0, 1, 2, or 3 independent R ₃ . R ₄ is phenyl which is optionally substituted with 0, 1, 2 or 3 independent occurrences of halo, A compound according to claim 1. R ₄ is phenyl which is optionally substituted with 0, 1, 2 or 3 independent occurrences of fluoro compound of claim 1. The compound according to claim 1, wherein R ₄ is 2,4-difluorophenyl. R ₅ is aryl which is optionally substituted with 0, 1, 2 or 3 independent occurrences of R _3, A compound according to claim 1. R ₅ is aryl alkyl which is optionally substituted with 0, 1, 2 or 3 independent occurrences of R _3, A compound according to claim 1. R ₅ is heteroarylalkyl which is optionally substituted with 0, 1, 2, or 3 independent occurrences of R _3, A compound according to claim 1. R ₅ is heteroaryl which is optionally substituted with 0, 1, 2 or 3 independent occurrences of R _3, A compound according to claim 1. R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is aryl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
The compound of claim 1. R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is heteroaryl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
The compound of claim 1. R ₁ is fluoro;
R ₂ is fluoro;
R ₄ is 2,4-difluorophenyl;
R ₅ is arylalkyl optionally substituted with 0, 1, 2 or 3 independent R ₃ ;
The compound of claim 1. R ₅ is benzyl which is optionally substituted with 0, 1, 2, or 3 independent occurrences of R _3, A compound according to claim 15. R ₅ is, -CH ₂ that is optionally substituted with 0, 1, 2, or 3 independent occurrences of _{R 3} - heteroaryl, A compound according to claim 15. R ₅ is, _-CH 2 -CF ₂ is optionally substituted with 0, 1, 2, or 3 independent occurrences of _{R 3} - aryl compound according to claim 15. 1- (5- (4-Chloro-2-fluorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (1);
1- (5- (2,4-Difluorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane -2-ol (2);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (3-fluorobenzyloxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (3);
1- (5- (4-Chlorobenzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane-2 -All (4);
4- (6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yloxy) benzonitrile (5 );
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (4-fluorophenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (6);
1- (5- (4-Chlorophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2- All (7);
2- (2,4-difluorophenyl) -1,1-difluoro-1- (5-methoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (8);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (9);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (10);
2- (2,4-difluorophenyl) -1,1-difluoro-1- (5-phenoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (11); Or 2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (2,2,2-trifluoroethoxy) pyridine-2- Yl) propan-2-ol (12);
1- (4-((2,4-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (13);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (vinyloxy) pyridin-2-yl) propan-2-ol (14 );
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) thio) Methyl) -3-fluorobenzonitrile (15);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) thio) Methyl) -3-fluorobenzonitrile (16);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy)- 2-fluorobenzonitrile (17);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((2,2,2-trifluoroethyl) thio) pyridine- 2-yl) propan-2-ol (18);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((4-fluorobenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (19);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((4- (2,2,2-trifluoroethoxy) benzyl ) Oxy) pyridin-2-yl) propan-2-ol (20);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((4- (trifluoromethoxy) benzyl) oxy) pyridine-2 -Yl) propan-2-ol (21);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((4- (trifluoromethyl) benzyl) oxy) pyridine-2 -Yl) propan-2-ol (22);
1- (5-((2,3-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (23);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((2-fluoro-4- (trifluoromethyl) benzyl) oxy) pyridin-2-yl) -3- (1H -Tetrazol-1-yl) propan-2-ol (24);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((3- (2,2,2-trifluoroethoxy) benzyl ) Oxy) pyridin-2-yl) propan-2-ol (25);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((3- (trifluoromethyl) benzyl) oxy) pyridine-2 -Yl) propan-2-ol (26);
1- (5-((4-chloro-3-fluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (27);
1- (5-((3,4-Difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (28);
2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) acetonitrile (29);
1- (5- (benzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2-ol ( 30);
1- (5- (benzyloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) propan-2-ol ( 31);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) ) Propan-2-ol (32);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) ) Propan-2-ol (33);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((3-methoxybenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (34);
1- (5-((3,5-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl ) Propan-2-ol (35);
1- (5-((3,5-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl ) Propan-2-ol (36);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyridin-2-ylmethoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (37);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyridin-2-ylmethoxy) pyridin-2-yl) -3- (2H-tetrazol-2-yl) propan-2 -All (38);
1- (5- (Cyclopropylmethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2-ol (39);
1- (5- (Cyclopropylmethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) propan-2-ol (40);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((4-methoxybenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (41);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-isopropoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (42) ;
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-isobutoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol (43) ;
1- (5-((2,3-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,3 -Triazol-1-yl) propan-2-ol (44);
1- (5-((2,3-difluorobenzyl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-1,2,4 -Triazol-1-yl) propan-2-ol (45)
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((2-fluorobenzyl) oxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane -2-ol (46);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((1,1,1-trifluoropropan-2-yl) Oxy) pyridin-2-yl) propan-2-ol (47);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) -1- (5-((1,1,1-trifluoropropan-2-yl) Oxy) pyridin-2-yl) propan-2-ol (48);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (thiophen-2-ylmethoxy) pyridin-2-yl) propane-2 -All (49);
6-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) nicotinonitrile (50);
6-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) nicotinonitrile (51);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (52);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (53);
2- (4-Chloro-2-fluorophenyl) -1- (5- (cyclopropylmethoxy) pyridin-2-yl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane-2 -All (54);
4-(((6- (2- (4-chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) Oxy) methyl) benzonitrile (55);
4-(((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) Oxy) methyl) benzonitrile (56);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -3-fluorobenzonitrile (57);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) -3-fluorobenzonitrile (58);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -4-fluorobenzonitrile (59);
2- (2,4-Difluorophenyl) -1- (5-((3,5-difluoropyridin-2-yl) methoxy) pyridin-2-yl) -1,1-difluoro-3- (1H-tetrazole -1-yl) propan-2-ol (60);
6-(((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) Oxy) methyl) nicotinonitrile (61);
6-(((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) Oxy) methyl) nicotinonitrile (62);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (4-chloro-2-fluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (63);
1- (5- (but-2-yn-1-yloxy) pyridin-2-yl) -2- (4-chloro-2-fluorophenyl) -1,1-difluoro-3- (2H-tetrazole-2) -Yl) propan-2-ol (64);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (65);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (66);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (67);
3-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) -2-fluorobenzonitrile (68);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-1- (5-isobutoxypyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2-ol ( 69);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-1- (5-isobutoxypyridin-2-yl) -3- (2H-tetrazol-2-yl) propan-2-ol ( 70);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (2,2,2-trifluoroethoxy) pyridine-2 -Yl) propan-2-ol (71);
2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-3- (2H-tetrazol-2-yl) -1- (5- (2,2,2-trifluoroethoxy) pyridine-2 -Yl) propan-2-ol (72);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) Methyl) thiophene-2-carbonitrile (73);
5-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) thiophene-2-carbonitrile (74);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (4- (trifluoromethyl) phenoxy) pyridin-2-yl) Propan-2-ol (75);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5- (4- (trifluoromethoxy) phenoxy) pyridin-2-yl) Propan-2-ol (76);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (3-fluorophenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (77);
3-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) benzo Nitrile (78);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy ) Benzonitrile (79);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy ) Benzonitrile (80);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy ) -2-fluorobenzonitrile (81);
4-((6- (2- (4-Chloro-2-fluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy ) -2-Fluorobenzonitrile (82);
4-(((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy) Methyl) benzonitrile (83);
1- (5- (3-Chlorophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propan-2- Oar (84);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (3-methoxyphenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (85);
1- (5- (3,4-Difluorophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) propane- 2-ol (86);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (4-methoxyphenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (87);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (2-fluorophenoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propan-2- All (88);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy)- 3-fluorobenzonitrile (89);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (2H-tetrazol-2-yl) propyl) pyridin-3-yl) oxy)- 3-fluorobenzonitrile (90);
Methyl 2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) thio) Acetate (91);
1- (5-((3-chloro-5- (trifluoromethyl) pyridin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro- 3- (1H-tetrazol-1-yl) propan-2-ol (92);
6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) nicochi Nononitrile (93);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((5- (trifluoromethyl) pyridin-2-yl) oxy ) Pyridin-2-yl) propan-2-ol (94);
1- (5-((5-chloropyridin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (95);
4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) picoli Nononitrile (96);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyrimidin-2-yloxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (97);
1- (5-((5-chloropyrimidin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (98);
1- (5-((5-Bromopyrimidin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (99);
5-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) pyrimidine -2-carbonitrile (100)
6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) nicotine An aldehyde (101);
(E) -6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl ) Oxy) nicotinaldehyde O-methyl oxime (102);
(E) -6-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl ) Oxy) nicotinaldehyde O-benzyloxime (103);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5-((3-fluoro-5- (trifluoromethyl) pyridin-2-yl) oxy) pyridin-2-yl)- 3- (1H-tetrazol-1-yl) propan-2-ol (104);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((5- (trifluoromethyl) pyrimidin-2-yl) oxy ) Pyridin-2-yl) propan-2-ol (105);
1- (5-((5-Bromopyridin-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (106);
2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) thiazole -5-carbonitrile (107);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (quinolin-2-yloxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (108);
1- (5-((5-chlorobenzo [d] thiazol-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H- Tetrazol-1-yl) propan-2-ol (109);
1- (5-((6-Chlorobenzo [d] thiazol-2-yl) oxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H- Tetrazol-1-yl) propan-2-ol (110);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((6- (trifluoromethyl) pyridin-3-yl) oxy ) Pyridin-2-yl) propan-2-ol (111);
5-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) oxy) picoli Nononitrile (112);
1- (5-((5-chloropyridin-2-yl) methoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (113);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((5- (trifluoromethyl) pyridin-2-yl) methoxy ) Pyridin-2-yl) propan-2-ol (114);
2- (2,4-Difluorophenyl) -1,1-difluoro-3- (1H-tetrazol-1-yl) -1- (5-((6- (trifluoromethyl) pyridin-3-yl) methoxy ) Pyridin-2-yl) propan-2-ol (115);
1- (5-((6-chloropyridin-3-yl) methoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (116);
1- (5-((2-chloropyridin-4-yl) methoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1 -Yl) propan-2-ol (117);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (pyridin-4-ylmethoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) propane-2 -All (118);
1- (5- (2,2-difluoro-2-phenylethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H-tetrazole-1- Yl) propan-2-ol (119);
1- (5- (2- (4- (difluoromethoxy) phenyl) -2,2-difluoroethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3 -(1H-tetrazol-1-yl) propan-2-ol (120);
1- (5- (2- (4-chlorophenyl) -2,2-difluoroethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- (1H- Tetrazol-1-yl) propan-2-ol (121);
4- (2-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-tetrazol-1-yl) propyl) pyridin-3-yl) Oxy) -1,1-difluoroethyl) benzonitrile (122);
1- (5- (2- (4- (difluoromethoxy) phenyl) -2-fluoroethoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -1,1-difluoro-3- ( 1H-tetrazol-1-yl) propan-2-ol (123);
2- (2,4-Difluorophenyl) -1,1-difluoro-1- (5- (2-fluoro-2-phenylethoxy) pyridin-2-yl) -3- (1H-tetrazol-1-yl) Propan-2-ol (124)
The compound of claim 1, which is one of   Chemical interactions or bonds to the following types of metals: to metalloenzymes by formation of one or more of sigma bond, covalent bond, coordination-covalent bond, ionic bond, pi bond, delta bond or reverse bond interaction 20. A compound according to any one of claims 1 to 19 that acquires affinity.   20. A compound according to any one of claims 1 to 19 which binds to a metal.   20. A compound according to any one of claims 1 to 19 which binds to iron, zinc, heme iron, manganese, magnesium, iron sulfide clusters, nickel, molybdenum or copper.   20. A compound according to any one of claims 1 to 19 which inhibits an enzyme class selected from the cytochrome P450 family, histone deacetylase, matrix metalloproteinase, phosphodiesterase, cyclooxygenase, carbonic anhydrase and nitric oxide synthase.   4-hydroxyphenylpyruvate dioxygenase, 5-lipoxygenase, adenosine deaminase, alcohol dehydrogenase, aminopeptidase n, angiotensin converting enzyme, aromatase (CYP19), calcineurin, carbamoyl phosphate synthetase, carbonic anhydrase family, catechol o-methyltransferase, Cyclooxygenase family, dihydropyrimidine dehydrogenase-1, DNA polymerase, farnesyl diphosphate synthase, farnesyl transferase, fumarate reductase, GABA aminotransferase, HIF-prolyl hydroxylase, histone deacetylase family, HIV integrase, HIV-1 reverse transcription Enzyme, isoleucine tRNA , Lanosterol demethylase (CYP51), matrix metalloprotease family, methionine aminopeptidase, neutral endopeptidase, nitric oxide synthase family, phosphodiesterase III, phosphodiesterase IV, phosphodiesterase V, pyruvate ferredoxin oxidoreductase, kidney peptidase, ribonuclease The compound according to any one of claims 1 to 19, which inhibits an enzyme selected from nucleoside diphosphate reductase, thromboxane synthase (CYP5a), thyroid peroxidase, tyrosinase, urease and xanthine oxidase.   1-deoxy-d-xylulose-5-phosphate reductoisomerase (DXR), 17-α hydroxylase / 17,20-lyase (CYP17), aldosterone synthase (CYP11B2), aminopeptidase p, anthrax lethal factor, arginase, β-lactamase, cytochrome P450 2A6, d-ala d-ala ligase, dopamine β-hydroxylase, endothelin converting enzyme-1, glutamate carboxypeptidase II, glutaminyl cyclase, glyoxalase, heme oxygenase, HPV / HSV E1 helicase, Indoleamine 2,3-dioxygenase, leukotriene A4 hydrolase, methionine aminopeptidase 2, peptide deformylase, phosphodiesterase VII, lira Sase, retinoic acid hydroxylase (CYP26), TNF-α converting enzyme (TACE), UDP- (3-O- (R-3-hydroxymyristoyl))-N-acetylglucosamine deacetylase (LpxC), vascular adhesion protein 20. A compound according to any one of claims 1 to 19, which inhibits an enzyme selected from -1 (VAP-1) and vitamin D hydroxylase (CYP24).   20. A compound according to any one of claims 1 to 19 identified as binding to a metal.   20. A compound according to any one of claims 1 to 19 identified as binding to iron, zinc, heme iron, manganese, magnesium, iron sulfide clusters, nickel, molybdenum or copper.   20. Any one of claims 1-19, identified as inhibiting an enzyme class selected from cytochrome P450 family, histone deacetylase, matrix metalloproteinase, phosphodiesterase, cyclooxygenase, carbonic anhydrase and nitric oxide synthase. Compound described in 1.   4-hydroxyphenylpyruvate dioxygenase, 5-lipoxygenase, adenosine deaminase, alcohol dehydrogenase, aminopeptidase n, angiotensin converting enzyme, aromatase (CYP19), calcineurin, carbamoyl phosphate synthetase, carbonic anhydrase family, catechol o-methyltransferase, Cyclooxygenase family, dihydroxypyrimidine dehydrogenase-1, DNA polymerase, farnesyl diphosphate synthase, farnesyl transferase, fumarate reductase, GABA aminotransferase, HIF-prolyl hydroxylase, histone deacetylase family, HIV integrase, HIV-1 reverse transcription Enzyme, isoleucine tRN Ligase, lanosterol demethylase (CYP51), matrix metalloprotease family, methionine aminopeptidase, neutral endopeptidase, nitric oxide synthase family, phosphodiesterase III, phosphodiesterase IV, phosphodiesterase V, pyruvate ferredoxin oxidoreductase, kidney peptidase, ribonucleoside 20. A compound according to any one of claims 1 to 19 identified as inhibiting an enzyme selected from diphosphate reductase, thromboxane synthase (CYP5a), thyroid peroxidase, tyrosinase, urease and xanthine oxidase.   20. A compound according to any one of claims 1 to 19, which inhibits (or is identified as inhibiting) lanosterol demethylase (CYP51).   20. A compound according to any one of claims 1 to 19 identified as having an activity range (e.g. C. albicans MIC <0.25 [mu] g / mL) against the target organism.   A composition comprising the compound of claim 1 and an agriculturally acceptable carrier.   A method of treating or preventing a metalloenzyme mediated disease or disorder in or on a plant, comprising contacting the compound of claim 1 with the plant or seed.   32. A method of inhibiting metalloenzyme activity in a microorganism on a plant, comprising contacting the compound according to any of claims 1 to 31 with the plant or seed.   32. A method of treating or preventing a fungal disease or disorder in or on a plant, comprising contacting the compound according to any of claims 1-31 with the plant or seed.   32. A method of treating or preventing fungal growth in or on a plant, comprising contacting the compound according to any of claims 1-31 with the plant or seed.   32. A method of inhibiting microorganisms in or on a plant, comprising contacting the compound according to any of claims 1 to 31 with the plant or seed.   33. An azole fungicide selected from epoxiconazole, tebuconazole, fluquinconazole, flutriahole, metconazole, microbutanyl, cycproconazole, prothioconazole and propiconazole. Composition.   33. The composition of claim 32, further comprising a strobilurin fungicide from the group of trifloxystrobin, pyraclostrobin, orisatrobin, floxastrobin and azoxystrobin.